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Abstract 
In treating many diseases, including cancer and bacterial infections, drug resistance has 
emerged as a major obstacle limiting the
 
therapeutic efficacy of chemotherapeutic agents.  
One area which may prove to be particularly attractive is Photodynamic Therapy (PDT). 
Reactive oxygen species (ROS) which cause damage to tumour tissue are not generated 
until the drug is activated by light, minimising generalised toxicity and giving a high 
degree of spatial control over the clinical effect.  
The application of nanoparticles (NPs) in the field of drug delivery is extensively studied 
as a potential for delivering high payloads of drugs site selectively. They can be 
targeted towards, and accumulate in, tumour tissue by the enhanced permeability and 
retention effect, if sequestration by the reticuloendothelial system (RES) is avoided.   
 
This project aimed to develop an efficient drug delivery system based on nano-sized 
particles. Polyacrylamide nanoparticles were chosen to deliver photosensitisers due to the 
chemical and biological inertness of polyacrylamide, in addition to its optical transparency. 
The porous three-dimensional particles produced from microemulsion polymerisation 
reactions are typically prepared in the nanometre range.  
 
In the study, two types of NPs loaded with photodynamic sensitisers are synthesised: 
photosensitiser (i.e. phthalocyanine) entrapped NPs (PCNP) and photosensitiser (i.e. 
phthalocyanine) entrapped NPs coated with a second photosensitiser (i.e. porphyrin) 
(PCNP-P) to enhance the capacity for ROS generation, and hence therapeutic potential. 
The mean sizes of these particles were 45±10nm and 95±10nm respectively.  
 
v 
 
NP uptake by human Caucasian colon adenocarcinoma cells (HT29) was determined 
by flow cytometry and confocal microscopy. Cell viability assays using two chosen 
NPs (PC-NP and PCNP-P) corresponding to the minimum uptake time (<5 minutes) and 
maximum uptake time (25 hours), quantified by flow cytometry, demonstrated that these 
cancer cells can be damaged by activation of the photodynamic NPs both when in the 
external media and post internalisation.  
 
Results suggest that in order to induce photodynamic damage, the NPs need only 
be associated with the tumour cell closely enough to deliver singlet oxygen - their 
internalisation within target cells may not be necessary. Clinically, this could be of great 
importance as it may help to combat the ability of many cancer cells to actively expel 
conventional anti-cancer drugs. 
 
Some of this work has already been published, under the title Polyacrylamide 
Nanoparticles as a Delivery System in Photodynamic Therapy , in Mol. 
Pharmaceutics, 2011, 8 (3), pp 920–931. 
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MR   magnetic resonance  
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MW         molecular weight 
NHS        National Health Service 
NHS Porphyrin  5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-
methylpyridimiumyl)porphyrin trichloride 
NMR   nuclear magnetic resonance 
NP   nanoparticles 
OPE   one-photon excitation  
ORMOSIL    organically modified silica 
PACT   photodynamic antibacterial chemotherapy 
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PBS   phosphate buffered saline 
PC  aluminium phthalocyanine tetrasulfonyl chloride 
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phthalocyanine entrapped nanoparticles 
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porphyrin conjugated nanoparticles 
PCS   photon correlation spectroscopy 
PDT  photodynamic therapy 
PEBBLE   probes encapsulated by biologically localized embedding 
PEG  polyethylene glycol 
PEG(750)Porphyrin 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-{PEG(750)-sulfanyl}patt-
phenyl)-porphyrin 
PGPs    P-glycoproteins 
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PI    propidium iodide  
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QDs   quantum dots 
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SSC   side scatter  
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TEM   transmission electron microscopy 
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TET   triplet energy transfer 
THF    tetrahydrofuran  
TLC   thin layer chromatography 
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TPE   two-photon excitation  
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1 Chapter 1: Introduction 
This chapter briefly discusses how drug delivery is carried out with polymers and 
nanoparticles (NPs) mainly for photodynamic therapy (PDT) and photodynamic 
antimicrobial chemotherapy (PACT). 
 
1.1 Polymers 
Polymers are large molecules (macromolecules), composed of repeating small elementary 
units joined by chemical bonds; these elementary units are called monomers [i.e. a vinyl 
polymer (polyvinyl) is composed of the vinyl monomer unit (–CH2-CH(X)-)]. A 
constitutional replicating unit incorporates more than one monomer in the formation of a 
polymer
1
.  
 
Polymers can be divided into two major categories, living polymers and non-living 
polymers. Living polymers are well-defined polymers with closely defined structures and 
sizes combined with low polydispersity (range of polymer lengths), whereas non-living 
polymers are significantly less well characterised and usually have much greater 
polydispersity.  
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1.1.1 Living polymers 
Living polymers are molecules with known molecular weights and architecture. These 
polymeric chains are dynamic objects that maintain a narrow molecular weight 
distribution
2, 3
. They adapt according to the environment (i.e. the addition of a monomer or 
a sudden change in temperature) by polymerisation and depolymerisation reactions 
allowing a new thermodynamic equilibrium to be attained.  
 
Living polymers are synthesised via ionic polymerisation. Living polymerisation is usually 
further categorised into cationic polymerisation and anionic polymerisation.  Cationic 
polymerisation involves addition of a positively charged monomer, whereas anionic 
polymerisation initiates with a negatively charged monomer
1
. Living polymers possess 
unique features: (i) the easy addition or subtraction of monomers from the chain ends
4
 and 
a fixed total number of chains
2
. These polymers can be synthesised by controlling the 
initiator and the active end-group monomers and can either be end-functionalised or block-
copolymerised with other monomers, enabling the synthesis of a variety of well 
characterised polymers (Figure 1.1). 
 
In a living polymer system, the polymerisation ceases only if all the monomers present are 
consumed as long as oxygen and water (i.e. free radical sources) are absent from the 
media. Addition of a monomer would resume the polymer chain growth, even if the “new” 
monomer added is different to the initial monomer used. 
3 
 
 
Figure 1.1: A schematic diagram of polymers synthesised using living polymerisation 
(modified from reference
3
) 
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Non-living polymers are synthesised by radical polymerisation. Some key differences 
between ionic and radical polymerisation are listed in the below table (Table  1.1)1,2. 
 
 Ionic polymerisation  Free radical polymerisation 
The distribution of chain lengths is very 
small. Poisson fluctuations around the 
mean with a low polydispersity index 
(~1) (Polydispersity index is a measure 
of the molecular mass range of a 
polymer sample.) 
The distribution of chain lengths of the 
polymers is broad with a relatively high 
polydispersity index (~2). 
Polymer architecture can be controlled. Architecture of the polymer cannot be 
controlled.  
Possibility of controlling the molecular 
weight of the polymer.  
Molecular weight of the polymer cannot 
be controlled.  
The solvent that is used in the reaction 
has a considerable influence on the 
nature of the polymers synthesised: 
polymerisation reactions are carried out 
in solvents with relatively low polarity. 
The solvent serves as a vehicle for the 
soluble species but shows no influence on 
the rate or the stereochemistry of the 
products.   
Polymer termination cannot involve two 
growing chain ends – due to charge 
repulsion. 
Polymer termination can involve two 
growing chain ends.  
Limitation in the range of monomers 
that can be used for polymerisation.  
A very broad variety of monomers can be 
used for the polymerisation reaction. 
Table ‎1.1: Comparison between ionic polymerisation and free radical polymerisation 
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1.1.2 Group Transfer Polymerisation (GTP) 
 
 
Figure ‎1.1: Copolymerisation of a porphyrin in a polymer chain 
 
GTP is a reasonably new technique for polymerisation of acrylic and methacrylic 
monomers. This is an easy, fast, living polymerisation method and can be carried out at 
room temperature or above. This method is appropriate for synthesising porphyrin 
copolymerised polymers (Figure  1.1), due to its cost efficiency and ability to control the 
architecture and molecular weight of the polymer
5
. GTP relies on functionalised groups 
such as methacrylate and acrylate as the monomers. 
 
Following on from microtechnology, nanotechnology has been referred to as the 
technology of the 21
st
 century.  Nanotechnology has already impacted significantly on the 
material world, in the fields of medicine, electronics and energy production. The section 
below briefly discusses the origin of nanotechnology by introducing different types of NPs 
used in biomedicine, mainly in drug delivery. The subsequent discussion focuses more 
specifically on NPs formed from a polyacrylamide matrix. The section ends with a 
discussion on how NPs can be taken up by cells.  
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1.2 Nanotechnology 
Nanotechnology is not new: Nobel Laureate Richard Feynman, inspired the concepts of 
nanotechnology back in 1959 in his visionary lecture,  
‘’There is plenty of room at the bottom”6. He noted “What I want to talk about is 
the problem of manipulating and controlling things on a small scale...What I have 
demonstrated is that there is room---that you can decrease the size of things in a practical 
way. I now want to show that there is plenty of room”.  
He further continued his vision,  
“The principles of physics, as far as I can see, do not speak against the possibility 
of manoeuvring things atom by atom. It is not an attempt to violate any laws; it is 
something, in principle, that can be done; but in practice, it has not been done because we 
are too big. The problems of chemistry and biology can be greatly helped if our ability to 
see what we are doing, and to do things on an atomic level, is ultimately developed, a 
development which I think cannot be avoided”.  
 
Although the concept of nanotechnology was laid down with this lecture in 1959, it did not 
emerge as a separate scientific discipline until some 20 years ago.  
 
Nanotechnology can be defined as the engineering of functional systems at a molecular 
level.  It modifies matter at the lower nanometric (1-100 nm) level. Particles of this size 
behave as an intermediate between macroscopic sized solids and atomic or molecular 
systems
7
. The properties and functions of NPs primarily depend upon their size
8
. The 
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increased surface area (surface area per mass) of the nanosized particle having a huge 
influence on its overall properties. 
 
The application of nanotechnology in medicine and biology is advancing rapidly in areas 
such as cancer therapy
9, 10
, manipulation of genetic materials
11-13
, rapid colorimetric 
detection
14
, disease diagnosis
11, 15
, intracellular glucose imaging
16
, detection of zinc
17
 
bioimaging
18
 i.e. brain tumour diagnosis and imaging
19
. Research is now expanding into 
rational delivery and targeting
 
of pharmaceutical, therapeutic and diagnostic agents 
through intravenous
 
and interstitial routes of administration with nanosized particles. A 
very interesting study was reported by Russell et al., on intelligent fingerprinting, where 
they showed how it’s possible to obtain direct chemical information from drugs or drug 
metabolites present in miniature amounts of sweat deposits
20
. Further, NPs can be 
embedded with proteins
21
, to provide ratiometric methods for pH measurement using 
fluorescent dyes
22, 23
 and horseradish peroxidise (HRP)
24
. 
 
Optical PEBBLE (probes encapsulated by biologically localized embedding) nanosensors, 
using ORMOSIL (organically modified silica) NPs as a matrix, have demonstrated some 
excellent results confirming the validity and high sensitivity of the delivery method for 
intracellular studies of PEBBLE sensors, which is required to achieve real-time 
measurements of intracellular dissolved oxygen concentration
25
. Another study by the 
same group developed a ratiometric singlet oxygen nano-optode where they observed 
relatively high singlet oxygen solubility due to the highly permeable structure, 
hydrophobic nature of the outer shell and longer lifetime of oxygen in the ORMOSIL 
matrix compared to the aqueous solution
26
. Josefsen et al. reported some excellent results 
on a nanosystem that can generate ROS and monitor the cell reaction as a function of 
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calcium ion concentration using a porphyrin conjugated calcium green entrapped NP 
system
27, 28
. 
 
Quarta et al. reviewed the most significant in vitro studies using magnetic-fluorescent 
nanocomposites based on colloidal iron oxide nanocrystals combined with different classes 
of fluorophores (i.e. cyanines and porphyrins) on living cells, applications in biology and 
medicine
29
. Further it also gives an insight into how fluorescent-magnetic NPs, previously 
mainly focused on diagnosis via MRI and fluorescence imaging, have now developed a 
step further towards a number of multifunctional magnetic targeting drug delivery systems 
for diagnosis and therapy in the past couple of years.  
 
Nanomedicine can be defined as the diagnosis, identification, monitoring, repair, 
construction and control of human biological systems at the molecular level using 
engineered nanodevices and nanostructures
30
. In short, particles in nanomedicine bridge 
the gap between the ‘structure’ and the biological ‘function’31. Multidisciplinary functions 
of these particles can be divided into pharmacogenomics, gene therapy
32
, DNA 
manipulation
33
, drug delivery
34
, nanodevices, nanotools and/or nanodiagnostics
31
.  
 
Selective subcellular delivery is more likely to have therapeutic benefits because the 
cytosolic delivery of drugs is generally affected by efflux mechanisms. However, 
entrapping the compound in a nanoparticle creates a barrier protecting the drug by acting 
as a drug/photosensitiser (PS) depot within the cell. Thus, nanotechnology can be used in 
certain therapies, establish sustained release drug profiles and protect therapeutic 
compounds within cells from efflux transporters such as multi-drug resistance proteins and 
P-glycoproteins which continuously reduce therapeutic drug concentrations
35
. 
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NPs are being extensively investigated as targeted and localised drug delivery systems
34, 36-
43
. Drug delivery using NPs is particularly promising due to the possibility of engineering 
NPs to control their fundamental properties such as drug release characteristics
44, 45
, 
solubility or diffusibility. Further, in tumour targeting, NPs can be used in antigen-
dependent (specific) or antigen independent (non-specific) mechanisms
19
. 
 
1.2.1 Nanoparticles  
Nanoparticles (NPs) represent a relatively new trend in drug delivery. Large particles 
(>200 nm) are usually captured by macrophages. However, NPs below 200 nm are more 
likely to be eventually removed from the body by renal clearance. Having small particles 
can help to maintain higher circulating levels of the therapeutic agents once 
administered
11
. Drugs or sensors can be entrapped in the nanoparticle matrix, conjugated 
to the nanoparticle surface or covalently linked to the matrix. There are advantages to 
entrapping drugs/sensors in the core of porous NPs
24
.  Primarily, the particle matrix acts as 
a barrier between the intracellular environment and potentially toxic dyes, while inhibiting 
interactions of the dye with circulating serum components which might alter its 
photophysical properties
46
. Surface conjugated NPs however retain many of the drawbacks 
of using free dyes.  
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1.2.2 Nanoparticles in Drug Delivery 
NPs used in drug delivery should be 3-200 nm in size, ideally ~100 nm
36
. Most of the 
properties, i.e. the surface curvature of the NP, especially relevant to surface interactions
47
 
that make NPs attractive for novel applications are found when the NPs are around 100 
nm. In targeting NPs to tumour tissue, provided they avoid sequestration by the 
reticuloendothelial system (RES), accumulation can occur in the tumour stroma as a result 
of the enhanced permeability and retention effect
48
. 
   
Particles synthesised to avoid the RES can lead to longer circulation times, resulting in 
greater potential to target the site of interest. Ideally, these NPs are ~100 nm in size, with a 
hydrophilic surface (to avoid clearance by fixed macrophages), this can be achieved by 
coating the particles with hydrophilic polymers that create a cloud of chains on the particle 
surface repelling plasma proteins
48
. This method creates a hydrophilic protective layer 
around the NPs that is able to repel the absorption of opsonin proteins via steric repulsion 
forces, thereby blocking and delaying the first step in the opsonisation process
4
. 
 
Depending on the method of preparation, drugs can either be physically
 
entrapped in 
(encapsulated) or covalently bound to the NPs
31
. Some of the different structures of NPs 
used in drug delivery such as polymeric NPs, polymeric micelles, dendrimers and 
liposomes can be seen in Figure  1.2. 
 
 
 
 
 
11 
 
 
Figure ‎1.2: Schematic representation of polymer based drug carriers  
(modified from reference
49
)
 
 
Nanospheres have matrix type structures, where drugs may be absorbed at the sphere 
surface or encapsulated within the structure
50
. Nanocapsules consist of an inner liquid core 
surrounded by a polymeric membrane, with the drug confined to its cavity. Generally, the 
active compounds are dissolved in the inner core of the nanoparticle but may also be 
adsorbed onto the surface
49
. Drugs can be conjugated to or encapsulated within polymeric 
NPs
36
. Liposomes are layered lipid structures, generally of much greater size, compared 
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with micelles and present both polar and non-polar regions within their structures. 
Polymeric micelles are self-assembled block co-polymers, with an inner hydrophobic core 
(that can be assembled to include hydrophobic drugs), and in an aqueous solution can 
arrange to form an outer hydrophilic layer. Quantum dots are fluorescent nanocrystals that 
can be conjugated to a ligand
49
. Dendrimers are monodispersed symmetric 
macromolecules. These are synthesised with a large number of reactive end-groups 
surrounding a small internal molecule. Viral-based NPs in general are multivalent self-
assembly protein cage structures. Carbon nanotubes are carbon cylinders composed of 
allotropes of carbon
36
. 
 
Drug encapsulating NPs are solid, nanosized (generally 3-200 nm), drug carriers that may 
or may not be biodegradable. They can be engineered to selectively deliver biologically 
active compounds to targeted tissues resulting in improved drug efficacy and low drug 
toxicity
51-53
. 
  
NPs can also be attached to other molecules that act as markers to detect the early stages of 
diseases
54
. As seen in Table  1.2, the unique properties of different nanoparticle materials 
make them appropriate for drug delivery
54
.  
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Nanoparticle Material/Technique Property 
NPs (50-100 nm). 
Penetrate easily through blood vessel 
pores. 
Nano-capsules and nano-porous materials.  
Avoid the host immune system and 
deliver the therapeutic vehicle to the 
target site. 
Polymers. High degree of engineering precision. 
Enhanced particle adhesion. 
Increase localised drug retention, 
slowing down drug release. 
Ligand attached NPs. High degree of engineering precision. 
Table ‎1.2: Nanoparticle Properties 
 
Further, there are cost benefits in using nanotechnology for drug delivery, including 
advanced performance characteristics of the product due to the enhanced delivery and 
effective patent protection
49
.  
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1.2.3 Nanoparticle Synthesis 
There are many methods and techniques described in the literature for nanoparticle 
synthesis
55-57
. The most common synthetic materials could be classified as pre-formed 
polymers, macromolecules and bio-based or inorganic materials
58-62
. Most commonly, NPs 
are synthesised by polymerisation reactions
63, 64
. This can be achieved either by emulsion 
or interfacial polymerisation. Emulsion polymerisation
65-69
 involves a radical 
polymerisation reaction that is initiated within an emulsion, including a monomer, Surface 
active substances (surfactant) and two immiscible liquids (i.e. water and oil).  
 
Emulsions are mixtures of two immiscible liquids such as oil and water, stabilised by an 
emulsifier. Emulsions do not form spontaneously. To form an emulsion, an energy input is 
required through a homogenizing process. Over time, the unstable phases convert to a 
stable state comprising the emulsion. The term microemulsion refers here to a system 
composed of non-polar phase (oil), water (containing monomers) and an amphiphilic 
compound. However, in the strictest sense, the phase rich in amphiphilic compound is a 
microemulsion. Depending on the size of the droplets emulsions can be classified as 
macroemulsions (droplet size 50–500 nm) or microemulsions (droplet size 5–50 mm). In 
relation to thermodynamics, this phase executes the condition of maximum mutual 
solubilisation of water and oil where the interfacial tension between aqueous phase and oil 
is at a minimum
70
.  Surfactants can increase the kinetic stability of emulsions greatly so 
that, once formed, most often the emulsion does not change significantly over years of 
storage. Interfacial polymerisation
71-75
 is a polymerisation reaction that occurs at or near to 
the interfacial boundary of the two immiscible solvents. Here, the monomers present in 
one of the solvents react with different monomers present in the other solvent. These 
15 
 
reactions are generally spontaneous. To stay within the scope of this review, the discussion 
will mainly focus on the emulsion polymerisation technique
65-69
. 
 
1.2.4 Emulsion Polymerisation 
Emulsion polymerisation can be divided into two categories based on the phases used in 
the polymerisation method (i) organic phase and the (ii) aqueous phase
50
. 
 
The organic phase method is the more widely used method for nanoparticle preparation 
and is a radical polymerisation involving a monomer, surfactant and water (See Table 1.1, 
for the characteristics of the radical polymerisation method). These are combined in 
suitable ratios
76
  to form emulsions, in which micelles of discrete dimensions are formed 
(Figure  1.3). 
  
Water
+
Polymer
Oil
Hydrophilic Head of the surfactant
Hydrophobic tail of the surfactant
Particle
Oil
Oil
 
Figure ‎1.3: Schematic representation of a synthesised nanoparticle via microemulsion 
technique 
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Micelles are particles that form due to the spontaneous arrangement/migration of 
surfactant molecules in the microemulsion reactions. The addition of an initiator (e.g. 
ammonium persulphate) initiates the polymerisation process/reaction and forms porous 
solid particles of nanometre dimensions. Assemblies of surfactant molecules trap the 
particles formed in one phase, preventing any aggregation in the early stages of the 
polymerisation. Size and porosity can be controlled by varying the composition of the 
mixture used to form the micelles. The ability to control the pore size, charge of the 
nanoparticle, and the ability to entrap PSs within the nanoparticle core, makes this an 
attractive method for the preparation of NPs for delivery of photodynamic agents
50
. 
 
In the aqueous phase method, the monomer is dissolved in an aqueous solution without 
having to use emulsifiers and surfactants in the solution. The polymerisation may be 
initiated when the monomer collides with an introduced initiator molecule, which could 
either be an ion or a free radical. Alternatively, a monomer molecule may be transformed 
into an initiating radical by a high energy radiation, such as strong visible light, gamma 
radiation, or UV radiation, leading to radical polymerisation
50
. 
 
  
17 
 
1.2.5 Potential of NPs to overcome drug resistance 
In treating diseases, such as cancer or bacterial infection, drug resistance has emerged as a 
major obstacle limiting the efficacy of chemotherapeutic and anti-bacterial agents.  
 
Among several
 
mechanisms of drug resistance
77-81
, P-glycoprotein mediates one of the best 
known
 
and most extensively investigated
82
. P-glycoproteins (PGPs) are part of the efflux 
transporter family found in the gut, kidneys, brain and other organs. They act as a localised 
drug transport mechanism actively exporting drugs out of the cell. Recent studies
83
 have 
suggested
 
that NPs may be able to circumvent P-glycoprotein–mediated resistance.  
 
One possible mechanism by which NPs may
 
avoid recognition by the P-glycoprotein 
efflux pump is as a result
 
of being enveloped in an endosome when entering the cell
84
. 
Ligand-targeting strategies involving NPs, especially those using receptor-
targeting
 
ligands, may have particular potential for overcoming drug resistance, as these 
ligands are generally internalised via receptor-mediated
 
endocytosis. It has been suggested 
that transferrin-conjugated
 
paclitaxel-loaded NPs
85
, folate receptor–targeted NPs, and pH-
sensitive
 
polymeric micelles containing doxorubicin
86
, all exhibit greater inhibitory
 
activity 
against the drug-resistant breast cancer cell line (MCF-7 cells) 
 
compared with their non-
targeted free drug counterparts. 
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1.2.6 Cellular uptake of NPs 
The eukaryote cell membrane is an active semi-permeable lipid bilayer that segregates the 
intracellular environment (cytoplasm) of a cell from the extracellular environment 
(Figure  1.4). It regulates and coordinates the entry and exit of small and large molecules to 
and from the cell. Small molecules, such as sugars, ions and amino acids can pass through 
the plasma membrane via protein pumps or channels present in the membrane. 
 
 
Figure ‎1.4: Schematic cell membrane model 
 
Cells have evolved a variety of strategies to absorb material from the external 
environment. Predominantly for particles of nanometre size endocytosis is one such 
strategy
87-90
. Endocytosis is the process by which cells internalise material by engulfing it 
with their cell membrane. It regulates many processes that are essential to cells including 
nutrient uptake, receptor signalling, neurotransmission, mitosis and growth. 
 
Endocytosis is one of the major pathways of nanoparticle cellular uptake
91-93
 and this 
process is both concentration and time dependent.  
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Endocytosis can be categorised into three broad categories, depending on the size of the 
vesicle formed and the cellular machinery involved: 
 
 Phagocytosis94,95: uptake of large particles  
 Pinocytosis95,96: uptake of fluid and solutes  
 Receptor-mediated endocytosis97,98: more specific active event where the 
cytoplasm membrane folds inward to form coated pits. 
 
Uptake of NPs via endocytosis can occur through phagocytosis, fluid phase pinocytosis or 
receptor mediated endocytosis. NPs less than 200 nm are known to be imported to cells by 
pinocytosis while larger particles (>500 nm) are internalised through phagocytosis
99
. 
Panyam and Labhasetwar reported no phagocytotic activity with NPs approximately 100 
nm in size
90
. 
 
Pinocytosis occurs in almost all cells
87
, whereas, phagocytosis (Figure  1.5) is typically 
restricted to specialised mammalian cells
87
 like macrophages
94
, neutrophils
100
 and 
monocytes
101
. Innes and Ogden in 1999
102
 described the possibility of pinocytotic 
endocytosis taking place in oral epithelial cells with microspheres of 0.01 µm and 0.1 µm. 
They found no endocytosis taking place with 1.0 µm microspheres
99
. In 2009 Hu et al. 
confirmed these findings by reporting that colloidal particles of less than 0.2 µm can be 
imported into cells by pinocytosis whereas larger particles (0.2-0.5 µm) would be 
internalised via phagocytosis
99
. 
 
Pinocytosis (Figure  1.5) can be sub-classified into at least four fundamental mechanisms: 
macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis 
20 
 
and clathrin and caveolae independent endocytosis. Macropinocytosis
103
 represents an 
efficient route for non-selective endocytosis of solute macromolecules and is preferred for 
the uptake of smaller particles. The remaining three uptake mechanisms are differentiated 
depending on the sizes of vesicles formed in particle uptake. Approximately, the sizes are 
clathrin ~120 nm, caveolin ~60 nm and clathrin-caveolin ~90 nm.  
 
 
Figure ‎1.5: Multiple means of particle entry to mammalian cells (modified from reference
87
) 
 
Clathrin mediated endocytosis
104
 occurs in all mammalian cells and is the most important 
mechanism for receptor mediated uptake. Caveolae can be found in endothelial cells, 
smooth muscle cells and adipocytes. In contrast to other mechanisms, caveolae 
endocytosis is interesting for nanoparticle delivery as the particles are neither trapped in 
endosomes nor degraded in lysosomes
105
. Technically, this makes the delivery of NPs to 
intracellular targets possible, with physical characteristics of the NPs resulting in delivery 
to the Golgi complex, endoplasmic reticulum or other sites by transcytosis. Transcytosis is 
a process by which various macromolecules are transported across the interior of a cell. 
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Clathrin and caveolae independent endocytosis is described only in few instances, i.e. 
recovery of neuron membrane proteins.  
 
Receptor-mediated endocytosis is an active event where the cytoplasm membrane folds 
inward to form coated pits in protein or particle uptake. In the event of uptake, the particles 
are first locked into ligands or receptors in the cells plasma membrane prior to the 
engulfing event. Any particles entering the cells in this mechanism are frequently 
enveloped by endosomes. This bypasses the initiation of one of the main drug resistance 
mechanisms involving P-glycoprotein
106
. 
 
It has been established that NPs can be taken up by cells and they are an effective drug 
delivery method
107
. Depending on the size of the NPs, theoretically, all the mechanisms 
described above could feature in the cellular uptake of the particles. However, it is still 
unclear as to how endocytosis can be selectively targeted by NPs
18,87
. The mechanism of 
internalisation and intracellular localisation of NPs could be determined by the surface 
properties of NPs.  
 
Exocytosis is the reverse process to endocytosis in eukaryotic cells
108
. Endocytosis and 
exocytosis are both dynamic and energy dependent processes
90
. At any point in time, the 
nanoparticle concentration within a cell results from the net difference between these two 
processes. The intracellular population consists of NPs that are recycling inside the cell, in 
the lysosomes or in the cytoplasm
90
. Jin et al. reported a comparison of internalisation 
(endocytotic uptake), exocytosis rates and net accumulation of carbon nanotubes over time 
(8000 s) compiled from single particle tracking and found that the net accumulation 
fluctuates with time
109
.  
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1.3 Photodynamic Therapy (PDT) 
Life on earth, directly or ultimately, depends on light. The energy of the sun promotes 
processes that maintain human existence through photosynthesis. In medicine, PDT 
represents a unique combination of light, a photosensitising drug and oxygen to treat 
cancer and bacterial infections. The following discussion highlights the properties of light, 
describes the photophysics, photochemistry and photobiology of PDT, and the various PSs 
used in PDT. 
 
Conventional therapies such as surgery, chemotherapy and radiation therapy involve a 
subtle balance between removing and/or destroying diseased tissue and sparing the 
surrounded healthy tissue from destruction.  Due to the indiscriminate cytotoxic properties 
of the latter two of these treatments towards healthy and diseased tissue, serious side 
effects may result. Hence, it is essential to focus the development of new treatments on 
selectively targeting the diseased tissue.  
 
The phenomenon of photodynamic reactions was first discovered by Raab in 1900 while 
studying the effects of light and dyes on paramecia
110
. Paramecia are a group 
of unicellular ciliate protozoa.  In his study, the paramecia that were exposed to sunlight 
and an acridine dye were killed, while the ones which were in the dark survived. This was 
an oxygen rich biological system, containing a sensitiser which absorbed light causing a 
photochemical reaction. This effect was given the name ‘photodynamisagerscheinung’ or 
‘photodynamic reaction’ by Tappeiner and Jodlebauer in 1904 differentiating it from the 
photochemical reactions that occur without involving oxygen e.g. the use of ultra violet 
light to treat psoriasis
111
. Since the origin of PDT, many researchers have been involved in 
its development. Excellent reviews from McCaughan in 1999
111
, MacDonald and 
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Dougherty in 2001
112
 and Josefsen and Boyle in 2008
113
 highlight the development of 
PDT.  
 
PDT requires the combination of light and photosensitising agents in an oxygen-rich 
environment. The technique relies upon selective accumulation of the PS in target tissue 
followed by activation with light
114-116
.
  
 
1.3.1 The Nature of Light 
Light is a form of radiant energy. All radiant energy exists as electromagnetic waves. Light 
exhibits wave-like and particle-like properties. Light can thus be described by wave-like 
properties: light undergoes reflection, refraction, interference, diffraction and polarisation. 
However, light can also be described by its particle-like behaviour, due to its photoelectric 
effect (the phenomenon in which electrons are emitted from matter after the absorption of 
energy from electromagnetic radiation). Light is composed of small packets of energy 
called quanta or photons travelling in periodic waves. 
 
Wavelength is inversely proportional to the frequency (the number of waves that pass a 
certain point in a second). Once the electromagnetic radiation is arranged in the order of 
increasing wavelength, it is called the electromagnetic spectrum (EMS). Visible light is the 
radiant energy to which the human (mammalian) eye responds and covers the region, 
approximately from 360-780 nm in the EMS. In fact, since the sensitivity of the 
human/mammalian eye to radiation is very low at the two extremes, the range visible to 
mammals is considered to be 380-720 nm
117
. Colour is ascribed to and associated with 
different/specific wavelengths.  
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Colour is said to require the presence of three factors: a source of illumination, an object 
for the light to interact with and the human/mammalian eye to observe
117
. Dean B. Judd, 
one of the founders of colour science, defined colour as,  
“that aspect of the appearance of objects and lights which depends upon the 
spectral composition of the radiant energy reaching the retina of the eye and upon its 
temporal and spatial distribution thereon”118.  
 
When light strikes any object, including cells, it can undergo one or more of the following 
processes: 1. reflection, 2. transmission, 3. scattering and 4. absorption. Light needs to first 
be absorbed for any photochemical/photobiological reaction to occur (as the source of 
energy)
111
.   
 
In the context of PDT, PSs are compounds which absorb light of a specific wavelength and 
utilise this energy to generate (via the interaction with molecular oxygen) highly cytotoxic 
singlet oxygen. Further, in PDT, the measurement of the absorption of light by the PS is 
called its ‘absorption coefficient’ for that wavelength. This phenomenon changes with 
their environment, i.e. tissue and wavelength
111
.  
 
The therapeutic outcome of PDT is related to the activation wavelength of the PS, which in 
turn is related to the depth of light penetration in human tissue. The optimal spectral 
window for biological tissue penetration of light lies in the red to near infrared part of 
electromagnetic spectrum  (Figure  1.6), approximately 600 to 800 nm119, implying that 
photodynamic sensitisers must have a strong absorption band in this region to be 
effective
120
. 
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Figure ‎1.6: Schematic diagram of the wavelength versus skin penetration (modified from
121) 
 
1.3.2 Photophysical Mechanisms in PDT 
Absorption of energy by chromophores occurs between the electronic energy levels of 
molecular orbitals. The various energy levels involved in the absorption and emission of 
light are classically represented by a Jablonski energy diagram. 
 
PSs absorb light energy and therefore increase the energy of the PS’s electrons from the 
ground state to the excited state. PSs in the ground state (
1
S0) possess electrons in a singlet 
state (no net spin, S=1). But once the light is absorbed by the sensitiser, the electron 
becomes ‘excited’ (1S*), and will remain in a singlet state unless one of the spin-paired 
electrons can undergo spin inversion, and via intersystem crossing (ISC), resulting in a 
spin aligned pair of electrons (Figure  1.7). 
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Figure ‎1.7:  A Modified Jablonski Diagram  
  
The PS is now in its triplet state (T) (net spin, S=3)
88
 and can react chemically in two 
ways: by Type I and Type II (Figure  1.7) pathways.  
 
Type-I reaction: the PS reacts directly with a substrate molecule resulting in hydrogen 
atom abstraction or electron transfer, both generating a reactive, cytotoxic free radical 
leading to oxidative damage
114,122
. 
 
Type-II reaction: in a biological system where oxygen is present, a PS transfers its energy 
to the stable triplet state of molecular oxygen. Gaining the energy provided from the PS, 
one of the oxygen’s unpaired electrons undergoes spin inversion, rendering the net 
electronic spin zero
111, 114, 123
. Thus, oxygen is now in its extremely reactive singlet excited 
state, referred to as singlet molecular oxygen. The type-II mechanism and the cytotoxicity 
of singlet oxygen is considered predominant in PDT
124
, although changes to oxygen levels 
in the microenvironment of diseased tissue may affect a greater dependence on type-I. 
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Photons can be absorbed repeatedly by PSs after it has returned to the ground state and the 
above processes can continue until the PS degrades (photobleaching)
111
. Once the PS is 
excited, excess energy can be lost via a number of pathways, including radiative and non-
radiative decay. Fluorescence results directly from radiative decay of a singlet excited 
state, while phosphorescence is the result of radiative decay of the triplet excited state. 
Since a change of spin is required, intersystem crossing and phosphorescence are quantum 
mechanically forbidden processes (Spin Selection Rule). The lifetime of fluorescence (τF) 
is in the range 10
-9
- 10
-6 s, whereas the life time of phosphorescence (τP) is in the range 10
-
3
- 1 s. Since phosphorescence allows more time for collision of the singlet oxygen with 
substrates in its environment, this longer triplet state life time (τP) is an important 
parameter in PDT.  
 
1.3.3 Two-photon Excitation (TPE) 
TPE is simultaneous absorption of two photons by a PS usually in the near-infrared region 
of the electromagnetic spectrum. TPE achieves the same effect as one-photon excitation 
(OPE) at half the wavelength, promoting a molecule into its singlet excited state, provided 
that the combined energy of the two photons matches the energy of a single photon that is 
required to excite the molecule using light of double the wavelength (Figure  1.8). 
Practically, this means that optimal excitation of PSs can be achieved by deeply 
penetrating light, thus maximising the clinical PDT effect. 
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Figure ‎1.8: Schematic diagram of photon excitation of a molecule 
 
1.3.4 Beer-Lambert Law (Beer’s‎law) 
The law states that absorbance (A) is directly proportional to the path length (l), of the 
sample and its molar concentration (c):  
A‎=‎εcl 
ε  - the molar extinction coefficient (with dimensions of dm3.mol-1cm-1) of the 
solute 
c  - the molar concentration (in moledm
-3
) 
l - the path length, is measured in centimeters 
The Beer-Lambert law is particularly important for determining the concentration of 
solutions from absorbance measurements.   
 
29 
 
1.3.5 Singlet Oxygen 
The first excited state of oxygen, which is commonly known as singlet oxygen, O2 (
1∆g) is 
an extremely reactive and highly cytotoxic species. It is responsible for many 
photochemical processes such as photodegradation of dyes and photocarcinogenesis. 
Reactions of singlet oxygen are associated with applications in several fields, including 
organic synthesis and bleaching processes. It is also the main damaging element in PDT
125, 
126
. Both type-I and type-II photochemical reactions occur in parallel
127
. The concentration 
of oxygen present and the PS used has a predominant effect on the ratio
128
. However, for 
most photosensitisers employed in PDT, the type-II photochemical reaction represents the 
dominant process
124
.  
 
A second excited singlet state, O2 (
1Σg
+
), can be formed in competition with the first 
excited state, O2 (
1∆g). In solution, this O2 (
1Σg
+
) deactivates very rapidly to the longer lived 
O2 (
1∆g) species
129
. Singlet oxygen reacts with a variety of electron rich bio-molecules, 
resulting in oxidised products, such as hydroperoxides and endoperoxides
122
. Singlet 
oxygen can also generate other reactive oxygen species (ROS), such as superoxide radicals 
causing damage to the cell’s DNA, lysosomes, mitochondria or membranes, which could 
result in cell apoptosis (programmed cell death) or necrosis (accidental cell death)
130
.  
 
Singlet oxygen can be detected directly through its extremely weak emission at 1270 nm. 
However, this is not visible to the naked eye. Nonetheless, at high singlet oxygen 
concentrations, dimolecular light emission (simultaneous emission from two singlet 
oxygen molecules upon collision) can be observed as a red glow at 634 nm
131
. 
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Oxygen exhibits a few rather unusual properties with respect to magnetic behaviour, 
spectroscopy, energy-transfer processes and chemical reactivity. These peculiarities are a 
result of the open-shell electronic structure of the molecule Figure 1.10126. In the isolated 
(molecular) oxygen molecule, the transition to form singlet oxygen is strictly forbidden by 
the Spin Selection Rules. In other words, direct excitation of ground state oxygen by light 
to form singlet oxygen is very unlikely.  
 
 
Figure ‎1.9: Molecular orbital diagram of oxygen (reproduced  with permission from
28
). 
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1.3.6 Photosensitisers  
Photosensitisers (PSs), in the context of PDT, are compounds which absorb light of a 
specific wavelength and utilise this energy, in combination with molecular oxygen (
3
O2), 
to generate highly cytotoxic singlet oxygen. PSs are generally, aromatic structures that are 
efficient at undergoing intersystem crossing and forming long-lived triplet excited 
states
132
. The selective accumulation of a drug in diseased tissue is the key requirement for 
photodynamic sensitisers
114
. An ideal PS
114, 119
 would have the properties listed in 
Table  1.3. 
Chemical Property Biological Reason for Property 
Chemically pure and of known constant 
composition. 
To effectively test, understand and 
formulate the PS. 
Minimal or no dark toxicity. To minimise damage to healthy tissue. 
Appropriate balance between 
lipophilic/hydrophilic characters. 
Rapid excretion from the body. Target 
localisation to minimise the damage to 
neighbouring healthy tissue. 
High singlet oxygen quantum yield (. 
To enable the efficient generation of singlet 
oxygen. 
A high molar absorbance at longer 
wavelengths. 
Longer wavelengths of light penetrate 
deeper into tissue (see Figure  1.6).  
Easy to dissolve and stable in aqueous 
media at physiological pH.  
To avoid aggregation of the PS and aid in 
drug administration. 
The pharmacokinetic elimination from the 
patient should be rapid i.e. less than one 
day. 
To avoid the necessity for post-treatment 
protection from light exposure and 
prolonged skin photosensitivity.  
Table ‎1.3: Properties of an ideal PS 
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Some common basic structures of PSs are represented in Figure 1.11. The majority of the 
PSs used in PDT are based on cyclic tetrapyrroles. However, the existence of efficient PSs 
such as methylene blue (MB) and indocyanine green suggest that it is not a prerequisite 
that efficient PDT agents possess similarities to naturally occurring porphyrins.  
 
 
Figure ‎1.10: Some basic structures of PSs 
 
Some photodynamic sensitisers cause cell death directly, while others cause cell death via 
vascular shutdown, thus depriving the cell of nutrients and oxygen. The exact means of 
tumour destruction depends on the specific PS, light dose used and localised oxygen 
concentration, which can vary depending on existing physiological conditions 
114, 123
. 
 
33 
 
Although there are numerous naturally occurring and synthetic agents which can act as 
PSs, very few have progressed to the commercial market, and hence, into clinical practice. 
Each PS has its own specific characteristics that can benefit patients but none of the PSs 
are totally acceptable. Below is a summary of few common drawbacks of clinically 
available PSs: 
 
- Hydrophobicity  
- Difficulty of synthesis 
- Suboptimal pharamacokinetic half life 
- Lack of specificity 
- Normal tissue uptake 
- Dark toxicity 
- Suboptimal wavelength for activation 
 
An excellent review by Konan et al. summarises the current state and the potential of PS 
delivery in PDT
133
.  
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1.3.7 Cancer 
It is estimated that about one in three people now living will develop some type of cancer. 
Cancer is an abnormal growth of cells caused by multiple changes in gene expression 
leading to deregulated balance of cell proliferation and cell death and ultimately evolving 
into a population of cells that can invade tissues and metastasize to distant sites causing 
significant morbidity and if untreated death of the host. One of the main problems in 
treating cancer is the inability to selectively target tumour cells and tissues
134
 without 
resulting in severe side effects to healthy tissues and organs. However, in treating this 
complex multiple abnormal cell growth, tumour vasculature has been identified as a 
potential target since the 1970’s52. 
 
In healthy tissue, the smooth muscle layer plays a significant role in responding properly to 
vascular mediators such as adrenalin and acetylcholine calcium. Autonomic nervous 
system and vascular mediators via receptors on smooth muscle cells generally control the 
muscle tone. Muscular tension surrounding the vessel walls achieving a constant blood 
flow, volume and blood pressure maintains the vascular tone. However, this refined system 
does not function in tumour vasculature. There is a highly abnormal transport dynamic 
across tumour capillaries. Further, significantly enhanced or almost unrestricted leakages 
of plasma proteins from the luminal side of the wide endothelial gap openings with large 
pore sizes are apparent in these tissues. Frequent signs of tumour tissue are blood vessels 
that are irregular in shape, leaky, defective, dilated, abnormal or missing perivascular cells, 
basement membrane, deficiency of smooth muscle layer in the vascular wall, vessels with 
fairly wide lumen, lack of functional lymphatics and lymphatic drainage. Angiogenesis 
supports the abnormal tumour growth and due to over expression of the vascular 
permeability factor/vascular endothelial growth factor gene, enhanced permeability and 
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retention (EPR) effect is apparent in all solid tumours. Hence, passive targeting should be 
appropriate to treat most solid tumours. Active targeting has the potential to selectively 
eradicate the tumour cells through specific binding of targeting moieties linked to a drug 
vehicle with tumour-derived specific markers. However, the drug needs to be first 
extravasated, as the tumour cells are generally located outside of microvasculatures
135
. Due 
to the deteriorated lymphatic system, the concentration of any introduced 
macromolecules/lipids would remain high for longer periods; the rate of accumulation of 
substances in tumour tissue is inversely proportional to their clearance rate. Thus, to 
conclude the EPR effect entails not only the passive delivery but also prolonged retention 
of macromolecular drugs over weeks or even months
134
. 
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1.3.8 PDT for Cancer 
PDT tumour destruction can be caused mainly by combination of the following three 
mechanisms. However for long term tumour control, a combination of all three would be 
suitable
136
: 
1. Direct tumour destruction 
- ROS that are generated by PDT can kill tumour cells directly137. However, 
obtaining complete tumour eradication is not always possible due to (a) non-
homogeneous distribution of the PS in the tumour and (b) shortage of available 
oxygen in tumour. 
 
2. Tumor vasculature shutdown  
- The viability of the tumour tissue depends on the nutrients received via the blood 
vessels and abnormally enhanced neovascularisation is the characteristic of tumor 
progression. In recent years, the focus on the tumor vascular shutdown has led to 
two novel therapeutic advancements, vascular targeting and anti-angiogenesis. 
 
3. Anti-tumor immune response 
- The formation and maintenance of blood vessels depend on growth factors 
produced by tumour or host cells. By activating an immune response against 
tumour cells, the intensity and nature in different tumour and normal cell immune 
response could contribute to PDT selectivity
136
. 
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1.4 NPs as delivery agents for PDT  
The main objective in the development of nanotechnology in PDT is to obtain targeted and 
efficient delivery of the appropriate levels of therapeutic or diagnostic agents for improved 
therapeutic efficacy, with reduced side effects to the patient. Different types of NPs, their 
recent developments, fundamental limitations and potential for improvement are reported 
in recent reviews
138-145
.  
 
1.4.1 Silica NPs 
Control of mesoscopic order, pore dimensions in the (macro) molecular size range, pore 
volume and surface area, morphology and selective surface functionality including 
attachment of any moiety against tumour cells are all possible with mesoporous silica NPs 
(MSNs). This robust, biodegradable ceramic matrix also has the potential to incorporate 
drugs, proteins, imaging agents and PSs. Brevet et al. designed a functionalised MSN by 
covalently anchoring a PS (porphyrin) to the surface of the NP and targeting cancer cells 
with mannose attached to the surface
146
. Through mannose dependent endocytosis and 
control experiments with non-functionalised NPs, they proved that these MSNs presented 
a much higher photodynamic effect in human breast adenocarcinoma (MDA-MB-231) 
cells. Advances of MSNs in biomedical applications, with a special focus on cancer 
therapy and diagnostics were reviewed in detail recently
147
.  
 
Hydrophobicity, charge and the size of PSs play a significant role in nanoparticle 
encapsulation. Gupta et al. studied this relationship recently using organically modified 
silica NPs (ORMOSIL)
148
. They did some comparative studies on the above factors, 
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photophysical characteristics and release kinetics to determine the possibility of using 
ORMOSIL NPs in PDT.  
 
PS encapsulated silica NPs have also been reported to excel in in vitro cell kill
149
. Liu et al. 
recently published a good review outlining few specific functionalised silica NPs as 
drug/gene delivery systems that have been applied in human disease therapy or detection 
(molecular and cellular imaging)
150
. 
 
1.4.2 Magnetic NPs 
Magnetic NPs in PDT have an exclusive advantage due to the dual functionality of the 
system i.e. simultaneous magnetic resonance (MR) detection and fluorescence imaging. 
Photosensitisers (i.e. Chlorin e6) can be covalently anchored on to the surface of a 
magnetic NP to enable near infrared fluorescence imaging, MRI and PDT in a single 
species
151
. Also, a recent study by Wang et al. reported the development of a 
multifunctional magnetic NP system with dual-imaging (MR and optical) capabilities 
(superparamagnetic magnetite NPs and fluorescent dyes were co-encapsulated inside non-
porous silica NPs), the PS (tetra-substituted carboxyl aluminium phthalocyanine) was then 
covalently linked   to the mesoporous silica shell. The surface was further modified with 
folic acid to enhance the delivery of PSs to cancer cells that over-express the folate 
receptor, also decreasing toxicity to the surrounding normal tissues
152
.  
 
Magnetic chitosan NPs tailored as a drug delivery system for PS are reported to provide 
excellent biocompatibility, biodegradability, low toxicity and water solubility without 
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compromising their magnetic targeting properties/abilities
153, 154
. They can be used in MRI 
monitored PDT, producing excellent photodynamic efficacy both in vitro and in vivo.   
 
1.4.3 Gold NPs 
Gold NPs possess unique size-dependent physicochemical and optical properties that make 
them ideal for transporting small molecules as well as biomacromolecules to diseased 
cells/tissues
155
.  
 
Russell et al. investigated a gold nanoparticle PS delivery system, where a thiol moiety 
was used to link the gold nanoparticle to a phthalocyanine, which enhanced the singlet 
oxygen quantum yield (by 50% as compared with the free PS156. This increase is 
assumed to be the result of the presence of the phase transfer agent (tetraoctylammonium 
bromide; TOAB), used to coat the particles, which increases the triplet energy transfer to 
molecular oxygen. Recently some excellent results were reported by the same group, with 
a similar nanoparticle system, but modified with PEG units and an anti-HER2 antibody
157
. 
This study confirmed the ability to generate high levels of singlet oxygen while 
specifically targeting breast cancer cells.  
 
Gold NPs can also be used as a biocompatible delivery vehicle to transport 5-
aminolevulinic (5-ALA) acid for selective and efficient PDT
158
. In this study, a 50% 
increase in cytotoxicity towards tumour cells, relative to 5-ALA alone, was reported along 
with selective destruction of tumour cells using 5-ALA-conjugated NPs in co-culture with 
dermal fibroblasts.  
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Another gold NP – hydrophobic phthalocyanine delivery study reported the passive 
accumulation of NPs using EPR effect, delivery, pharmacokinetics and excretion dynamics 
in vivo
159
. They carried out a series a quantitative chemical analysis to show that gold NPs 
themselves did not enter the cells; however the adsorbed phthalocyanine was released and 
diffused into hydrophobic areas within tissues (cellular membrane). According to this 
study, the EPR effect was the driving force to accumulate the NP conjugates. While the 
drug (phthalocyanine) localised essentially in the tumour, NPs kept circulating in the body 
and had their own bio-distribution profile until excretion.   
  
Recently, a gold nanosystem study was reported
160
 with two porphyrin-brucine quaternary 
ammonium salts, and it was observed that the gold nanoparticle-bound conjugates were 
less effective than unbound conjugates in killing cells in in vitro studies. However, with 
the basaloid squamous cell carcinoma PE/CA-PJ34 cell line, the same system was reported 
to be more effective in reducing tumour size in vivo.  
 
While there have been many developments in the area of gold NPs in recent years as  
cancer therapy and diagnostic agents, there are few challenges (biodistribution, 
pharmacokinetics and possible toxicity) that need overcoming to improve gold NPs as a 
drug delivery system
155
. 
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1.4.1 Polyacrylamide NPs 
Polyacrylamide NPs are synthesised through microemulsion polymerisation techniques 
and have been engineered for the intracellular delivery of sensors
16, 17, 23, 27, 161
 drugs and 
PSs
28, 162, 163
. Some optimistic in vivo and in vitro studies have been reported recently with 
regard to NP distribution in cells
163
 and tissue, pharmacokinetics and elimination of the 
NPs
164
. 
 
 
The PS encapsulated NP matrix has the potential to prevent the PSs from interacting or 
degrading in the physiological conditions i.e. methylene blue (MB) can be reduced to an 
inactive form by plasma enzymes and thus is not approved for systemic delivery. 
However, MB encapsulated in a polyacrylamide matrix can be used in intravenous 
applications due to the barrier between the PS and the enzymes
46
. By conjugating the dye 
with a monomer during the microemulsion polymerisation process it was also reported that 
there was a large increase in the loading of MB per nanoparticle and minimisation of dye 
leaching, which resulted in some excellent PDT effects
165
. Another interesting study was 
reported from the same group where MB was covalently loaded to polyacrylamide NPs 
while protecting the MB from the effects from the enzymes in the biological environment 
and leaching
166
. 
 
Multifunctional polyacrylamide NPs with targeting moieties i.e. Human breast cancer 
(MDA-435) cells using Photofrin
®
 and iron oxide encapsulated NPs for detection using 
MRI and treatment of cancer using PDT
167
 have shown some excellent prospects. 
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1.4.2 Quantum Dots 
Quantum dots offer great promise as an emerging material in a variety of applications in 
PDT. The key benefit of quantum dots over molecular PSs is their tunable optical 
properties and surface chemistries. Targeting and imaging using semi-conductor quantum 
dots
168
, generation of a photodynamic effect and of folic acid-conjugated QDs for targeted 
PDT
169
 have been reported. Bakalova et al. demonstrated that quantum dot anti-CD 
antibody conjugates sensitised leukaemia cells to UV irradiation and promoted the effect 
of the classical PS, sulfonated aluminum phthalocyanine
170
. QDs could be used to sensitise 
the PS through a fluorescence resonance energy transfer (FRET) mechanism, or interact 
directly with 
3
O2 via a triplet energy-transfer process (TET) in PDT
171
.  
 
An excellent review by Samia et al. assess the potential of using quantum dots and 
quantum dot conjugates as PSs for PDT while giving the recent developments in the 
preparation and photophysical characterisation of quantum dot energy transfer processes 
up until 2006
171
. Further, an interesting review by Yaghini et al. summarised the potential 
of QDs for photosensitisation in PDT compared with, and in combination with, 
conventional photosensitising organic dyes
172
.  
 
Ionisation radiation (X-rays and gamma rays) may be another novel approach to treat 
tumours in internal organs that needs a deeper penetration of light. Although less safe than 
visible light, this may be used in quantum dots and NPs to yield electrons and radicals in 
PDT
142
.   
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1.5 Photodynamic Antimicrobial Chemotherapy (PACT) 
1.5.1 Bacteria 
Bacterial cells are extremely small (1-2 μm3) and possess different shapes including 
coccus (spherical), bacillus (rod-like), spirillum (spiral) and filamentous. Bacteria fall into 
two categories, Gram-positive (e.g. Staphylococcus, Streptococcus, Enterococcus) and 
Gram-negative (e.g. Escherichia coli and Pseudomonas auroginosa).  
 
Surrounding the cytoplasmic membrane, a rigid structure of peptidoglycan gives the 
bacteria its shape. Peptidoglycan is a polymer of interlocking chains of identical monomers 
connected by interpeptide bridges. All bacteria cells are similar from the peptidoglycan 
inwards. But, depending on how the peptidoglycan cell wall is structured, bacteria can be 
divided into two major classes: Gram-positive (Gram +) and Gram-negative (Gram -) 
(Figure  1.11). 
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Figure ‎1.11: Schematic comparison of the thickness of peptidoglycan cell walls of Gram-
positive and negative bacteria 
 
In Gram-positive bacteria, the outermost membrane is made with peptidoglycan which 
makes up as much as 90% of the thick, compact cell wall, whereas in Gram-negative 
bacteria, the cell wall is more chemically complex, thinner and less compact. In Gram-
negative bacteria, peptidoglycan makes up only 5–20% of the cell wall, and lies between 
the plasma membrane and an outer membrane. This outer membrane is similar in 
composition to the plasma membrane, but is less permeable and composed of 
lipopolysaccharides (LPS)
173
. In a Gram-staining test, Gram-positive bacteria retain the 
blue-violet colour in the test (crystal violet dye) contrasting to Gram-negative bacteria, 
which does not retain the colour.  
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1.5.2 Existing Treatments of Bacterial Infections  
Chronic bacterial infection of wounds and ulcers is a major problem which costs the 
National Health Service (NHS) millions of pounds annually to treat. Orenstein et al. 
(1998)
174
 have identified the following complications associated with surface infections 
(burn wounds). Direct heat on skin makes the resulting wound susceptible to infection i.e. 
the denatured protein present in the infected site becomes rich media for bacterial growth 
and proliferation. Additionally, thermal thrombosis (an obstruction formed inside a blood 
vessel disturbing the blood flow) prevents the delivery of cellular components of the host 
defence system and systemic antibiotics to the microorganisms in the infected site. The 
proliferating organisms in the infected site may penetrate the dead tissue by moving along 
hair follicles to reach the interface between non-viable and viable tissue, which will result 
in infection of the viable tissue underneath. 
 
Generally, bacterial diseases are treated with antibiotics and antiseptics. These drugs, when 
incorporated into delivery vehicles (for example, creams and ointments), can be applied to 
the skin for local effect.  
 
But there are problems associated with these treatments including the development of 
resistance towards drugs in the targeted organisms and disruption of the endogenous 
microflora
175
. Non-targeted drug delivery could also result in collateral damage to the 
nearby healthy cells, metabolism and excretion of drugs before reaching their target, 
difficulties in maintaining an appropriate drug concentration at the target site and cell 
permeability issues
51, 176
.
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1.5.3 Bacterial Antibiotic Resistance 
A combination of rapid replication and mutation allows the microbial population to 
develop into different strains and it is this process that has led to the rise in antibiotic 
resistant strains of bacteria such as methicillin resistant Stapholococus aureus (MRSA).  
 
Gram-positive bacteria lack the outer membrane, which plays a vital role in the resistance 
to antibiotics that is displayed by Gram-negative bacteria. Thus, Gram-positive bacteria are 
more susceptible to photodynamic inactivation, while Gram-negative bacteria are resistant 
to many PSs
177, 178
. 
 
Cationic PSs have been shown to be active against both Gram-positive and Gram-negative 
bacteria, while in general, neutral or anionic PS molecules only inactivate Gram-positive 
bacteria. Cationic PSs interact at sites on the outer membrane surface at which divalent 
cations cross bridge adjacent lipopolysaccharide molecules causing a destabilisation of the 
outer membrane and allowing ingress of the PS (self-promoted uptake). Neutral or anionic 
PS molecules bind only to the outer membrane of Gram-negative bacteria and thus, do not 
inactivate them after illumination
179
.  
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1.5.4 Photodynamic Antimicrobial Chemotherapy (PACT) 
PACT has the potential for treating bacterial infections by exploiting the combination of 
the PS and the appropriate wavelength of light and molecular oxygen, to result in excited, 
toxic oxygen which damages the bacteria
179, 180
. In the last decade, different approaches to 
combine nanotechnology with PACT have been investigated: NPs can either be used to 
improve the inactivation kinetics or to improve the delivery of PSs to the bacteria
181
. 
Photodynamic inactivation of bacteria is carried out in three stages. In the first stage, the 
PS accumulates in the targeted microbial cells. Next, the infected area is illuminated at the 
appropriate activation wavelength for the PS. Finally, the singlet oxygen that is produced 
results in oxidative damage to the targeted bacteria
182
. 
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1.6 Concluding remarks 
Polymer and nano-technology have shown great potential towards revolutionising cancer 
treatment in the last couple of decades. PDT is a rapidly evolving cancer treatment with 
significant advantages. One of the key challenges faced by PDT, inefficient delivery of 
drugs, has been addressed by NP based delivery systems and has demonstrated many 
advantages with fewer side effects. Although in vitro and in vivo studies have shown 
promising results, so far no NP based PDT agents are used in the clinic. However with the 
development of suitable NPs, we might finally bring PDT to the forefront of cancer 
treatment and other potential clinical applications. 
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1.7 Aim 
 
The aim of the project was to synthesise a multiple PS delivery system based on a 
polyacrylamide nanosystem.  
 
- To develop an efficient drug delivery system based on nano-sized particles for PDT and 
PACT.  
 
- In the search for an efficient drug delivery system, a wide range of different NPs were 
investigated
34, 36-43
. This project primarily focuses on encapsulating a range of PSs (with 
different functionalities) within NPs and studying the systems behaviour in cell uptake, 
PDT and PACT.  
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1.8 Methodology 
 To accomplish the requirements, first, a nanosystem with appropriate PSs was 
synthesised.  
 Once successfully synthesised, a delivery method was developed for cellular 
internalisation of polyacrylamide NPs, which were then be qualitatively and 
quantitatively studied.  
 Following, PDT in vitro studies were carried out (i) targeting cells when NPs are 
internalised and targeting the cellular environment when NPs have definitely not 
entered the cells. This would reflect in vivo targeting internalised NPs in tumour 
cells and the tumour vasculature.  
Initially the project focused on two novel drug delivery approaches involving polymer 
based particles.  
 
 In one route, the project investigates a nanotechnology based delivery system for 
PDT and PACT agents. NPs are produced from a bio-compatible matrix, 
polyacrylamide. These polymers were chosen as they are chemically inert, have 
shown efficient drug delivery and controlled and sustained release properties. The 
microemulsion environment used in synthesising these NPs gave rise to the 
techniques reliability and reproducibility in producing NPs of controlled size. PDT 
is a promising modality for removal of harmful or unnecessary cells that has been 
recently accepted in the clinic for cancerous and non-cancerous conditions 
114, 127
.
  
A range of PSs have been synthesised with varied physical properties: size and net 
charge. These PSs have been entrapped in the polyacrylamide matrix for 
investigation. NPs combined with PSs could mitigate many of the current problems 
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associated with drug delivery in PDT including drug resistance. In the project, 
nanoparticle uptake by cells (Human Caucasian colon adenocarcinoma cell line-
HT29), has been quantified using fluorescence activated cell sorting (FACS). PDT 
cytotoxicity will be quantitatively investigated using PDT and PACT assays: 
cancer cell lines and bacteria assays and correlated with size, charge and porosity 
of the NPs carriers.  
 
 Further in this project, it is considered important to recognise the approximate 
concentration of PS present per specified weight of NPs. This would be beneficial 
in biological studies allowing direct comparisons to be made.  
 
 In the second approach, cationic hydrophilic polymers copolymerised with known 
amounts of porphyrin molecules were to be synthesised and compared with 
published results that have been obtained by attaching PSs to cationic 
polylysines
183, 184
. 
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2 Chapter 2: Investigations and synthesis of 
photosensitiser entrapped nanoparticle systems 
 
The aim of the project is to synthesise a multiple PS delivery system using polyacrylamide 
NPs to study their application in anticancer applications, i.e. PDT, and PACT. This chapter 
describes the attempts taken to synthesise/modify a number of PSs; their entrapment in 
polyacrylamide NPs, the cellular uptake and PDT cytotoxicity of the subsequent NPs.   
 
2.1 Nanoparticle synthesis and characterisation 
In this project, NPs are synthesised by adopting a well-documented microemulsion 
polymerisation method used in previous work from this laboratory
28
 and others
185
. This 
procedure facilitates synthesising porous polyacrylamide NPs that have been shown to be 
compatible with biological environments
185-191
. 
 
The synthesis is carried out in a water-in-oil (W/O) microemulsion system where the 
monomers (acrylamide and N,N’-methylenebisacrylamide) and initiators (ammonium 
persulphate (APS) and NNN'N'-tetramethylethylenediamine (TEMED)) are brought 
together in an oily phase (hexane) containing surfactants (Brij
®
 30 and dioctyl 
sulfosuccinate sodium salt). The reaction mixture is a transparent media with a continuous 
oily domain and an aqueous domain compartmentalised by surfactants
16
. Surfactants host 
the reaction and act as steric barriers, inhibiting polymerisation between droplets during 
the reaction. Hydrophilic monomers and cross linking agents are effectively incorporated 
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in the reverse micelles and their hydrophilicity dictates their presence in the aqueous core 
of the micelle droplet. APS initiates the radical reaction in the presence of the co-
monomers: acrylamide and N,N’-methylenebisacrylamide. APS is used for the generation 
of free radicals necessary for the polymerisation and is used with an accelerator, TEMED. 
TEMED enhances the formation of radicals from persulphate and they increase the rate of 
polymerisation
192
. 
 
These free radicals convert acrylamide monomers into free radicals which react with 
unactivated monomers to begin the polymerisation chain reaction
193
. It is assumed that the 
acrylamide polymerisation begins in water droplets containing monomers due to the 
initiator hydrophilicity. The polymerisation of the monomer leads to an increase in the 
viscosity of the water droplets. Initially it forms a gel and then inverts the phase of the 
W/O dispersion. When a sufficient amount of polymer is formed in the aqueous phase, a 
polymer dispersion containing water is formed due to the constant stirring of the 
microemulsion. A possible mechanism for the polyacrylamide polymerisation is shown in 
Scheme  2.1.  
 
Once initiated, the chain grows by repeated additions of the co-monomer molecules until 
the free radical site is terminated. This can occur due to several reasons
1
: 
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1. A collision mechanism  
 
- by collision of a growing particle containing a radical centre with a ‘dead’ particle 
containing a monomer combining their unpaired electrons to form a bond 
- two chain ends simply coupling together to form one long chain 
 
2. Disproportionation  
 
- transfer of hydrogen atom to give a ‘dead’ polymer molecule  
- a radical from one chain end can be abstracted to another, producing a polymer 
with a terminal unsaturated group and a polymer with a terminal saturated group 
 
3. Combination of an active chain end with an initiator radical  
 
4. Interaction with impurities or inhibitors i.e. oxygen 
 
5. If all the monomers are consumed. 
 
The number of propagation steps could vary due to several factors such as radical and 
chain reactivity, the solvent, and the temperature. 
 
The elongating polymer chains are randomly crosslinked by N,N’-methylenebisacrylamide 
which results in the characteristic porosity of the NP. The porosity also depends on the 
polymerisation conditions and the monomer concentrations. A thorough literature review 
on porosity of polyacrylamide NPs was documented by Josefsen
28
.  
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Scheme ‎2.1: Possible mechanism for polyacrylamide NP synthesis 
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The polymerisation can occur for up to 2 hours and thus the reaction typically is left 
undisturbed for two hours at room temperature, with constant stirring under a strictly 
controlled environment with argon gas. Purification of the polymeric NPs follows an 
ethanolic centrifugation after in vacuo removal of the hexane phase. The success of the 
polymerisation reaction was demonstrated by the recovery of porous three dimensional 
NPs by microfiltration.  A reaction pathway with chemical structures and reagents of the 
NP synthesis procedure is shown in Scheme  2.2.   
 
 
Scheme ‎2.2: Reaction pathway of the polyacrylamide NP preparation procedure 
  
C. Monomer solution addition 
(acrylamide, 
N,N’-methylenebisacrylamide 
D. Initiator addition  
(1. APS; 2.TEMED) 
F. Purification  
i. Centrifuge with ethanol 
     ii. Microfiltration 
A. Stir Surfactants  
 (Brij® 30 and sodium salt) under 
argon 
E. Stir the reaction for 2 hours 
under argon 
B. Addition of degassed hexane 
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To understand the suitability of the polyacrylamide NPs for use in drug delivery, first it 
was important to characterise the NPs and understand their behaviour under different 
conditions. General characterisation techniques for NPs include size and polydispersity. In 
the project the size of the NPs was determined by both TEM and PCS techniques. PCS 
technique further enabled the size distribution of the NP populations to be quantified.  
 
The NP size and size distribution were measured by the PCS using the Zetaplus
TM 
particle 
size analyser (Malvern 3000) at 25°C and at a scattering angle of 90°. To support the 
results obtained in NP characterisations, NPs were dispersed in MilliQ water. 3 mL of (1 
mg/mL dispersion) was used to obtain a dilute sample for the size measurement. NPs 
synthesised in this technique are polydisperse. To obtain an approximately homogeneous 
suspension, the NPs used in all the applications in the project were filtered through a 0.22 
µm filter unit, assuring that the size of the NPs that were used were less than 0.22 µm.  
Rapid sonication (30 seconds) was used to break up any loosely-held agglomerates. For 
NPs the intensity of the scattered light is uniform in all directions. So it was only necessary 
to measure scattering at a single angle. Thus 90° scattering angle was used in the 
measurements. The value was recorded as the average of 30 measurements. A typical size 
(Zave) distribution of a NP population is shown in Figure 2.1. 
   
58 
 
 
Figure ‎2.1: PCS spectrum of a typical NP: size distribution (zave 48 nm) 
 
Transmission electron microscopy (TEM) was used to obtain images of the polyacrylamide 
NPs [18]. The first approach to obtain images was to stain the NPs with a negative stain 
i.e. uranyl acetate. In brief, a drop of uranyl acetate (1% solution) was deposited onto a 
drop of NP suspension that was deposited on a copper grid. After few seconds and once 
the grid was dry, the heavy metal salt, uranyl acetate, was deposited around the relatively 
transparent particles causing the NPs to appear light against the dark background acting as 
a negative stain (Figure 2.2).  
 
In Figure 2.2, the visible spots are much smaller than 20 nm (scale bar). Zave of the NPs 
was 30 nm. These spots should be aggregates of uranyl acetate which either penetrated 
through porous NPs or attached to the surface during the staining procedure. The dark 
shadows seen in the image have subsequently been identified as NPs (Figure 2.3). Figure 
2.3 is an image of one of those NPs with high resolution. 
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Figure ‎2.2: TEM image of a blank NP distribution (scale bar 20 nm) 
 
 
Figure ‎2.3: TEM image of a single blank NP (scale bar 20 nm) 
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The quality of obtained images was further improved by imaging NPs with uranyl acetate 
entrapped within the NP itself. To synthesise uranyl acetate encapsulated NPs [23], uranyl 
acetate (1 mg, 2.4 µmol) in water (50 µL) was added to the NP reaction mixture 
(Scheme  2.2) along with the monomer/at the monomer stage. In this way, the encapsulated 
uranyl acetate can be captured in the TEM images and circumvent the need to stain NPs 
prior to imaging. Figure 2.4 shows an image of an uranyl acetate encapsulated NP. 
Suspensions prepared for TEM imaging were used in imaging almost instantly, omitting 
any opportunity for leaching.  
 
 
Figure ‎2.4: TEM image of an uranyl acetate encapsulated NP (scale bar 100 nm) 
 
Uranyl acetate entrapped polyacrylamide NP population in Figure 2.5 confirms that the 
NPs synthesised in this procedure are polydisperse. 
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Figure ‎2.5: TEM Image of a polydisperse distribution of the uranyl acetate encapsulated NPs 
(scale bar 50 nm) 
 
The method of imaging was optimised further to get a better quality image. One drop (5 
µL) of a dilute suspension of uranyl acetate encapsulated NPs was added to the glow 
discharged carbon/copper grid. In imaging, glow discharge is used to make the power unit 
(carbon coated copper grid) hydrophilic. Once this was dried, a drop of ethanol was added 
and TEM images were taken (Figure  2.6).  
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Figure ‎2.6: TEM image showing polydisperse distribution of the uranyl acetate encapsulated 
NPs in ethanol (scale bar 100 nm) 
 
When using NPs in drug delivery, NP stability in suspension and the surface charge plays 
a vital role. The colloidal suspension stability and NP stability with time were also studied 
using size as a major factor. 
 
Since in a colloidal system particles in a suspension can adhere to each other and form 
aggregates, it was interesting to observe whether or not NPs in suspension are susceptible 
to a high degree of aggregation over time. To this end, two suspensions of MB entrapped 
NPs [21] and dextran fluorescein entrapped NPs [29] were prepared with equal 
concentrations (10 mg NPs in 3 mL water). Due to the nature of the experiment, the 
suspensions were not filtered nor sonicated prior to measurement readings.   
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Size (Zave) measurements were taken at 0, 24, 48 and 72 hours by the PCS technique, 
Zetaplus
TM 
particle size analyser (Malvern 3000) at 25°C and at a scattering angle of 90°. 
The average NP size and the polydispersity increased from 37.1 nm to 76.6 nm over 72 
hours. The reason for this increase in size could be flocculation. However, the NP 
population remained a normal distribution (Gaussian distribution); size distribution of the 
polydispersed NPs still clustered around the mean (Figure 2.7). 
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Figure ‎2.7: Size distribution (Zave) over 72 hours 
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These aggregates are named ‘flocs’ and the process is called ‘flocculation’. Weak flocs can 
be stable and cannot be broken up by Brownian motion but may disperse under an external 
force such as vigorous agitation. The denser form of flocculation is named coagulation and 
the result could be sedimentation or creaming. Once sonicated for 10-20 seconds, average 
NP size decreased back to the 37 nm. The increased stability in solution confirmed the 
suitability of NPs to be used in longer experiments. 
 
Further, since the NPs synthesised in the project are expected to be used in cellular assays, 
it was important to study the stability of the colloidal system. 
 
There are two fundamental mechanisms that could affect dispersion stability. 
 
• Steric repulsion – this is obtained by adding polymers to the system to adsorb onto the 
particle surface therefore preventing the particle surfaces coming into close contact. 
 
• Electrostatic or charge stabilisation – this is the effect on particle interaction due to the 
distribution of charged species in the system. Due to the higher affinity of either cations or 
anions to one of the phases, there is usually electric charge separation occurring in 
interfacial layers. A layer of ions bound to one of the phases is called “surface charge” in a 
NP suspension; this is referred to as the charge of the NPs. 
 
Since the NPs used in the project are synthesised by polymerisation a steric repulsion was 
clearly expected
194
. In order to further understand whether there is any surface charge zeta 
potentials of the suspensions were measured. Zeta potential is a parameter characterising 
electric properties of interfacial layers in dispersions, emulsions and porous bodies.   
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NP suspensions were prepared as for size determination and were measured using the 
Zetaplus
TM 
zeta potential analyser. The pH of the samples was recorded prior to each 
analysis. The value of a single sample was recorded as the average of 10 measurements. 
Most of the suspensions synthesised in the project were of zeta potential zero or slightly 
negative {(-1)-(- 3)}. Although large voltage measurements (>25 mV) were not obtained 
for zeta potentials, Josefsen carried out a series of polyacrylamide NP stability studies and 
confirmed that the NPs synthesised using the mentioned method were stable up to 6 
months
28
. Therefore, the stability of the polyacrylamide NPs should be primarily 
controlled by steric repulsion. 
 
Due to the nature of the NP synthesis technique only hydrophilic compounds could be 
entrapped in the aqueous core of the micelle droplet of the polyacrylamide NPs. Further, 
the identified compound needs to be compatible with radical polymerisation (NP 
synthesis), i.e. the compound needs to remain active when entrapped within the polymer 
matrix and the polymerisation process should not have any noticeable effect on the activity 
of the compound.   
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2.2 Synthesis/modification of photosensitisers and probes to 
entrap in nanoparticles 
 
First, to verify the possibility of entrapping a PS in the NP matrix, commercially available 
PSs were investigated, initially the cyanine type PS indocyanine green (ICG,  
Figure  2.8) was chosen. The strong absorption band of ICG at 780 nm195 (red /IR region) 
was one of the major reasons for this selection.  An aliquot (30 µL, 1.3 mmoldm
-3
) of a 
solution of ICG (1 mg, 1.3 µmol) in water (1 mL) was added to the reaction mixture at the 
same time as the monomer mixture.  
 
 
Figure ‎2.8: Indocyanine Green (ICG) 
 
Within a few minutes of reaction initiation, the ICG colour transformed from green to 
yellow. Purification of the polymeric NPs followed an ethanolic centrifugation after in 
vacuo removal of the hexane phase. The spectroscopic analysis of the product using 
absorbance and emission spectroscopy revealed that ICG was no longer present in the NPs.  
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The ICG molecule contains a sequence of non-aromatic double bonds. The synthesis of the 
NPs follows a radical polymerisation mechanism. This raised the question whether or not 
the non-aromatic double bonds were attacked during the polymerisation reaction. 
Following this consideration, two parallel reactions were set up to find out whether or not 
the ICG was affected by the radical initiators.  
 
Experiment-1: Monomers present and initiators absent - solution contained ICG, 
surfactants, water, hexane and monomers (acrylamide and N,N’-methylenebisacrylamide) 
 
Experiment-2: Initiators present and monomers absent - solution included ICG, surfactants 
(Brij 30, sodium salt), water, hexane and initiators (APS and TEMED) 
 
Results of the experiments were as follows. 
 
Experiment-1: The solution was green in colour for the whole duration (2 hours) of the 
experiment. Spectroscopic analysis of the final aqueous media indicated the presence of 
ICG confirming that the monomers didn’t have any influence on the reaction. 
 
Experiment-2: The solution turned yellow as soon as the APS (radical initiator) was added, 
even before the addition of TEMED (initiator catalyst). The solution was stirred for 2 
hours followed by spectroscopic analysis. The characteristic ICG absorbance and 
fluorescence peaks were not observed, suggesting that in fact, ICG was attacked by 
initiators in the radical reaction. It was concluded therefore that ICG was not a suitable PS 
to be encapsulated into the NPs, which use ammonium persulphate as the initiator in the 
radical polymerisation reaction which forms them.  
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Kopelman et al. has recently reported the possibility of post loading ICG into blank 
polyacrylamide NPs at room temperature by adding dyes in dimethyl sulfoxide into the NP 
mixture in PBS
162
. As most of the initiators are targeted to attack double bonds and ICG 
contains multiple non-aromatic double bonds, the above method might be the only method 
to use ICG with polyacrylamide NPs. However, the aim of the project at this stage was to 
verify the possibility of entrapping a PS in the NP matrix.  
 
Following the disappointing results of ICG encapsulated NP synthesis, it was decided to 
attempt encapsulating MB (Figure  2.9), another PS with good absorbance at wavelengths 
suitable for PDT (668 and 609 nm) and with known activity in both PACT
196
/ PDT
197
, but 
which contains no non-aromatic multiple bonds. 
 
 
 
 
Figure ‎2.9: Methylene Blue (MB)  
 
In synthesising MB encapsulated NPs [21] the NP synthesis procedure was followed as 
before but in this instance an aliquot (100 L, 15.6 mmoldm-3) of a solution of MB (5 mg, 
15.6 µmol) in water (1 mL) was added to the monomer mixture to successfully obtain 
polyacrylamide particles (Zave 36 nm) (Figure 2.10).  
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Figure ‎2.10: PCS spectrum of MB encapsulated NPs 
 
Absorbance and emission spectra of MB showed no degradation and the MB entrapped 
concentration in NPs was determined using UV-vis. absorbance and the Beer-Lambert law. 
The calibration “straight” line (Figure 2.11) was plotted using the absorbance at 665 nm 
against known concentrations of MB. This calibration “straight” line was used in 
quantifying the approximate concentrations of MB present in a pre-determined weight of 
NPs (i.e. 1 mg) in 1 mL of H2O by measuring its absorbance. Due to the heterogeneous 
nature of the nanoparticles and its contents, 1 mg of nanoparticles in 1 mL of H2O was 
chosen as the standard to quantify the concentration of photosensitiser entrapped. The 
concentration of MB per 1 mg of NPs in 1 mL of H2O is 5.6 µmoldm
-3
.  
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Figure ‎2.11: MB calibration‎“straight”‎line 
 
Physically entrapped dyes in polyacrylamide NPs have previously been reported to leach 
45-50% in a 48 hour
24, 189
 period and up to 100% over seven days
189
 when in an aqueous 
suspension. Factors such as the molecular size and hydrophilicity of the dye play a 
significant role in leaching properties of the dye from a polyacrylamide matrix
187
. Smaller 
hydrophilic dyes have an inclination to diffuse out through the pores of the matrix and into 
the hydrophilic environment. However, to comply with the aim of the project, it was 
important to entrap the dyes/PSs within the NPs, minimising dye leaching into the cellular 
environment. Thus, leaching experiments were performed to quantify the leached MB 
from the polyacrylamide NPs synthesised in the project. 
 
Absorbance of the leached MB was measured to assess the porosity of the NPs. 200 mg of 
NPs were dispersed in 80 mL of MilliQ water and the dispersion was kept stirring at room 
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temperature. At given time intervals (hourly), three 2 mL samples were drawn from the 
suspension and the absorbance was measured using UV-vis. NP suspensions were 
microfiltered (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filter) and the absorbance readings 
of the leachates were analysed. Average readings at each time point before and after 
filtration were taken for 24 hours. The results indicated that MB does leach from the 
polyacrylamide matrix over a 24 hour time period and is capable of slow release (Figure 
2.12).  
 
Figure ‎2.12: Leaching study of MB NPs  
 
Percentage of leached MB was calculated using the formulae below. 
 
% Leached = (Filtrate absorbance/NP suspension aliquot absorbance) * 100 
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The calculated results indicated that nearly 90% of MB does leach from the 
polyacrylamide matrix over a 24 hour time period (Figure 2.13).  
No. of 
hours 
% 
Leaching 
0 0.00 
1 3.47 
2 9.24 
3 24.24 
4 21.18 
5 24.94 
6 31.88 
7 46.59 
8 44.35 
12 68.82 
24 87.06 
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Figure ‎2.13: Percentage leaching study of MB NPs 
 
Having successfully characterised the MB NPs the project progressed to synthesise NPs 
with further PDT agents entrapped. 
 
As discussed previously, only hydrophilic compounds can be used in the w/o radical 
polymerisation reaction (NP synthesis). Thus, the synthesis of a non-macrocyclic 
hydrophilic PS, disulphonated 4,7-diphenyl-1,10-phenanthroline ruthenium (II) chloride; 
DSRuCl (Figure 2.14) was attempted using commercially available RuCl3. The singlet 
oxygen Φ for Ru(dpp(SO3)2)3 free in solution is 0.80±0.05
191
. Although the production of 
singlet oxygen by DSRuCl is relatively modest it is still sufficient for PDT activity.  
 
RuCl3 was reacted with 3.5 molar equivalents of 4,7-diphenyl-1,10-
phenanthrolinedisulfonic acid disodium salt in deionised water and refluxed with stirring 
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for 48 hours. The colour of the reaction mixture changed from dark green to red over a 48 
hour period. The solution was cooled to room temperature, filtered and excess solvent 
removed in vacuo. The resulting red-brown solid was purified by size exclusion 
chromatography using Sephadex G25 (solvent distilled water). The bright red fraction was 
collected and concentrated in vacuo to obtain the hydrophilic DSRuCl [1]. It should be 
noted that this compound is a mixture of several isomers as SO3Na substituents on the 
phenyl rings are randomly positioned. 
 
 
 
Figure ‎2.14: Disulphonated ruthenium chloride dye (disulphonated 4,7-diphenyl-1,10-
phenanthroline ruthenium (II) chloride; DSRuCl) 
 
The characterisation of the product was determined using elemental analysis. Elemental 
analysis of the compound demonstrated some discrepancies between the expected and 
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actual results
198
. This could be accounted for by extra water molecules in the sample. A 
comparison of the expected
199
 and actual results for elemental analysis can be seen in 
Table  2.1: . 
 
Element Expected results % Actual results % 
Carbon 47.18 42.61 
Hydrogen 3.96 2.81 
Nitrogen 4.23 4.08 
Sulphur 9.69 7.88 
Table ‎2.1: Expected and actual results for elemental analysis for DSRuCl 
 
Despite the discrepancies observed between the actual and expected elemental analysis, 
the characteristic absorbance peak associated with complex formation was observed in the 
UV-visible spectrum (Figure  2.15)198, 199. The absorbance and fluorescence peaks 
(Figure  2.16) were consistent with the literature198 and no changes to the spectral shape or 
peak wavelengths were observed. The elemental analysis variation could have occurred 
due to a problem with the sample, instrumental contamination or instrumental 
inaccuracy
199
. Elemental analysis measures all material in the sample but absorbance and 
fluorescence only measure chromophoric material, so the error in the elemental analysis 
was most likely due to contamination of the sample with non-chromophoric impurities (for 
example salts). 
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Figure ‎2.15: Absorbance spectrum of DSRuCl  
 
 
Figure ‎2.16: Emission spectrum of DSRuCl  
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NPs were synthesised encapsulating the obtained hydrophilic DSRuCl [24]. In the 
synthesis, the previously developed (see above) procedure was followed with the 
exception of adding an aliquot (100 L, 2.8 mmoldm-3) of a solution of DSRuCl (5 mg, 2.8 
µmol) in water (1 mL), along with the monomer mixture. Size (zave) 58 nm (Figure  2.17). 
 
 
Figure ‎2.17: Size distribution of DSRuCl encapsulated NPs 
 
After isolation of the NP the absorbance (Figure  2.18) and emission spectra (Figure  2.19) 
of a suspension of the particles confirmed the presence of the DSRuCl. 
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Figure ‎2.18: DSRuCl before and after encapsulation - absorbance spectra comparison 
 
 
Figure ‎2.19: DSRuCl before and after encapsulation - emission spectra comparison 
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The calibration “straight” line (Figure  2.20) for DSRuCl was plotted against the 
absorbance at 461 nm for a known concentration range of the DSRuCl (solvent water). 
This calibration “straight” line was then used in quantifying the approximate 
concentrations of DSRuCl present in a pre-determined weight of NPs (i.e. 1 mg) in 1 mL 
of H2O by measuring its absorbance. The concentration of DSRuCl per 1 mg of NPs in 1 
mL of H2O was 4.0 µmoldm
-3
. 
 
 
Figure ‎2.20: DSRuCl calibration‎“straight”‎line 
  
Although the synthesised DSRuCl (hydrophilic) was successfully entrapped in the 
polyacrylamide NPs, since the DSRuCl was not 100% pure, the NPs were not used in any 
biological applications. However the compatibility of the DSRuCl in the polyacrylamide 
synthesis procedure encouraged the attempts to entrap other hydrophilic PSs. To this end, a 
small cationic porphyrin, 5,10,15,20-tetrakis-(4-N-methylpyridiniumyl)porphyrin 
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tetraiodide (PyPorphyrin), was chosen to be entrapped in the NP matrix. The porphyrin has 
previously shown good PDT/PACT activity against cultured cancer cells and bacteria
200
. 
The Adler
201
 method was adopted to synthesise 5,10,15,20-tetrapyridyl porphyrin 
(Scheme  2.3). Briefly, pyrrole and pyridine-4-carboxyaldehyde were refluxed in propionic 
acid for 30 minutes and the reaction mixture was left to cool down to room temperature 
and filtered. The resulting solid was washed with methanol to yield 5,10,15,20-tetrapyridyl 
porphyrin as a purple solid. Subsequent functionalisation to achieve hydrophilicity was 
obtained by methylation of the pyridinium nitrogen atoms by adding excess iodomethane 
to a solution of the porphyrin in dimethylformamide (DMF). The reaction mixture was 
stirred for 17 hours at 40°C. After cooling, the product was precipitated and washed with 
diethyl ether to remove any remaining iodomethane. The product recovered was re-
precipitated from acetone:water (1:1) to obtain PyPorphyrin [2] as a purple crystalline 
solid in a 98% yield (Scheme  2.3).  
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Scheme ‎2.3: PyPorphyrin synthesis 
The porphyrin was then entrapped in polyacrylamide NPs [26] using the polyacrylamide 
NP synthesis procedure described (see Scheme 2.2) with the exception of the addition of 
an aliquot (100 L, 4.2 mmoldm-3) of a solution of PyPorphyrin (5 mg, 4.2 µmol) in water 
(1 mL), along with the monomer mixture to the hexane solution (zave = 48 nm). The 
absorbance (Figure  2.21) and emission spectra (Figure  2.22) confirmed that the 
PyPorphyrin was compatible with the radical polymerisation procedure.  
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Figure ‎2.21: PyPorphyrin before and after NP encapsulation - absorbance spectra 
comparison  
 
 
Figure ‎2.22: PyPorphyrin before and after NP encapsulation - emission spectra comparison 
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A calibration “straight” line (Figure  2.23) was used to measure the approximate 
concentrations of PyPorphyrin present per set weight of NPs by measuring its absorbance 
(solvent deionised water).  This calibration “straight” line was then used in quantifying the 
approximate concentrations of PyPorphyrin present in a pre-determined weight of NPs (i.e. 
1 mg) in 1 mL of H2O by measuring its absorbance. The concentration of PyPorphyrin per 
1 mg of NPs in 1 mL of H2O was 0.34 µmoldm
-3
. 
 
 
Figure ‎2.23: PyPorphyrin calibration “straight”‎line 
 
Due to the smaller size of the entrapped porphyrins they were expected to leach from the 
NP matrix when in suspension. Thus, experiments were carried out to investigate potential 
leaching of PyPorphyrin. Fluorescence readings were taken at given intervals over 24 
hours (Figure  2.24). After modest fluctuations for 6 hours the intensity started to increase.  
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Figure ‎2.24: Leaching study of PyPorphyrin NPs 
 
One of the main purposes of encapsulating/entrapping PSs in a particle matrix is to prevent 
loss of drug en route to the target tissue.  Thus, now the most crucial problem that needed 
addressing was to reduce leaching. Most of the encapsulated molecules are prone to leach 
out of the particle over time unless they are anchored within the NP core
202, 203
.  
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In principle, leaching can be minimised/stopped in two ways:- 
 
- NP modification: variation in the particle pore size 
 
To overcome leaching from the NP matrix, NP pore size can be decreased by varying the 
type and the concentration of the cross linker used in the NP synthesis
189
 covalently 
attaching the dye to the NP matrix
23
 or by adding cages or lipophilic tails
186
 to the dye.  
 
- PS modification: trapping the PS in the NPs by making the porphyrin more 
sterically bulky  
As the dyes have the potential to leach out during the final washing stages of NP synthesis, 
we proposed that by attaching the PS to a soluble anchor, such that the size of the dye 
conjugate could be increased to prevent or minimise the leaching from the NP structure. 
Following this initiative, synthesis of cationic, water-soluble and reasonably sterically 
bulky PSs were attempted.   
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2.3 Sterically bulky PS synthesis 
Sterically bulky PSs can be synthesised either by attaching a bulky group (i.e. dextran, 
polylysine or PEG) or covalently incorporating the PS into co-block polymers. 
Copolymerised porphyrins, which have shown some promising results in antibacterial 
PDT, have been obtained by attaching PSs to cationic polylysines
183,184
. Following a 
similar notion, cationic hydrophilic polymers copolymerised with known amounts of 
porphyrin molecules were investigated. The group transfer polymerisation (GTP) method 
was used in the copolymerisation synthesis.  
 
2.4 Copolymerisation of porphyrins using group transfer 
polymerisation (GTP) 
 
GTP relies on the functionalised groups methacrylate and acrylate.  Thus, it was decided to 
synthesis a porphyrin with an acrylate reaction handle.  First, it was decided to synthesise a 
copolymerised porphyrin using GTP. The procedure to synthesise 5-(4-propenoxyphenyl)-
10,15,20-triphenylporphyrinatozinc [5] was completed in three steps. 
 
- Adler method201 was used in the synthesis of 5-(4-hydroxyphenyl)-10,15,20-
triphenylporphyrin [3].  
- Zinc was inserted into the porphyrin cavity to minimise interference with the 
polymerisation process by the exchangeable inner hydrogen atoms [4].  
- Finally, the targeted acrylate group was incorporated onto the porphyrin204 [5] as 
shown in Scheme  2.4 
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Scheme ‎2.4: 5-(4-Phenylpropionate)-10,15,20-triphenylporphyrinatozinc synthesis 
 
The monomer [5] was used in the GTP polymerisation technique investigated by Dr. T. 
Georgiou’s research group at the University of Hull. Unfortunately, gel permeation 
chromatography (GPC) data indicated that the monomer did not copolymerise. The GPC 
supported the hypothesis that only the 2-(dimethylamino)ethyl methacrylate monomer 
polymerised to form a homopolymer, while the porphyrin compound did not react. This 
can be attributed to the steric hindrance of the porphyrin molecule. The porphyrin is 
relatively large and/or may be too close to the acrylamide group, thus interfering with the 
polymerisation process. Bulky monomer reagents could be expected to take longer to 
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polymerise. GPC suggested that the reference monomer polymerised but without being 
copolymerised with the porphyrin monomer.   
 
To facilitate the above unsuccessful copolymerisation reaction, the steps to consider were 
to increase the length of the link between the functional handle of the porphyrin to enable 
spacing the steric bulk of the porphyrin further from the polymerisation centre and to 
perform the reaction over a longer period. However, since the scope of this project was not 
specifically concerned with optimising this polymer reaction, the reaction was not further 
persuit. However optimising the above copolymerisation reaction would be an interesting 
area of future research. 
 
With the aim of synthesising a sterically bulky PS to entrap in the NP matrix, the project 
was directed towards synthesising a reasonably sterically bulky porphyrin by conjugating a 
relatively large group onto the porphyrin molecule. 
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2.4.1 Bulky group incorporation 
The attributes of the compound to synthesise were - that it should be water-soluble and 
have relative steric bulk in order to minimise leaching from the porous polyacrylamide 
NPs. Thus, as a starting point it was decided to synthesise a PEG substituted porphyrin. 
PEG can act as if it were 5-10 times as large as a soluble protein of comparable molecular 
weight
205
 (Figure  2.25). PEG is soluble in both organic solvents and aqueous media, is 
often used to solubilise hydrophobic drug molecules, it typically binds 2-3 water molecules 
per ethylene oxide molecule and has a high degree of backbone chain flexibility.   
 
 
 
 
 
Figure ‎2.25: Structure of a PEG molecule 
 
In order to couple PEG units to a porphyrin, it was first necessary to identify suitable 
functionalities on each of the two components. The method of Batinic-Haberle et al. 
(2006)
206
 was adopted for this purpose: monomethoxy tri(ethylene glycol) is pre-activated 
by 4-toluene sulfonyl chloride, converting it to the corresponding tosyl derivative. This 
activated 4-toluenesulfonic acid 1-(2-(2(-2-methoxy)ethoxy)ethoxy)ethyl ester (TEGTs) 
[6] can then be coupled with tetrapyridyl porphyrin to obtain 5,10,15,20-tetrakis-(4-N-(1-
(2-(2-(2-methoxyethoxy)ethoxy)ethyl)pyridiniumyl)porphyrin. To pre-activate the 
monomethoxy tri(ethyleneglycol) a dry chloroform solution was reacted with 4-
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toluenesulfonyl chloride. The solution was stirred at room temperature for 17 hours under 
nitrogen before toluene was added and the solvents removed in vacuo. The residue was 
dissolved in ethyl acetate and the triethylammonium chloride removed by vacuum 
filtration, followed by further washing with ethyl acetate, base (sodium hydrogen 
carbonate solution) and water. The crude oil was separated by flash chromatography and 
was confirmed as 4-toluenesulfonic acid 1-(2-(2-(2-methoxy)ethoxy) ethoxy)ethyl ester 
(TEGTs) by 
1
HNMR, 
13
CNMR and mass spectrometry (MALDI).   
 
The tosyl activated PEG was then treated with 5,10,15,20-tetrapyridyl porphyrin in dry 
dimethylformamide to facilitate the conjugation of the PEG to the pyridyl groups of the 
porphyrin. The reaction (Scheme 2.5) was followed by TLC and after 48 hours was 
terminated upon consumption of the starting material. Diethylether was added to the 
reaction mixture and the precipitated solid was washed with methanol. 
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Scheme ‎2.5: PEGylated porphyrin synthesis 
 
Several attempts were made to purify the product by gel permeation chromatography 
(LH20) and using a number of different solvents. However, the PEGylated porphyrin 
remained contaminated with residual tosyl PEG as indicated by 
1
H NMR.   
 
To this end, 5, 10, 15, 20-tetra-(4-tributylaminomethylphenyl)porphyrin tetrabromide was 
chosen as the next target molecule and a synthesis was designed based on previously 
reported work by Hall
207
. This involved using the Adler
201
 method to obtain  5,10,15,20-
tetra-(4-carbomethoxyphenyl)porphyrin followed by hydride reduction, bromination and 
finally the Menshutkin reaction with tributylamine (Scheme 2.6). 
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Scheme ‎2.6: 5, 10, 15, 20-Tetra-(4-tributylaminomethylphenyl)porphyrin tetrabromide 
synthesis 
 
In the synthesis of 5,10,15,20-tetra-(4-carbomethoxyphenyl)porphyrin[7], pyrrole and 
methyl-4-formylbenzoate were refluxed in propionic acid for 30 minutes, cooled and 
filtered. The crude reaction mixture was precipitated with methanol from dichloromethane 
(DCM) to obtain 5,10,15,20-tetra-(4-carbomethoxyphenyl)porphyrin  as a fine purple solid 
in 22.2% yield. The next step in the synthetic sequence, reduction of the four 
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carbomethoxy groups to hydroxymethyl groups, proved problematic. The procedure of 
Datta-Gupta (1966)
208
 was attempted.  
 
The reaction was monitored by thin layer chromatography (TLC), however only 
incomplete reduction resulted. In an attempt to optimise the reaction a variety of 
conditions were employed which are summarised below: 
 
 As lithium aluminium hydride (LiAlH4) can decompose rapidly due to a number of 
factors (i.e. humidity) the ratio of excess LiAlH4 to porphyrin was altered ranging 
from 18–200 (18, 31, 112, 115, 118, 200) molar equivalents. However, LiAlH4 
used in the experiments was always stored in a desiccator under vacuum.  
 To understand whether changing the temperature would optimise the reaction, it 
was carried out at room temperature, 30°C, 40°C and 60°C (reflux).  
 The reaction was also carried out for different lengths of time from 2 hours - 4 days 
analysing the progress by TLC. 
      - 2 hours refluxing; 18 hours at room temperature; 18 hours refluxing; 41 hours at 
room temperature; 41 hours refluxing 
   - 48 hours at room temperature with different LiAlH4: porphyrin equivalents (molar 
equivalents of 18, 115, and 200) 
   - 50 hours at room temperature followed by one hour refluxing;  
   - 70 hours at room temperature (both LiAlH4 and porphyrin in tetrahydrofuran 
(THF) solution and very slow addition of porphyrin in THF to the lithium 
aluminium hydride solution – so that the LiAlH4 was in excess for porphyrin to 
react during the addition); 
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  - 96 hours at room temperature 
 Solvent alteration: DCM was attempted as a substitute for THF. THF was used in 
the reaction as LiAlH4 is considered to be stable in THF. However, this solvent was 
changed due to increased porphyrin solubility in DCM.  However, this substitution 
was also unsuccessful. 
 Purification methods:  
- A celite bed was used to absorb the porphyrin followed by methanol: DCM 
(30:70), water wash and drying with magnesium sulphate.  
- Acid, base, water washes followed by drying with magnesium sulphate. 
After several attempts to optimise and purify this porphyrin, the desired product [8] was 
obtained only once, in extremely low yield (1.2 mg, 1.4%). The conditions used to yield 
the desired porphyrin were: porphyrin: LiAlH4 ratio - 115; reaction condition - room 
temperature for 48 hours; purification method - celite bed to absorb the porphyrin followed 
by methanol: DCM (30:70), washed with water and drying over magnesium sulphate. 
 
5,10,15,20–Tetra-(4-hydroxymethylphenyl)porphyrin was a key intermediate and appeared 
to be accessible via a simple hydride reduction. A possible mechanism for the LiAlH4 
reduction relating to the ester reduction is shown in Scheme 2.7. Although, the mechanism 
appears to be relatively straightforward, stage (d) of the mechanism requires addition of H
+
 
to complete the reaction. The fact that this intermediate involves complexation of the 
porphyrin with the aluminium centre, combined with the presence of four reducible groups 
per porphyrin, suggested that large supramolecular structures may form, which could 
hinder access to residual carbomethoxy groups. Indeed, reduction of some proportion of 
the carbomethoxy groups always occurred but driving the reaction to completion, so that 
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there was no contamination of the tetra-hydroxymethyl product with tri-, di- and mono- 
reduction products proved impossible. This hypothesis could be a possible explanation for 
the disappointing reaction results.  
 
It is noteworthy that this particular reaction, which would seem to be useful for gaining 
access to a variety of tetra-substituted porphyrins, is referred to in only two papers in the 
literature
208, 209
: Datta-Gupta 1966 and Robic et al. 1990. 
 
 
Scheme ‎2.7: Possible mechanism for the LiAlH4 reduction of the ester 
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Due to the difficulty in obtaining pure 5,10,15,20-tetra-(4-hydroxymethylphenyl) 
porphyrin, the next step of the reaction, 5,10,15,20-tetra-(4-bromomethylphenyl) porphyrin 
[9] was aimed to be synthesised using a procedure found in the literature
210
. 
 
Briefly, 4-bromomethylbenzaldehyde and pyrrole were added to a solution of chloroform 
and after degassing the mixture for 30 minutes, boron trifluoride etherate (BF3.OEt2) was 
added and the reaction was allowed to stir at room temperature for an hour. After this 
period, triethylamine and tetrachlorobenzoquione were added, the temperature was raised 
and the reaction kept under reflux for 1 hour. The volume of the reaction was then reduced 
to approximately 250 mL and filtered through a short plug of silica gel. The product was 
obtained pure after precipitating with methanol over dichloromethane. The solvent was 
degassed under argon for 30 minutes. TLC (30:70 hexane:DCM). The product was 
confirmed by 
1
HNMR, 
13
CNMR and mass (MALDI) spectroscopy. 
 
In parallel to this experiment, the following 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-
{PEG(750)-sulfanyl}-phenyl)-porphyrin (PEG(750)Porphyrin) entrapped NPs was 
synthesised and observed leaching from the matrix. This observation ruled out taking 
forward the relatively less bulky 5, 10, 15, 20-tetra-(4-
tributylaminomethylphenyl)porphyrin tetrabromide synthesis. 
 
The attachment of a PEG chain with a high molecular weight to a porphyrin could enable 
to obtain a sterically bulky hydrophilic PS. Thus, the direct attachment of a PEG chain to 
the porphyrin molecule was explored (Scheme 2.8). A commercially available 
monomethoxy PEG (750) was first converted to its mono halide form. In the project, 
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methoxy PEG (average MW=750) chains with a primary bromide  (Figure  2.26) was 
supplied by Dr Ryan E. Mewis, The University of Hull
211
. 
 
 
Figure ‎2.26: Structure of a methoxy PEG (average MW=750) chains with a primary bromide   
 
To briefly outline the procedure: PBr3 in DCM was added to a monomethoxy capped PEG 
with an average MW of 750 dissolved in DCM at 0°C over a 30 minutes period and left 
stirring for one hour. The reaction was quenched with brine, the organic layer separated, 
washed with brine repeatedly and concentrated in vacuo to give PEG(750)Br and was 
identified by 
1
HNMR and 
13
CNMR. 
 
 
Scheme ‎2.8: 5,10,15,20-tetra(pentafluorophenyl)porphyrin and monomethoxy PEG (750) 
reaction 
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To synthesise 5,10,15,20-tetra(pentafluorophenyl)porphyrin [10] (5FPorphyrin), pyrrole 
was added drop wise to a refluxing mixture of acetic acid, nitrobenzene and 
pentafluorobenzaldehyde, refluxing was continued for 45 minutes. Once the mixture had 
cooled to room temperature, the solvents were removed in vacuo. The product was purified 
by flash chromatography (silica, eluent CH2Cl2:C6H6 3:7).  The next step of the synthesis 
was to couple the synthesised porphyrin to the PEG(750)Br (Scheme 2.8). The mono- 
halogeno PEG was reacted with 5,10,15,20-tetra(pentafluorophenyl)porphyrin and sodium 
sulphide at room temperature until all the starting material was consumed (72 hours), 
followed by TLC. The reaction mixture was quenched with saturated sodium hydrogen 
carbonate. The precipitate was recovered by filtration. The filtrate was concentrated in 
vacuo and the resulting violet oil was washed thoroughly with ethanol to yield 5,10,15,20-
tetrakis[2,3,5,6-tetrafluoro-4-{PEG(750)-sulfanyl}-phenyl]-porphyrin 
(PEG(750)Porphyrin) [11]. The porphyrin was characterised by several techniques. 
1
H 
NMR confirmed the presence of the desired porphyrin and the PEG groups. Gel 
permeation chromatography confirmed that the PEG was attached to the porphyrin (eluent 
hexane). 
19
F NMR spectra confirmed the substitution of the para-fluorine atom: the 
disappearance of the characteristic resonance of the para-fluorine atoms at -150 ppm, 
meta-fluorine atom shift from -160 ppm to -130 ppm and ortho-fluorine atoms resonances 
remaining near -140 ppm. The absorbance (Figure  2.27) and emission spectra 
(Figure  2.28) of the porphyrin before and after conjugation further confirmed the presence 
of the porphyrin in both instances. 
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Figure ‎2.27: 5FPorphyrin and PEG(750)Porphyrin - absorbance spectra comparison  
 
 
Figure ‎2.28: 5FPorphyrin and PEG(750)Porphyrin - emission spectra comparison  
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The successfully synthesised PEG(750)Porphyrin was then entrapped inside the 
polyacrylamide NPs [27]. In synthesising the NPs an aliquot (100 L, 1.3 mmoldm-3) of a 
solution of PEG(750)Porphyrin (5 mg, 1.3 µmol) in water (1 mL) was added along with 
the monomers to the NP reaction mixture (Scheme  2.2) to obtain polyacrylamide particles 
(Zave) 37 nm (Figure  2.29). 
 
 
Figure ‎2.29: Size distribution of PEG(750)Porphyrin encapsulated NPs 
 
The characteristic absorbance (Figure  2.30) and emission peaks (Figure  2.31) confirmed 
the presence of PEG(750)Porphyrin in the NPs.  
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Figure ‎2.30: PEG(750)Porphyrin before and after encapsulation - absorbance spectra 
comparison 
 
 
Figure ‎2.31: PEG(750)Porphyrin before and after encapsulation - emission spectra 
comparison 
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The calibration “straight” line for PEG(750)Porphyrin was plotted using the absorbance at 
410 nm and known concentrations of the porphyrin (solvent deionised water) 
(Figure ‎2.32).  
 
This calibration “straight” line was then used in quantifying the approximate 
concentrations of PEG(750)Porphyrin present in a pre-determined weight of NPs (i.e. 1 
mg) in 1 mL of H2O by measuring its absorbance. The concentration of 
PEG(750)Porphyrin per 1 mg of NPs in 1 mL of H2O was 0.34 µmoldm
-3
. 
 
 
Figure ‎2.32: PEG(750)Porphyrin calibration‎“straight”‎line 
 
Leaching of the synthesised porphyrin NP was studied using fluorescence spectroscopy. 
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the supernatant was analysed by fluorescence microscopy over 24 hours. Maximum 
leaching of the porphyrin from the NPs peaked at 2 hours (Figure  2.33) and the level of 
fluorescence increased with the time. The relatively high increase within the first three 
hours may suggest that the majority of loosely trapped porphyrin molecules are ‘removed’ 
from the nanoparticle suspension within this time.  
 
 
Figure ‎2.33: Leaching study of PEG(750)Porphyrin NPs 
 
Since the PEG(750)Porphyrin (MW~3900) leached from the matrix, minimising leaching 
was addressed by an approach that relies on an increase in the overall (MW 10,000) size to 
retain the dye conjugates within the matrix: the incorporation of dextran conjugated dyes. 
This approach is limited by the number of commercially available dyes.  
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Following this initiative, as a useful bulky standard in the project, a NP system loaded with 
a commercial fluorescent probe, fluorescein conjugated to a dextran polymer (MW 10,000 
Da) was designed. To synthesise the fluorescent NPs [29] the same synthetic method was 
followed as used in the production of acrylamide NPs, with the exception of the monomer 
phase. An aliquot (100 L, 50 mmoldm-3) of a solution of fluorescein conjugated to a 
dextran polymer (MW 10,000 Da) (5 mg, 50 µmol) in water (1 mL) was added to the 
hexane solution along with the monomers. Size (zave) 46 nm, emission 520 nm (ex = 480 
nm). The NPs containing the dextran-fluorescein conjugate were then used in initial 
investigations of leaching of bulky chromophores from NPs. The data from the leaching 
experiment can be seen in Figure 2.34. The sterically bulky dyes minimised leaching from 
the particles, however leaching was not completely suppressed. In the first 4 hours NPs 
clearly leach fluorescein. This could be due to the presence of surface bound fluorescein 
dextran which has leached from the complex polymeric matrix. 
 
 
Figure ‎2.34:  Leaching study of fluorescein dextran (M.W. 10,000) NPs 
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One of the main aims of the project was to study the activity of PS encapsulated NPs that 
have minimal or no PS leaching. Following from the dextran (MW 10,000 Da) fluorescein 
entrapped NPs it was decided to synthesise a variety of sterically bulky and linker 
anchored PSs suitable for incorporation into NPs. Initially, it was proposed to attach a PS 
(a phthalocyanine) to a soluble anchor, such that the size of the dye conjugate would be 
increased, preventing/minimising leaching from the NP structure. 
 
Phthalocyanines can be excited via visible light with wavelengths higher than 630 nm and 
can effect a deeper penetration into the tissue and eradication of larger tumours
212
. 
However since the size of a phthalocyanine is approximately the same as porphyrin and 
since it is now established that porphyrins do leach (Figure  2.24 and Figure  2.33) from the 
polyacrylamide NPs it was decided to conjugate a phthalocyanine molecule to a high 
molecular weight polylysine.  
 
The AlPC-tetrasulfonyl chloride reaction with 6-aminohexanoic acid published by 
Brasseur et al.
213
 was adopted to synthesise the MW 15,000-30,000 polylysine conjugated 
aluminium phthalocyanine (POLPC) [12] (Scheme 2.9). In the reaction Al-phthalocyanine 
chloride, tetrasulfonic acid and chlorosulfonic acid was stirred at 100°C for 3 hours, 
followed by the addition of thionyl chloride. The reaction mixture was allowed to stir at 
80°C for 2 hours. Once cooled to room temperature the solution was poured onto ice and 
the product was collected by centrifugation followed by filtration. The recovered product, 
Al phthalocyanine tetrasulfonyl chloride (PC), was concentrated in vacuo and added, in 
small portions, to a solution of MW 15,000-30,000 poly-D-lysine (4 equivalents) and 
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sodium carbonate in water. The solution was agitated (Vortex

) for 1 minute after each 
addition.  
 
Scheme ‎2.9: Polylysine conjugated Al-phthalocyanine (POLPC) reaction  
 
The dispersion was dialysed against PBS buffer using ultra membrane filters (MWCO 
14,000) over 4 days to remove any unconjugated PC. The absorbance and emission spectra 
of the POLPC confirmed the presence of the phthalocyanine after conjugation 
(Figure  2.35).  
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Figure ‎2.35: PC and POLPC excitation and emission spectra comparison  
 
The synthesised POLPC were then entrapped in polyacrylamide NPs (PCNPs) [30] using 
the described method. The absorbance and emission spectra confirmed that the POLPC is 
entrapped intact within the nanoparticle matrix (Figure  2.36 and Figure  2.37). It should be 
noted that all the nanoparticle suspensions were prepared in deionised water and filtered 
through a Millex
®
 GP, 0.22 µm filter unit prior to any preliminary characterisations or 
secondary experiments unless stated otherwise. 
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Figure ‎2.36: Absorbance spectrum of PCNP 
 
 
Figure ‎2.37: Emission spectrum of PCNP 
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The mean particle size, 45 (±10 nm) was determined by PCS and TEM images 
(Figure  2.38).  
 
Figure ‎2.38: TEM image of a PCNP 
 
 Leaching of the PCNP was studied using fluorescence spectroscopy. In the experiment, 
three 2 mL aliquots (hourly) were drawn from the suspension (200 mg of NPs in 80 mL 
MilliQ water), the NPs were microfiltered and the supernatant was analysed by 
fluorescence microscopy. Maximum leaching of the POLPC (MW 15,000 – 30,000) from 
the NPs peaked at 3 hours (Figure  2.39) and the level of fluorescence remained the same. 
Interestingly, this is very similar to results obtained with the MW 10,000 dextran 
fluorescein conjugate encapsulated in the same NPs. This may suggest that the majority of 
loosely trapped POLPC molecules are ‘removed’ from the nanoparticle suspension within 
this time.  The fluorescence intensity of the filtrate dropped slowly between 3-24 hours. 
Thus, it can be hypothesised that no further leaching occurred after the first three hours. 
The slight drop in the fluorescence level of the filtrate after three hours could be due to 
photobleaching due to the much smaller concentration of fluorescent material (POLPC) in 
the filtrate.   
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Figure ‎2.39: Leaching study of PCNPs (MW 15,000 – 30,000)  
 
The concentration of the entrapped PC was quantified using the Beer-Lambert law and the 
reported molar extinction co-efficient (ε) 1.5 x 105 M-1cm-1 (for Al-Pc calculated from 
absorbance at 666 nm)
214
 and  was found to be 0.41 µmoldm
-3 
per 1 mg of PCNPs (MW 
15,000 – 30,000) (ST DEV 3.5 x 10-8 moldm-3  (within 20%)). However, as the maximum 
absorbance of the PC used in the project was 680 nm, it was considered important to 
confirm the concentrations using a PC calibration “straight” line plotted against the 
absorbance at 680nm and known concentrations of the phthalocyanine (Figure  2.40). The 
approximate concentration of PC present per 1 mg of NPs in 1 mL obtained using the 
calibration “straight” line was 0.36 µmoldm-3. This was within the standard deviation 
expected above. 
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Figure ‎2.40: PC calibration‎“straight”‎line  
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2.5 Biofilms 
Although the main focus of the project was to fully entrap dyes in NP matrix, slow release 
of PSs from NPs is known to be useful in many applications, mainly in PACT
215
. Thus 
having successfully entrapped the MB in NPs and quantifying the leachate, the project 
focused on in-vitro bacterial assay development, in order to study the possibility of using 
MB entrapped NPs in PACT.  
 
There has been a variety of research carried out on the ability of NPs to circumvent 
antibacterial resistance over the years, primarily focusing on issues such as antibacterial 
drug uptake and altered drug targets
215, 216
. Unfortunately, to date these trials have not been 
successfully carried through to the clinic. This drew our attention to analysing the mode of 
action of nanoparticles in biofilms (models of bacterially infected wounds). Biofilm 
studies were undertaken in collaboration with Professor M. Wilson and his group at 
University College, London (UCL).  
 
Biofilms are colonies of micro-organisms (single or multiple microbial species) growing in 
a polymeric matrix. The reason for bacterial resistance in biofilms is rather uncertain
217
  
however inefficient penetration and distribution of antibacterial agents is likely to be a 
significant factor. It was interesting to determine whether NP delivery could enhance the 
delivery of therapeutic agents into biofilms.  
 
Fluorescein conjugated to a dextran polymer (M.W. 10,000 Da) entrapped within the NPs 
[29] were sent to Professor Wilson’s research group to observe whether the NPs were able 
to penetrate through the biofilms. The observations were made using laser scanning 
confocal fluorescence microscopy (LSCM). Biofilms were grown in 6 microtitre plates. 
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Dextran fluorescein entrapped NPs were then incubated with the biofilm for one hour. 
Confocal images were taken from above and from the side of the film (side of the well) 
and z-series acquired from top to bottom of the film (Figure  2.41 and Figure  2.42). In the 
figures the fluorescence is produced by NPs in the biofilm. 
 
 
Figure ‎2.41: LSCM image of the biofilm from side and top 
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Figure ‎2.42: LSCM image of the biofilm from side and bottom 
 
The images confirmed that the NPs do indeed penetrate through the biofilms to the bottom 
of the well. With this discovery the next step of the project was to use MB NPs in biofilms 
to use in PACT studies.  
 
Prior to using MB NPs in PACT assays, a primary bacteria assay used a Gram negative 
and Gram positive bacteria with free MB. To this end, Staphylococcus aureus and 
Staphylococcus epidermis (Gram positive) and Pseudomonas aeruginosa and Escherichia 
coli (Gram negative) bacteria were chosen as the primary bacteria assay. Bacteria cultures 
were obtained from Dr. T.Paget’s group at the Medway School of Pharmacy (Kent 
University).  
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2.6 Bacterial assays 
The initial protocol consisted of two 96 well plates: dark control and light control. Two 
organisms were assayed on one plate and the detailed protocol can be found in  5.4.7  
(Figure  2.43).  
 
 
Figure ‎2.43: Schematic diagram of the 96 well plate in relation to general bacteria protocol 
 
Briefly, overnight bacteria culture was added to each well of a 96 conical well plate 
followed by MB in distilled water and Luria-Bertani (LB) media. The cultures were 
incubated at 37°C, in an atmosphere of 5% CO2 in a humidified shaker incubator. The 
plates were centrifuged, the supernatant was removed and fresh LB added. The pellets 
(cells) were thawed and transferred to a flat bottom 96 well plate. The light controlled 
assay was irradiated with red light (40 J/cm
2
) and incubated for 30 minutes with shaking. 
The sample was irradiated (40 J/cm
2
) again and incubated at 37°C, in an atmosphere of 5% 
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CO2 in a humidified shaker incubator overnight. The dark controlled assay culture was 
transferred to a flat bottom well plate and was also incubated at 37°C in an atmosphere of 
5% CO2 in a humidified shaker incubator.  
 
Following the overnight incubation period, the absorbance of each well was taken at 630 
nm using a microtitre plate reader. 630 nm is considered one of the most appropriate 
wavelengths to measure the turbidity caused by bacteria to minimize absorbance by the 
medium because most bacterial growth media are brown or brownish-yellow. This was 
followed by a CellTiter 96
®
 aqueous non-radioactive cell proliferation assay: 20 µL of 
MTS/PMS combined reagent was added to the wells, incubated for 1-4 hours and the 
absorbance of the samples read by a micropipette reader.  
 
CellTiter 96
®
 aqueous non-radioactive cell proliferation assay
218
 is a colorimetric method 
that determines mammalian cell survival and proliferation. The reagents used in the assay 
are 3-(4,5-dimethyl thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt: MTS and an electronic coupling reagent (phenazine methosulfate, 
PMS).  
 
The cells reduce MTS into formazan which is soluble in tissue culture medium (Scheme 
2.10). Hence, this method can be used to measure the cytotoxicity, proliferation or 
activation of cells. The absorbance of formazan is measured at 490 nm and consequently 
can be read using a micropipette reader. The quantity of formazan produced is directly 
proportional to the number of living cells in culture. 
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Scheme ‎2.10: MTS conversion to formazan in the MTS assay 
 
The MTS assay is capable of providing quick
219
 results and doesn’t include any radio-
isotopes that are typically used in killing assays or washing steps. The above protocol was 
repeated 3-5 times using the described conditions and parameters. The assays were 
prepared in triplicates. Unfortunately, no significant differences between the dark and light 
controls were observed with any of the organisms used. Hence, the protocol needed 
optimising. 
 
Generally, in a bacteria assay post-PDT treatment, the bacteria culture needs incubating 
over night before the absorbance of the system is measured. Further, in measuring 
absorbance, to avoid any false readings, the turbidity of the culture should be at a low 
level, even at 100% growth (bacteria on its own in culture, without PS). Usacheva et al. 
have demonstrated due to scattering effects how the absorbance peak of MB (both at 631 
and 665 nm) progressively decreased, reached a minimum and began to rise again when 
high concentrations of Gram-negative bacteria [more than 10
9
 CFU/ml (colonies on the 
plate)] were added to the dye solutions
220
. Hence, before optimising the protocol it was 
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important to determine the bacteria concentration in the media that would be suitable for 
measuring absorbance. 
 
The light doses used to irradiate the culture were varied according to the light source and 
PS concentration chosen. The light sources used were Omnilux
®
 EL1000A with a 
wavelength of 633 ±3 nm and Oriel Model 66188 wavelength set from 550 to 2000 nm. In 
PDT treatments it is important to achieve a balance between the PS concentrations, light 
dosage and the light source. Further, the chosen PS, MB, can behave differently under 
certain circumstances, such as increasing dye concentration, presence of anionic polymers 
(chromotropes) or inorganic salts. In short, MB is a methacrymatic dye - appears different 
colours depending upon the wavelength of light under which they are viewed which results 
in different spectra. Generally, the accepted criteria for these changes (metachromasy 
effect) are a shift in the absorption maximum of the dye to a shorter wavelength 
(hypsochromic effect) and a decrease in its molar absorbance at the long wavelength 
absorption maximum (hypochromic effect)
220
. This is due to electrostatic and hydrophobic 
interactions between the dye molecules and the nearest partner and the interaction of the π-
electrons between adjacent dye molecules. These interactions result in dye aggregation, 
which in some cases is restricted to dimerisation
221
: the process by which two molecules of 
the same chemical composition form a condensation product or polymer. Usacheva
220
 et 
al. established that the spectral behaviour of increasing concentrations of MB was due to 
these metachromatic effects and was caused by the increase in dye concentration. The 
effect on MB in distilled water results in an enhancement of the dye dimerisation with 
increased concentrations
221
. Furthermore, it has suggested that low-level light irradiation 
may proliferate cell growth under certain conditions during a set of photochemical 
reactions, this is referred to as biostimulation
222
. However, phototoxic inhibitory reactions, 
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post-irradiation of natural or artificially inoculated cells, are possible with the appropriate 
dosage of light. Hence, it was vital to determine the appropriate light and dosage to 
stimulate a phototoxic effect using MB.  
 
Further, the incubation time of a bacteria culture loaded with a PS is a significant factor. 
Additionally, the cell washing step is an important one in photodynamic experiments to 
remove any unbound PS from the bacteria wall in order to avoid any false positives. 
Bacterial organisms were tested to confirm their identity using several tests. Gram positive 
and Gram negative bacteria are differentiated according to a particular staining procedure. 
The technique was developed by Christian Gram, a Danish bacteriologist in the 1800’s. 
The Gram stain protocol involves the application of a series of dyes. The detailed 
procedure is as described below. The dyes stain some bacteria purple (Gram-positive) and 
others pink (Gram-negative). In a Gram-staining test Gram-positive bacteria retain the 
blue-violet colour in the test (crystal violet dye) contrasting to Gram-negative bacteria, 
which does not retain the colour.  
 
For the staining test (Table 2.2) a heat-fixed bacteria smear was prepared. A clean 
microscope slide was passed through a Bunsen flame twice to ensure that the slide was 
free of grease and contamination. A small sample of overnight bacteria was mixed with a 
drop of distilled water and placed in the middle of the slide. Once the sample was air dried 
(using a forceps to minimise contamination) the slide was passed rapidly through the 
hottest part of the flame and then cooled. 
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Procedure Rationale 
Flood the slide with crystal violet Primary stain 
After 1 minute rinse the slide with distilled  
water 
To remove any excess stain 
Flood the slide with iodine Iodine is a mordant that binds with crystal 
violet, rendering it unable to exit the Gram-
positive peptidoglycan cell wall 
After 1 minute rinse the slide with water To remove any excess stain 
Flood the slide with acetone  
 
Acetone is a decolouriser that removes the 
stain from the Gram-negative cells 
After 2-3  seconds rinse the slide with water Do not leave the decolouriser on too long or 
it may remove stain from the Gram-positive 
cells as well 
Floodslide with safranin The counter stain 
After 1 minute rinse the slide with water To remove any excess stain 
Gently blot the slide dry  To view under oil immersion (x1000) with a 
bright-field compound microscope 
 
Table ‎2.2: Procedure and the reason for the Gram staining test 
 
After the staining procedure and having retained the primary stain, Gram-positive cells 
appeared purple, whereas Gram-negative cells appeared pink, retaining the counter stain 
after the primary stain is removed by the decolouriser. The test was carried out in order to 
identify all four organisms that were tested in the project: Staphylococcus aureus (Gram-
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positive), Staphylococcus epidermis (Gram-negative), Pseudomonas aeruginosa (Gram-
negative) and Escherichia Coli (Gram-negative).  
 
Having confirmed the Gram charge of bacteria, they were further characterised. The API
®
 
20 E system (Figure  2.44) following the procedure described in API® 20 E system  5.4.6.1 
was used to identify and confirm the presence of Escherichia coli. This is a standardised 
system containing 20 microtubes of dehydrated substrates to identify Enterobacteriaceae 
and other non-fastidious Gram–rods which use 21 miniaturised biochemical tests and an 
international database.  
 
 
Figure ‎2.44: API
®
 20E Strip 
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Every microtube on the API
®
 20E strip represents a test (Table 2.3).  
Test 
sequence 
Biochemical test API abbreviation 
1 o-Nitrophenyl-f8-D-galactosidase ONPG 
2 Arginine dihydrolase  ADH 
3 Lysine decarboxylase  LDC 
4 Ornithine decarboxylase  ODC 
5 5 Citrate utilization  CIT 
6 H2S production  H2S 
7 Urease URE 
8 Tryptophan deaminase  TDA 
9 Indole production  IND 
10 Acetoin production  VP 
11 Gelatinase GEL GEL 
12 Glucose fermentation  GLU 
13 Mannitol fermentation  MAN 
14 Inositol fermentation  INO 
15 Sorbitol fermentation  SOR 
16 Rhamnose fermentation  RHA 
17 Sucrose fermentation  SAC 
18 Melibiose fermentation  MEL 
19 Amygdaline fermentation AMY 
20 Arabinose fermentation  ARA 
 
Table ‎2.3: API
®
 20E biochemical tests 
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Staphylococci are perfectly spherical cells about 1 µm in diameter. Staphylococcus aureus 
form fairly large golden yellow colonies on agar whereas S. epidermidis forms a relatively 
small white colony. Further identification was possible using API STAPH strips. Roughly, 
the same procedure that was used for API
®
 20E was adopted in performing the API 
STAPH test. The strip was prepared in the same way as API
®
 20E, creating a humid 
atmosphere and the detailed of this test can be found in  5.4.6.2. Every micro tube on the 
API (Table 2.4) STAPH strip represents a test and the Staphylococci strains were 
identified. 
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Test 
sequence 
Active ingredient Test 
1 No substrate 0 
2 D-glucose  GLU 
3 D-fructose  FRU 
4 D-mannose MNE 
5 D-maltose MAL 
6 D-lactose (bovine origin)  LAC 
7 D-trehalose TRE 
8 D-mannitol MAN 
9 xylitol  XLT 
10 D-melibiose  MEL 
11 Potassium nitrate  NIT 
12 ß-naphthyl phosphate PAL 
13 Sodium pyruvate VP 
14 D-raffinose RAF 
15 D-xylose  XYL 
16 D-saccharose (sucrose) SAC 
17 methyl-αd-glucopyranoside MDG 
18 N-acetyl-glucosamine NAG 
19 L-arginine ADH 
20 Urea URE 
Table ‎2.4: API STAPH biochemical tests 
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Pseudomonas aeruginosa was preliminarily identified by its rod shape and grape-like 
odour. This was further confirmed by its characteristic feature- the ability to grow at 42°C. 
 
Once the bacteria had been tested, protocols with different concentrations of bacteria and 
MB were developed. However, a significant difference in the PDT effect (between the 
dark control and light control) could not be observed even with the optimised bacteria 
protocol. The final optimised protocol is detailed in  5.4.8. Throughout the experiment it 
was very important to protect both the dark and light control plates from any light (as 
practically as possible) in order to minimise any unwanted PDT effect on the cultures 
except from desired effect (the light irradiation on the light controlled plates). Due to the 
rapid growth of bacteria it was vital that pipetting was done with extra care to avoid any 
false absorbance readings.  
 
The best results from Gram-positive bacteria - Staphylococcus aureus (Figure  2.45) and 
Gram-negative bacteria - Pseudomonas aeruginosa (Figure  2.46) are as below. According 
to the results, Staphylococcus aureus showed a significant difference between the dark and 
25 µM will be considered as the optimum MB concentration for future experiments/assays. 
12.5 µM concentration will be considered the optimum MB concentration for future 
Pseudomonas aeruginosa experiments/assays. 
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Figure ‎2.45: Staphylococcus aureus MTS reduction assay 
 
 
Figure ‎2.46: Pseudomonas aeruginosa MTS reduction assay 
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Even with the optimised protocol the bacteria kill was not satisfactory. However, a minor 
difference between the dark and light controls was observed. Due to the time restraints and 
with the intention of accomplishing the goal of the Project: to synthesise a multiple PS 
delivery system using polyacrylamide NPs and exploit its application in anticancer 
applications, the Project required more focus on investigating the biological effects of the 
PDT agents that were entrapped in NPs to establish an efficient and universal delivery 
system.  
 
With this unsuccessful experiment series the project moved towards determining if 
PCNPs, the most successful entrapped PS in the project so far, could be internalised into 
cells via natural uptake. 
 
As mentioned in Chapter 1 endocytosis is one of the major pathways of nanoparticle 
uptake by cells
91-93
. This process is both concentration and time dependent. Uptake of NPs 
via endocytosis can occur through phagocytosis, fluid phase pinocytosis or receptor 
mediated endocytosis. NPs less than 200 nm are known to be imported into cells by 
pinocytosis while larger particles (>500 nm) are internalised through phagocytosis
99
. 
Panyam and Labhasetwar reported no phagocytic activity with NPs approximately 100 nm 
in size
90
.    
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2.7 Nanoparticle Cell Uptake – Quantification 
It was found that polyacrylamide NPs do accumulate in cells provided they are incubated 
with cells for a sufficient time period. To this end, flow cytometry was used to develop a 
method for quantifying the NP uptake. Flow cytometry measures and analyses multiple 
physical and optical characteristics of individual cells/particles as they flow in a fluid 
stream through a beam of light.  
 
Fluorescence-activated cell sorting (FACS) was used to sort the heterogeneous mixture of 
cells, with and without the NPs. FACS is based upon the fluorescent and light 
characteristics of the system and provides an objective and quantitative measure of 
fluorescent signals from individual cells as well physically separating the cells. The main 
parameters of FACS include: fluorescence intensity, particle size, granularity or internal 
complexity by the degree of forward scatter produced by the laser passing through the 
cell/particle.  
 
To identify FACS as the method to quantify the internalisation it was important to identify 
that the blank NPs on their own do not appear as a population on their own and do not 
fluoresce. To this end, a NP suspension (made in water) was run through the flow 
cytometer and the resulting FSC, SSC and fluorescent plots were empty. Further more it 
was important to find out whether the media that the cells were to be grown (McCoy’s 
media supplemented with 10% fetal calf serum (FCS) and 1% L-glutamine (all purchased 
from PAA)) fluoresced. Fluorescence – 1 detector (FL1, 515-545 nm) detected some 
fluorescence; however this was easily nullified by updating the settings of the FL1 
detector. Further, by using a cell-only sample as a negative control at each time point any 
interference from the environment would be avoided. 
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2.7.1 Fluorescein dextran (MW 10,000 Da) entrapped NP uptake 
Before studying the uptake of the synthesised PCNPs it was aimed to study NP uptake 
with a reference dye (fluorescein dextran (MW 10,000 Da) entrapped within the NPs. The 
human Caucasian colon adenocarcinoma cell line (HT29) was chosen for the cell uptake 
studies due to the large amount of data published on PDT effects of PSs using these 
cells
223
. 
 
The NPs were prepared using the method described in chapter  5.2.12. The average size of 
the synthesised NPs (Zave) was 45 nm. Fluorescein was chosen due to the close match of 
the excitation and emission properties of fluorescein with the argon ion laser and detectors 
found in commercial flow cytometers. NPs entrapped with fluorescein conjugated to 
dextran were used so that minimum fluorescein would leach into the aqueous media (due 
to the high molecular weight).  
 
A time course experiment was carried out by setting up controls (cells only) and samples 
(cells and NPs). Cell-only controls contained 50,000 cells in 400 µL of McCoy’s media 
(complete) and each sample contained 50,000 HT29 cells and 5 mg of filtered (through a 
220 nm filter) dextran conjugated fluorescein encapsulated NPs in 400 µL media (i.e. 5 mg 
of NPs in 200 µL media were added to a sterile sample tube containing 50,000 cells in 200 
µL media). 
 
Both the control and NPs samples were incubated at 37°C in an atmosphere of 5% CO2 
within a humidified incubator. Every 15 minutes duplicate sample tubes and a control tube 
were taken out of the incubator, washed and resuspended in PBS/BSA/azide before 
preparation for flow cytometry. 
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Since both endocytosis and exocytosis are energy dependent functions
93
 washing steps 
were considered to have a minimal
224
 and/or constant effect on nanoparticle uptake study. 
Further, it should be noted that the HT29 cell line used in the experiment naturally divides 
with time effectively reducing the quantity of NPs in each cell by a factor of two with each 
division
189
, which could potentially impact on the internalisation studies. 
 
Following incubation, 4 mL of PBS/BSA/azide was added to all three tubes, the cells were 
pelleted by centrifugation at 404 x g for 5 minutes. The supernatant was removed and 
discarded and the cells were resuspended in 1 mL of PBS/BSA/azide and transferred to a 
clean tube. The cells were washed again by adding a further 3 mL of PBS/BSA/azide. The 
cells were pelleted by centrifugation at 404 x g for 5 minutes. The wash procedure was 
repeated twice more before the cells were resuspended in 200 µL of PBS/BSA/azide. 
Repeated washing steps washed away most of the fluorescein or NPs present in the 
surrounding media. Further, to quench any extracellular fluorescence, 10 µL of Trypan 
blue 4% was added to the washed cells to differentiate between membrane bound and 
internalised NPs. 
 
After 5 minutes the cell suspension was loaded into a haemocytometer to count the cells. 
Trypan blue quenches extracellular fluorescence
225
 therefore guaranteeing that any 
fluorescence seen was due to the internalised NPs and not due to those merely attached to 
the cell surface. Results were then acquired using a Becton Dickinson FACS Calibur
TM
 
flow cytometer with the following settings: forward scatter (FSC) E -1 752, side scatter 
(SSC) 369; fluorescence (FL1) log 415; fluorescence (FL2) log 550. A minimum of 
10,000 cells was measured in each sample. 
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The fluorescein loaded NPs were detected in the fluorescence level (FL1) channel of the 
flow cytometer. Analysis was performed using CellQuest Pro V software (Becton 
Dickinson) and histograms plotted of FL1 fluorescence vs cell counts for each time point 
(Figure  2.47).  The cell-only sample provided the negative control at each time point.  
 
A gate was drawn on this control (M1) which contained less than 3% of the cell population 
(i.e. sample No.005 on Figure  2.47). The M1 gate was then copied and pasted onto the 
histogram plots generated from the cells plus NPs at each time point.  Statistical analysis 
then determines the percentage of cells within the M1 gate, i.e. the percentage of cells 
containing fluorescent NPs. The M1 gate is always relative to the negative control at that 
particular time point. The experiment was continued for 4 hours. 
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Figure ‎2.47: An example of a FACS reading * 
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*Key:  
- Purple - negative control 
- Pink and green - duplicate representation of cells incubated with fluorescein NPs 
- Sample 5 - negative control (cells only) 
- Sample 6 & 7 (cells and NPs) 
Recorded uptake % at any given point is the difference between the sample and the 
negative control. 
 
NP uptake was measured as a percentage of fluorescence detected (by FL1) in the cell 
population.  Two different concentrations were studied to confirm whether ‘uptake’ was 
affected by the NP concentration (Figure  2.48). 
  
 
Figure ‎2.48: Cell uptake (Fluorescein dextran NPs) over 4 hours quantified using FACS 
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Now that the uptake of NPs had been established and an oscillation pattern observed 
within the first few hours, the uptake pattern at longer incubation times was determined. 
To enable this it was important to find out the time period over which the HT29 cells can 
be kept alive under the chosen conditions.  
 
Propidium iodide (PI) is a DNA intercalator used to label the dead cells via the FL3 
channel of the flow cytometer, which measures PI signals at 617 nm. PI is membrane 
impermeant and generally excluded from viable cells. However, it has the potential to bind 
to dead cell DNA as well as to RNA. Although its molar absorptivity (extinction 
coefficient) is relatively low once the dye is bound to nucleic acids its fluorescence is 
enhanced 20 to 30 fold. Further, the fluorescence excitation maximum shifts 
approximately 30–40 nm towards the red end of the spectrum and the fluorescence 
emission maximum approximately 15 nm towards the blue part of the spectrum, exhibiting 
an adequately large Stokes shift to allow simultaneous detection of nuclear DNA and 
fluorescein entrapped NPs. Thus, PI was chosen for use in the flow cytometry experiments 
in order to determine cell death over a given period of time in the presence of NPs. 
 
Cell viability by flow cytometry was studied over 48 hours using fluorescein dextran NPs 
with HT29 cells incubated at 37°C in a humidified environment of 5% CO2. Every 3 
hours, for the duration of the experiment, duplicate sample tubes and a control tube were 
taken out of the incubator, cells washed and resuspended cells in 30 µL PI/Triton X-100 
staining solution before preparation for flow cytometry.  
 
Results were then acquired using a Becton Dickinson FACS Calibur
TM
 flow cytometer 
with the following settings: forward scatter (FSC) E -1 752, side scatter (SSC) 369; 
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fluorescence (FL1) log 412; fluorescence (FL2) log 474, fluorescence (FL3) log 427. A 
minimum of 10,000 events (counts) was measured in each sample. 
 
No peaks were observed in the FL3 and FL4 detectors. Only a FL1 peak was observed, the 
fluorescence peak of fluorescein. Although it could have been possible to continue the 
experiment and observe how much longer these cells can be kept alive under the present 
conditions, as 48 hours is generally much more time than required for assay experiments, 
the study was discontinued at 48 hours and it was confirmed that the HT29 cells can be 
used in NP assays up to 48 hours.  
 
This method could have been developed to quantify the cytotoxicity of PSs in PDT by 
using PI provided the PSs encapsulated in the NPs absorb at lower wavelengths. However, 
since the main PS that would be used in the project was a PC which absorbs at 
approximately 670 nm, the cell cytotoxicity would not be measured with PI, but with MTT 
assays.  
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2.7.2 PCNP uptake 
Next, the fluctuation of the NP net uptake by flow cytometry was studied over 28 hours 
using PCNP with HT29 cells incubated at 37°C in a humidified environment of 5% CO2 
(Figure  2.49). At every hour for the duration of the experiment, duplicate sample tubes and 
a control tube were taken out of the incubator, the cells washed and resuspended in 
PBS/BSA/azide solution before their preparation for flow cytometry.  
 
Two concentrations (3 mg/mL and 5 mg/mL) of NPs were studied and the percentage 
uptake values confirmed that NP uptake by HT29 was concentration dependent 
(Figure  2.49). 
  
According to the quantified NP uptake profile, NP uptake reaches its maximum within 18 
hours and then remains constant but with regular fluctuations. Alberola and Rädler showed 
a similar oscillation pattern in uptake of NPs by epithelial cells using fluorescence 
microscopy
226
.  
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Figure ‎2.49: PCNP net uptake with HT29 over time quantified using FACS 
   
The PCNP uptake study was carried out to develop a protocol for PDT in vitro studies. In 
PDT a PS does not need to  be internalised but mere attachment to the cells surface can be 
suffice to cause cell kill. Thus, external fluorescence does not need to be quenched.  
 
  
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 
%
 o
f 
P
C
P
O
L
 N
P
 U
p
ta
k
e
 
Time (hours of incubation) 
PCNP net uptake with HT29 over time 
PC NP - conc. 3mg/mL PC NP - conc. 5mg/mL 
139 
 
2.8 Intracellular distribution of NPs  
According to the cell uptake studies the maximum uptake of NPs should have been 
reached within 18 hours. The confocal microscopy images below display the localisation 
of the PCNP which have been incubated with HT29 cells for 20 hours and washed three 
times with media prior to imaging. The confocal images were captured by exciting at 633 
nm (Figure  2.50) by Leica Microsystems CMS GmbH (LAS AF version: 2.2.1 build 
4842). 
 
Figure ‎2.50: Confocal images of PCNP internalised in HT29 cells*  
 
*After incubating for 20 hours; A - HT29 cells only, B - PC emission, C - merged image 
B A 
C 
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Further, if a PS is to be used in PDT the polyacrylamide matrix (i.e. the NP) should 
facilitate the production and diffusion of singlet oxygen by the PS and be compatible with 
the biological environment to be able to be useful in PDT.  
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2.9 Determination of singlet oxygen production 
Singlet oxygen is known to reactive with cholesterol via an oxidation pathway to give a 
dihydroxy sterol product which can be visualised by TLC and quantified by HPLC.  
 
DCM and cholesterol 10 mM (1:9 DCM:MeOH) were added to a  PCNP (MW 15,000–
30,000 Da., 5 mg/mL MeOH) suspension. Oxygen was bubbled through the resulting 
suspension mixture which was then irradiated with white light (400 – 700 nm) for one 
hour. The mixture volume was reduced to dryness by flowing argon into the suspension. 1 
mL of MeOH was added and the suspension was filtered through a 15 nm filter (Whatman 
Nuclepore-Track Etch membrane; 25 mm, 0.015 µm). 200 µL of this solution was 
transferred to an Eppendorf
® 
tube and 200 µL of methanol was added. 1-2 crystals of 
NaBH4 were added to the solution which was left for 1 minute until complete reduction 
had taken place. The volume of the solvent was reduced to approximately 100–150 µL by 
flowing argon over the solution.   
 
TLC plate development was carried out using the method described by van Lier (1991)
227
. 
Briefly, a TLC plate was placed in a tank containing a 1:1 hexane: ethyl acetate mixture. 
The solvent was allowed to migrate 2/3 of the way up the plate; the plate was then 
removed from the TLC chamber and allowed to air dry. Once dried, the plate was returned 
to the tank and the solvent was allowed to migrate to the top of the plate and was left dry 
again. To visualise the sterols on the TLC plate, a 5% H2SO4 in ethanol mist was sprayed 
onto the TLC plate and the plate placed on a 100-120°C hot plate to allow development of 
the blue coloured spot at TLC retention factor (Rf = 0.38) indicating the presence of the 
dihydroxy product than the purple spot indicating the cholesterol starting material at Rf = 
1.0.
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The HPLC method for quantifying and analysing the singlet oxygen production was 
adopted from Osada et al.
228
.  Cholesterol and its oxidised derivatives were separated on a 
Phenomenex Luna 5 µm C18 column (250 x 4.60 mm) using a mixture of 
methanol:acetonitrile (60:40 vol/vol) mobile phase. The flow rate was maintained at 
1.0mL/ min. for 20 minutes prior to analysis. UV detection was performed at 205 nm. 10 
µL of the sample was injected manually into the HPLC analysis system and the separation 
was detected using the Azur software version 5.0.  
 
The HPLC chromatogram showed a mixture of 7α-, 7β-, 25-, 26- hydroxycholesterols, 7-
ketocholesterols. The oxidised derivatives were quantified as a percentage of the intensity 
of cholesterol (0.59%). The aim of this excercise was to quantify the singlet oxygen 
production of PS entrapped NPs and to compare it to other NPs that will be synthesised in 
the project. Thus, this value cannot be directly compared to the PC only. However, the 
above value will be used for comparison purposes (with other NPs) in the project. 
 
Since the singlet oxygen production and leaching was established and quantified, the next 
step of the project was to study the PCNP PDT cytotoxicity upon maximum 
internalisation.  
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2.10 PDT – In vitro studies (Maximum uptake) 
Prior to using the NPs in the cytotoxicity assays it was important to sterilise them to avoid 
any bacterial growth in the culture. Thus 10 mg of 15,000-30,000 M.W. PC entrapped NPs 
were added to ethanol, decanted and dried in the class II biological hood. Then, 1 mL 
McCoy’s media was added, vortexed (60 seconds), sonicated (60 seconds) and was added 
to a volume of cells (2.5 × 10
5
 cells/1 mL) in a Falcon polystyrene (12 x 75 mm) tube. As 
concluded from the uptake studies the maximum amount of NPs were internalised within 
24 hours and thereafter remained fluctuating around the maximum region. Thus, in the 
Project, the cell populations were incubated with NPs for 25 hours before preparing the 
samples for PDT cytotoxicity analysis. The volume of the media was adjusted to 4 mL and 
the supernatant discarded to eliminate any interference from NP conjugates that had not 
been internalised or attached to the HT29 cells. The volume of media was adjusted to the 
initial volume (1 mL). HT29 cells were plated with 100 µL per well in two 96 well plates. 
One row of 96 well plates with cells was used as control without the addition of NPs.  
 
One plate was irradiated with 25 J/cm
2
 [~23 min] of light from the Patterson system with a 
filter chosen to match the PC absorbance 630 nm centred. The second plate was kept in the 
dark outside the incubator while the previous plate was being irradiated. The plates were 
left to incubate overnight for 18-24 hours in the dark. To determine cell viability, the 
colorimetric MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide; 
purchased from Sigma)  metabolic activity assay developed by Mossman
219
 and 
subsequently modified by Prasad and co-workers (to incorporate a cell irradiation 
protocol
149
) was used. The cell viability was determined using a Biotek ELX80 universal 
microplate reader. 
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However, even after repeated experiments, no noticeable cell viability difference was 
observed in both the irradiated and the dark control. NPs gave 31.9% and 32.8% cell 
survival rate for the irradiated (light control) and non-irradiated (dark control) respectively. 
It is reported that ethanol has the potential to disrupt the cell membranes even when 
present in small quantities
229
. Thus, it is possible that the unpredicted cell toxicity was 
observed when incubating for longer periods due to minute amounts of ethanol present 
from the NP sterilisation step. This hypothesis was further confirmed by the cytoxicity 
results of NPs alone without the sterilisation step that showed no effect on the viability of 
the cells. The NPs ‘sterilised’ in ethanol indicated that the effect was none or minimal if 
the cells were not in contact with them for too long (<1 hour). Long contact however 
halved the viability.  
 
Thus, the experiment was repeated without washing NPs in ethanol. Without any 
sterilisation method in place the cells were contaminated with bacteria in the 25 hour 
incubation (prior addition of MTT).  
 
Following from these unfortunate results a new sterilisation approach was considered. It 
was decided to filter the NPs through a 220 nm filter syringe. The experimental set up was 
followed as described earlier with the exception of the sterilising step. After 25 hours of 
incubation cells were not contaminated with bacteria and no unexpected cell death was 
observed. However with the irradiated experiment no significant PDT toxicity was 
observed (Figure 2.51). 
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Figure ‎2.51: PDT cytotoxicity of PCNP (MW 15,000-30,000)   
at its maximum uptake 25 hr incubation period 
 
This insignificant difference could be a result of the low concentration of the PC present in 
the NPs. The concentration of PC in the NPs can be increased by either increasing the 
amount of NPs used in the assays or by synthesising NPs with more PC entrapped. 
Although, increasing the amount of NPs used in the assays seems to be the easier option, it 
was found to be problematic to make a homogeneous suspension with more NPs. Thus, 
NPs with a higher concentration of entrapped PC were synthesised.  
 
To this end, first it was attempted to synthesis three batches of PCNPs with (PC attached 
to polylysine with MW 15,000-30,000 Da) using the procedure described in 5.2.13 with 
more POLPC concentrations. However, after the washing steps the similar concentrations 
of PC were present in the NPs.  
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Thus as another approach, a relatively higher molecular weight polylysine i.e. 30,000 – 
70,000 to the PC was conjugated. In synthesising NPs with the MW 30,000 -70,000 
POLPC, three batches with different concentrations of POLPC were synthesised using the 
same NP synthesis procedure (Chapter  5.2.15) 
 
The mean particle size 45 (±10 nm) was determined by PCS and TEM. After a series of 
experiments with different PC concentrations it was found that the highest concentration of 
PC that can be entrapped in NPs was with the initial concentration 1.34 moldm
-3 
(30 
mg/mL) (Figure  2.52). 
 
 
Figure ‎2.52: NPs synthesised with different concentrations of POLPC (M.W. 30,000 - 70,000) 
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The concentration of PC entrapped has a direct correlation to the amount of singlet oxygen 
produced (for procedure details see Chapter  5.3.5). MW 30,000 – 70,000 Da PCNP 
produced 360% more singlet oxygen compared to the MW 15,000 – 30,000 Da PCNP.  
 
The concentration of the entrapped PC was quantified using the calibration “straight” line 
(Figure 2.40): 1.9 x 10
-4 
M per 1 mg of nanoparticles (ST DEV 5.09 x 10
-8
 (within 30%) in 
1 mL of H2O. Leaching experiments using these NPs showed the similar pattern to POLPC 
(MW15,000 – 30,000) study (Figure  2.39). 
 
The PDT experiments (procedure details Chapter  5.4.3) carried out also showed a 
relatively high cell toxicity (Figure  2.53). Thus, optimising the PC concentration entrapped 
in NPs was an important step in the project.  
 
 
Figure ‎2.53: PDT cytotoxicity (maximum uptake) of PCNP (MW 30,000 -70,000) 
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2.11 PDT – In vitro studies (Minimum uptake) 
NPs are reported to accumulate in tumour neovasculature due to selective retention
134
. 
Exploiting this notion in vitro HT29 cells surrounded with NPs in the extracellular media 
and at the minimum uptake time (<5 minutes) were irradiated under identical conditions to 
those used for the 25 hour uptake time. MTT assays were then performed as before and 
cell viabilities determined (Figure  2.54). 
 
The cell viability of PCNP was 33%. However, no noticeable dark toxicity was observed 
with PCNP. This result could be due to, in this instance, the NPs being mixed with cells 
only for the duration of the irradiation (approximately 90 minutes).  
 
These results are potentially very interesting from a clinical perspective as it is likely that a 
significant proportion of NPs would accumulate in the stroma of the tumour i.e. in the 
extracellular space. It is demonstrated here that if this localised NP concentration is high 
enough cancer cells can be effectively killed without the requirement that the NPs be 
internalised. 
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Figure ‎2.54: PCNP - PDT cytotoxicity (minimum uptake) 
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2.12 Summary 
The primary intent of the Project was to synthesise PSs/probes suitable for entrapping 
within NPs and to study their behaviour in cellular uptake, PDT and PACT. To this end, a 
number of PSs/dyes have been entrapped within a range of polyacrylamide NPs: MB, 
DSRuCl, PyPorphyrin. However, as leaching from the matrix was identified as a challenge 
to overcome, sterically bulky groups were attached to the PSs/probes entrapped within the 
NPs and characterised.  To this end, dextran (MW 10,000) conjugated fluorescein 
(reference dye), PEG(750)Porphyrin and PCNP (MW 15,000- 30,000 and 30,000-70,000) 
were successfully entrapped in the polyacrylamide matrix. Once the PSs/probes were 
entrapped, the NPs were characterised for their size, presence of PSs/probes within the 
NPs by spectroscopic investigation (absorbance and/or fluorescence) and the concentration 
of entrapped PSs/probes (using absorbance spectroscopy).  
 
5-(4-Phenylpropenoate)-10,15,20-triphenylporphyrinatozinc was successfully synthesised 
to be copolymerised using GTP. However, the porphyrin molecule (monomer) did not 
copolymerise in the reaction and thus, with the limited time frame of the Project this 
concept has not been pursued further.  
 
Another interesting result that was not pursued further was the NP penetration into 
biofilms. This would be an interesting area for future research. 
  
Uptake of the NPs by HT29 cells was quantified using the encapsulated fluorescein 
reference dye (fluorescein dextran 10,000MW) and PCNP. Intracellular distribution of 
NPs was determined by confocal microscopy and maximum uptake was observed after 18 
hours of incubation. Production of the main PDT agent, singlet oxygen, was quantified and 
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the PDT cytotoxicity assays were carried out using the maximum and minimum uptake 
times with the chosen NP-PCNP.  
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3 Chapter 3: Investigations and synthesis of 
photosensitiser entrapped and conjugated nanoparticle 
systems 
In addition to the synthesis of PS entrapped NPs another objective of the project was to 
selectively add features to the PS entrapped NPs. This was attempted via altering the net 
charge and lipophilic character of the NPs. This chapter describes the attempts taken to 
optimise the functionality of the most successful PS (entrapped within the nanoparticle) 
discussed in the previous chapter; PCNP (MW 30,000 – 70,000Da). Once the alterations 
have been established the effect on NP penetration and distribution in cells will be 
investigated. 
 
3.1 Surface functionalisation of photoactive NPs 
The size, composition, network porosity and surface chemistry of NPs dictate the 
selectivity and the functionality of the NPs in cellular environments. In the synthesis of 
polyacrylamide NPs in the Project, these parameters were selectively controlled by varying 
the ratio of the synthetic reagents and the microemulsion environment. The ability to 
control surface chemistry is useful in increasing the retention/circulation time of the NPs in 
the body.  
 
In targeting NPs to tumour tissue, provided the NPs can avoid sequestration by the 
reticuloendothelial system (RES), accumulation can occur in the stroma as a result of the 
enhanced permeability and retention effect
48
. Particles synthesised to avoid the RES can 
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lead to longer circulation times
230
, resulting in a greater potential to reach the site of 
interest
35
. These NPs are approximately 100 nm in size with a hydrophilic surface (to 
avoid clearance by fixed macrophages). This can be achieved by coating the NPs with 
hydrophilic polymers (i.e. PEGylation) that create a cloud of chains on the particle surface 
repelling plasma proteins
48
. To this end, there are few functional groups that can be 
incorporated into the surface of the NPs i.e. hydroxyl (OH), sulphonate (SO3
-
), carboxylic 
acid (COOH) and amino (NH2) groups or bio-reactive groups such as folate and 
antibodies. The addition of secondary functional groups can be incorporated into the NP 
surface either during particle synthesis or post-synthesis, i.e. functionalised monomers can 
be incorporated into the microemulsion reaction mixture or can be grafted directly onto the 
NP surface.  
 
3.1.1 Amino functionalisation 
Josefsen
28
 previously synthesised amino functionalised NPs (see Chapter  5.2.2 for 
procedure). In this way net charge and lipophilic character can be altered to investigate the 
effect on penetration and distribution in cells and bacteria.  The procedure differed only 
from the above described polyacrylamide NP synthesis by the addition of N-(3-
aminopropyl)methacrylamide hydrochloride (1% equivalent to acrylamide) to obtain 
amino functionalisation. A similar procedure was followed in the project to synthesis NPs 
in the range Zave 42 nm. The presence and reactivity of the primary amino groups was 
confirmed using a non-fluorescent reagent, fluorescamine (Figure  3.1). 
 
Fluorescamine reacts with primary amines to form a fluorescent product which can be 
identified through optical spectroscopy and is commonly used in the assay of primary 
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amines. The reaction is almost instant in aqueous media at room temperature and forms 
highly fluorescent products (λex. ~365 nm and λem. ~ 465-485 nm).  
 
 
 
Figure ‎3.1: Reaction of Fluorescamine and Primary Amines 
 
The fluorescence of a solution containing primary amines plus fluorescamine is 
proportional to the quantity of free amine groups present. 
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3.1.2 Amine quaternisation 
As the study of charge effects on NP uptake and biological activity was of interest, amino 
functionalised NPs were quaternised using methyl iodide (Figure  3.2).  
 
 
Figure ‎3.2: Structure of a quaternised amino group 
 
Blank amino NPs (no surface functionalisation/no PS entrapped) and methyl iodide were 
added to a dry DMF solution at 40°C under an argon atmosphere. After one hour, the 
argon supply was removed and the solution was kept stirring for 72 hours at 40°C. 
Aqueous triethylamine was added and the solution was microfiltered (Whatman
®
 Anodisc 
25, 0.02 µm, 25 mm filter). The particles were then repeatedly washed with ethanol (4-5 
times). The product was filtered and vacuum dried (5 hours) to obtain dry cationic 
polyacrylamide NPs.  
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These NPs were characterised using solid-phase 
1
H NMR and 
13
C NMR. The spectra were 
obtained using a 4 mm double resonance magic angle spinning probe on a Bruker Avance 
II. 500MHz NMR instrument and the samples were spun at 8 kHz. The chemical shifts 
were referenced externally to TMS at 0 ppm. 
 
1
H NMR suggested the presence of methyl groups (CH3) attached to nitrogen atoms, 
indicated by a characteristic peak around 3.3-3.4 ppm (Figure 3.3). In spite of the expected 
singlet, a multiplet is observed. The resolution of a MAS NMR spectrum (Magic-Angle 
Spinning Nuclear Magnetic Resonance) is generally too poor to resolve J-coupling 
splitting. However, this resonance can be attributed to the 2 CH3 groups in differing 
environments. The 
13
C NMR spectrum shows a peak around 55-60 ppm, where a CH3 
group attached to a nitrogen atom would be expected (Figure  3.4).  
 
 
Figure ‎3.3: Solid phase 
1
H NMR spectra: red - blank NPs, blue - cationic NPs 
157 
 
 
 
Figure ‎3.4: Solid phase 
13
C NMR spectra: red - blank NPs, blue - cationic NPs 
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3.1.3 Attaching a second PS  
Amino functionalised NPs can be used to conjugate a further photosensitising moiety to 
the NP. While synthesising a multi PS conjugated NP system, this would also enable a 
hydrophilic polymer cloud around the NP to be created. As discussed previously in this 
Chapter, if such a NP was introduced to human cells, this would minimise NP clearance by 
the RES pathway. In order to assemble a conjugated system of this nature, the NPs and the 
PS molecules must possess reactive functional groups capable of promoting the binding 
reaction. It was anticipated that this coupling criteria could be easily met, provided the 
functional group that would enable the desired coupling of the two components be 
accomplished and a desired hydrophilic PS is identified.  
 
Since the entrapped PS in the chosen NP is a phthalocyanine it was decided to attach a PS 
which absorbs around 400-500 nm enabling the use of a wider window in the visible 
spectrum. To this end, a porphyrin was chosen to attach to the surface of the PCNP. The 
ability to deliver more than one class of PS could be advantageous clinically as the larger 
spectral region covered could lead to more efficient absorption of light. 
 
3.1.3.1 N-hydroxysuccinimide functionalised porphyrins (NHS Porphyrin) 
Porphyrins can be functionalised while protecting the hydrophilicity of the molecule to 
enable the creation of a bifunctional system for applications such as directed delivery in 
PDT and cellular imaging tools. Following the procedure of Boyle et al.
231
 5-[4-
(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin 
trichloride [17] was synthesised. Briefly, the Rothemund reaction
232
 was followed to 
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synthesis 5-(4-carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin [14] from 4-
formylbenzoic acid, 4-pyridinecarboxaldehyde and pyrrole. At the next step, although 
activation with NHS decreases water solubility of the modified carboxylate molecule, the 
reactive arm, N-hydroxysuccinimide, was introduced to the reaction, followed by addition 
of methyl iodide to increase the hydrophilicity of the other three pyridyl groups. Increased 
water-solubility of the charged porphyrin was consequently achieved via an anion 
exchange reaction utilising the Dowex 1x8 20-400 Cl, whereby the counter iodide ions of 
porphyrin [17] were replaced by the chloride ions from the resin (Scheme  3.1). 
 
 
Scheme ‎3.1: N-hydroxysuccinimide functionalised porphyrin (NHS Porphyrin) synthesis 
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3.1.3.2 NHS Amino coupling reaction 
In order to maintain the primary amino groups of the NPs in a non-protonated (reactive 
form), it was necessary to carry out the coupling reaction in a slightly basic medium, that 
itself is free from any primary amines. A sodium bicarbonate buffer, pH 9, was first 
considered for the conjugation. The reaction was carried out ranging from a 5 minute to 2 
hours period in the basic suspension and filtered through the microfiltration kit. There 
were some practical problems faced during this step.  
 
Polyacrylamide NPs formed a creamy suspension in water which appeared to block the 
microfiltration kit (Millipore filter unit (fritted glass) with 0.02 mm, 25 mm, Whatman
®
 
Anodisc 25 filters). It was found that the creamy suspension could only be precipitated 
using very high rpm centrifuge (i.e. 60,000) for 1 hour. The product required washing at 
least 3 times to remove any sodium bicarbonate residue. These NPs were dried under 
vacuum at 37°C. However, after drying, the NPs seemed to have lost their characteristic 
suspension properties, i.e. forming a clear suspension in water, thought to be due to huge 
variations in the nanoparticle size. Freeze drying was chosen as an option to dry the NPs, 
however the NPs no longer showed suspension properties once again. 
 
Generally polyacrylamide NPs were washed with ethanol in the project. NPs, precipitate in 
ethanol without any difficulty. However, since the above experiment requires a basic 
medium, ethanol could not be used. Thus, triethyl amine was identified as a basic solution 
that would remain as a liquid in both water and ethanolic media while being compatible 
with the polyacrylamide matrix and the synthesised porphyrin.  
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3.1.3.3 Conjugation of porphyrin to NPs 
To synthesise the PCNP-P (Figure  3.5) briefly, polymer bound amino functionalised 
tetrasulfonato-aluminium phthalocyanine entrapped nanoparticles (PCNP-A) (in 
suspension) was mixed with the porphyrin engineered to bear a single amine-reactive 
succinimide–N-oxycarbonyl-phenyl group in water. An aliquot of 5-[4-(succinimide-N-
oxycarbonyl)phenyl]-10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin trichloride (500 
µL, 2.2 mmoldm
-3
) was added to a dispersion (10 mL) of filtered (Millex
®
 GP, 0.22 µm 
Filter unit) amino functionalised PC-polylysine entrapped NPs (50 mg) and triethylamine 
(250 µL). The mixture was spun in Falcon polystyrene tubes (12x75 mm) for 2 hours on a 
spinning rotator at room temperature, protected from light. The resulting suspension was 
washed with ethanol, centrifuged (7x50 mL, 10 minutes, 5500 rpm), microfiltered 
(Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) and dried for 8 hours at 40°C to yield the 
desired porphyrin conjugated PC entrapped NPs as a green solid. Yield 78% (39 mg). The 
NPs were then precipitated and washed (5 times, 50 mL) with ethanol.   
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Figure ‎3.5: PCNP –P 
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The successful conjugation of the NHS Porphyrin to PCNP-A was confirmed by clear 
absorbance peaks at 424 nm (porphyrin Soret band) and 680 nm (PC Q band) respectively 
(Figure  3.6). When excited at 424 nm, the PCNP-P emission spectra showed two clear 
fluorescence peaks (656 nm and 708 nm) corresponding to the porphyrin and a minor peak 
relative to PC at 685 nm (Figure  3.7). However, when excited at 650 nm (close to the PC 
max of 680 nm), a clear emission peak relating to the PC at 685 nm was observed 
(Figure  3.8). 
. 
 
Figure ‎3.6: Absorbance spectrum of PCNP-P  
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Figure ‎3.7: Emission spectrum of PCNP-P (λex 424 nm) 
 
 
Figure ‎3.8: Emission spectrum of PCNP-P (λex 650 nm)  
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As confirmed by PCS and TEM images the mean size of the PCNP-P was 95±10 nm 
(Figure  3.9). The size of a porphyrin molecule is 18 Å and thus the maximum size increase 
that was expected was ~36 Å. Experiments were carried out to study the reasons for this 
unexpected increase in size of PCNP-A after conjugation to the porphyrin molecule.  
 
 
Figure ‎3.9: TEM - PCNP-P 
 
One hypothesis was that the increase in the mean particle size upon porphyrin conjugation 
to PCNPs could be a result of aggregation caused by porphyrin interactions on adjacent 
particles. This type of π-π interaction could be detected in the fluorescence spectra of the 
NHS porphyrin used for conjugation and is similar to the split fluorescence peaks reported 
for the interactions with the related 5,10,15,20-tetrakis(4-N-methylpyridyl)porphyrin
233
 
(Figure  3.10). 
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Figure ‎3.10: Fluorescence spectra - 5,10,15,20-tetrakis(4-N-methylpyridyl)porphyrin 
 
Polyacrylamide hydrogels/nanogels are known to swell in aqueous environments
234
. Thus, 
an alternative hypothesis was that this effect was due to polyacrylamide swelling. In water 
the swelling is controlled by several factors:  the cross linker concentration, pH and ionic 
strength
234, 235
. However, experiments were carried out to study whether the diameter 
increase was a result of this swelling behaviour; the studies indicated that these parameters 
were not involved.  
 
Leaching studies carried out with the PCNP-P showed no filtrate fluorescence: two PSs 
(PC and porphyrin) were successfully conjugated to a polyacrylamide nanoparticle system 
(without leaching).  
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1 mg of each PCNP-P and PCNP-A were prepared in water. The absorbance spectra were 
compared to observe any differences in the PC concentration. The Q band of PCNP-P 
showed a slight decrease (15-20%) in intensity than PCNP-A (Figure  3.11).This could be 
either any loosely entrapped PC being washed away during the conjugation procedure 
and/or the mass added by the conjugated porphyrin in the total weighed sample. The 
porphyrin–nanoparticle conjugation procedure generally takes approximately 3 hours and 
the PC leached only in the first 3 hours. During the conjugation procedure it is possible 
that any loosely entrapped PC was washed away leaving only the tightly entrapped PC in 
the nanoparticle. 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.11: PCNP-A and PCNP-P absorbance spectra comparison 
 
The concentration of the entrapped PC and porphyrin were quantified using the Beer-
Lambert law and the plotted calibration “straight” lines (Figure  2.40 and Figure  3.12): 1.6 
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x 10
-4 
moldm
-3 
of PC and 1.8 x 10
-4 
moldm
-3
 porphyrin respectively for PCNP-P (ST DEV 
5.09 x 10
-8
 moldm
-3
; within 30%). 
 
 
Figure ‎3.12: NHS Porphyrin calibration‎“straight”‎line 
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3.2 Singlet oxygen production quantification 
Following the procedure described in chapter 2.9, the production of singlet oxygen by 
PCNP-P was qualitatively (by TLC) and quantitatively (by HPLC) measured. The HPLC 
chromatogram showed a mixture of 7α-, 7β-, 25-, 26-hydroxychoelsterols, 
7ketocholesterols. The oxidised derivatives were quantified as a percentage of the 
cholesterol.  This was a 20% increase in singlet oxygen production in comparison to PCNP 
(MW 30,000 -70,000).  
 
Theoretically, the singlet oxygen (
1
O2) produced via the Type II process act near to their 
site of origin, within a radius of action of approximately 20 nm. Size of PCNP-P was 
95±10 nm and PCNP was 45 (±10 nm). As the radius of the NPs is above 20 nm, any 
singlet oxygen produced at the centre of the NP might have not reached the cholesterol in 
the suspension. PC closer to the NP surface and the surface bound porphyrin should be the 
key singlet oxygen originators contributed to the oxidised derivatives produced by the 
PCNP-P system. 
 
Ideally, NPs synthesised to avoid the RES should be ~100 nm in size, with a hydrophilic 
surface (to avoid clearance by fixed macrophages)
36, 47, 48
. Thus, one of the aims of the 
project was to synthesise a NP system that would produce sufficient amount of singlet 
oxygen while maintaining the NP size ~100 nm and PCNP-P nano system fulfilled these 
criteria. 
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3.3 Nanoparticle uptake dynamics 
The percentage of nanoparticle uptake was quantified using the procedure described in 
Chapter  2.7.2. Identical concentration (5 mg/1 mL) of PCNP-A and PCNP-P were used in 
the experiment and both demonstrated a similar but more intense fluctuation pattern as for 
PCNP (Figure  3.13).  
 
 
Figure ‎3.13: Net uptake with HT29 over time - PCNP, PC NP-A, PCNP-P  
 
All three nanoparticle types showed a relatively high uptake at 25 hours. Thus, in the PDT 
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3.4 PDT – In vitro studies (Maximum uptake) 
Since PCNP-P contained both porphyrin and phthalocyanine the Patterson light system 
with one filter was not appropriate for irradiation. To this end, the Oriel light system (> 
580 nm, with a red Schott glass filter, 51310/59510) was chosen to irradiate both PSs. 
However, to provide the same amount of energy with the Oriel system, it was necessary to 
irradiate the NP system for approximately 82 minutes. Due to the stress this longer 
duration could cause, it was important to find an amount of energy that was sufficient to 
observe a PDT effect with minimum damage caused to the cells due to temperature strains.  
 
In vivo PDT one parameter that limits direct tumour cell destruction is the availability of 
oxygen within the tissue that is targeted. Oxygen shortage can arise as a result of 
photochemical consumption of oxygen during the photodynamic process. Two ways to 
reduce oxygen consumption rates are (i) fractionate the PDT light dose to re-oxygenate the 
tissue and (ii) to lower the light fluence rate
136
. Fractionated drug dose have been found to 
be the most effective way to target tumour cells. Compared to the single dose regimens 
this type of PDT is able to induce long term tumour growth control
236
.  
 
Thus, multiple fractionated radiation could benefit from a higher volume of oxygen to a 
single extensive photoirradiation process. This model is employed in several occasions in 
the literature
135
. 
 
After trial experiments to find the optimum amount of energy using the fractionated 
modaility, the Oriel light system was used to compare the PDT activity of PCNP and 
PCNP using the following measures. As per Chapter  2.10, NPs were filtered through a 200 
nm filter to ‘sterilise’ the particles. The plated NPs were incubated for 25 hours with HT29 
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and the cells were irradiated with a dose of energy (7 J/cm
2
,~23 min) followed by 40 
minute recovery period in the incubator and a further dose of 7 J/cm
2
. The light dose (14 
J/cm
2
) was fractionated with a 40 minute recovery period to allow re-oxygenation of the 
media. The plates were left in the incubator overnight (18-24 hours) in the dark. MTT 
activity assays were then used to determine the cell viability.    
 
PCNP-P showed improved cell viability post PDT treatment. After irradiation the viability 
of cells loaded with PCNP-P was 20% while the non-irradiated dark control was 91%. To 
elaborate the results, if the NPs were 100% efficient, irradiated cell viability is expected to 
be 0% and non-irradiated 100%. Using the same conditions as for PCNP-P, cell viability 
of the PCNP loaded cells post irradiation was 30% and the dark control was 70% 
(Figure  3.14). The dark toxicity of the PCNP could have been due to the leached 
phthalocyanine from the NPs during the incubation period. This hypothesis further 
confirmed that PCNP-P, which does not leach from the NPs, showed almost no dark 
toxicity. 
 
Russell et al.
156
 reported cell viability (after irradiation) of  43% and 77% for an analogous 
experiment without irradiation with gold NPs coated on the surface with phthalocyanines 
(diameter 2-4 nm). In this case, HeLa cells were incubated with the NPs for 4 hours and 
irradiated with light at 690 nm (1.84 mWcm
-2
) for 20 minutes.  
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Figure ‎3.14: PDT cytotoxicity (maximum uptake) - PCNP and PCNP-P (MW 30,000 -70,000) 
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3.5 PDT - In vitro studies (Minimum uptake) 
As discussed in Chapter 2, NPs accumulate in tumour neovasculature due to selective 
retention
134
. It is interesting to try and determine whether there is also an impact by having 
a component attached to the surface of a particle. Exploiting this notion in vitro, HT29 
cells surrounded with PCNP-P in the extracellular media and at the minimum uptake time 
(<5 minutes) were irradiated under identical conditions to those used for the 25 hour 
uptake time. MTT assays were then performed as before and cell viabilities determined 
(Figure  3.15).  
 
 
Figure ‎3.15: PDT cytotoxicity (minimum uptake) - PCNP and PCNP-P (MW 30,000 -70,000) 
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PCNP-P showed the lowest cell viability post irradiation with only 3.7% of cells surviving 
whereas the cell viability of PCNP was 33%. However, the cell survival with both non-
irradiated PCNP and PCNP-P was 100%. This result could be due to, in this instance, the 
NPs being mixed with cells only for the duration of the irradiation (approximately 90 
minutes). These results are potentially very interesting from a clinical perspective, as it is 
likely that a significant proportion of NPs would accumulate in the stroma of the tumour 
i.e. in the extracellular space. It is demonstrated here that if this localised concentration is 
high enough cancer cells can be effectively killed without the requirement that the NPs be 
internalised. 
 
The reason for the high PDT activity of the minimum nanoparticle uptake study could be 
due to the presence of NPs in the surrounding area during irradiation. A higher 
concentration of NPs carries more PSs enabling greater singlet oxygen production. From 
the nanoparticle uptake studies it was established that only 60 - 90% of the NPs were 
internalised at the maximum uptake time. However, in the minimum uptake studies, 
irradiation was performed while 100% of the NPs were present in the cell environment.  
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3.6 Intracellular distribution of NPs  
According to the cell uptake studies, the maximum uptake of NPs should have been 
reached in 18 hours. The confocal microscopy images below display the localisation of the 
PCNP-P which have been incubated with HT29 cells for 20 hours and washed three times 
with media prior to imaging. The confocal images were captured at 633 and 405 nm 
(Figure  3.16) using Leica Microsystems CMS GmbH (LAS AF version: 2.2.1 build 4842). 
Although, the PC absorbs significantly at approximately 400 nm, excitation at 405 nm 
gave no fluorescence from the PCNP. Thus, the fluorescence observed with PCNP-P 
(excited at 405 nm) was considered to be only that emitted by the porphyrin. PC emission 
was captured by NP excitation at 633 nm.  
 
 
Figure ‎3.16: Confocal images (Leica) of PCNP-P internalised in HT29 cells*  
A 
 
B 
C D 
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*After incubating for 20 hours - (Red – excited at 633 nm; green – excited at 405 nm); A - 
PC emission, B - porphyrin emission, C - HT29 cells only, D - merged image 
 
As can be seen from Figure  3.16, cells show granular fluorescence (PC and porphyrin) 
suggesting localisation of the NPs in endocytic vessels 
58
.  
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3.7 Summary 
Successfully entrapped photosensitiser NP systems described in Chapter 2 were 
functionalised and a chosen PCNP was further developed to conjugate another 
photosensitiser (porphyrin) onto the matrix. This enhanced system was studied for in vitro 
uptake and intracellular distribution in HT29 cells. Production of singlet oxygen was 
quantified and the PDT cytotoxicity assays were carried out using the maximum and 
minimum uptake times with the chosen NP–PCNP-P system and showed some excellent 
results. After irradiation (maximum uptake) the viability of cells loaded with PCNP-P was 
20% while the non-irradiated dark control was 91%. In the minimum uptake study, PCNP-
P showed the lowest cell viability post-irradiation with only 3.7% of cells surviving and 
the cell survival for non-irradiated cells was 100%. In the project, PCNP-P is established 
as a potential delivery system to use in vivo (Table 3.1).  
Positive characteristic of the PCNP-P The advantage for efficient delivery 
These NPs are 95±10 nm in size NPs less than 100 nm are able to avoid the 
RES36, 237 
The ability to deliver more than one class of 
PS 
Larger spectral region covered could lead to 
more efficient absorption of light 
Cationic nature of PCNP-P Could potentially be attractive for PACT 
No leaching from the NPs Assured maximum passive targeting 
Almost no dark toxicity Selective targeting – efficient PDT 
treatment 
Table ‎3.1: PCNP-P Summary  
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4 Chapter 4: Concluding remarks 
The aim of the project was to synthesise PSs/dyes suitable for encapsulation within NPs, 
both functionalised and non-functionalised, and to study their behaviour in cell uptake, 
PDT and PACT.  
 
To this end, a number of PSs/dyes have been entrapped within a range of polyacrylamide 
NPs and amino functionalised: MB, DSRuCl, PyPorphyrin. However, leaching from the 
matrix was identified as a challenge to overcome. To this end, sterically bulky groups, 
PEG(750)Porphyrin and PCNP (MW 15,000- 30,000 and 30,000-70,000) were synthesised 
whilst dextran (MW 10,000) conjugated fluorescein (reference dye) and MB dyes were 
purchased to entrap in the polyacrylamide matrix. The mean NP size, 45 (±10 nm) was 
determined by PCS and TEM images. Further they were characterised for the presence of 
PSs within the NPs by spectroscopic investigation (absorbance and/or fluorescence) and 
the concentration of entrapped PSs/probes (using absorbance spectroscopy).  
 
Production of the main PDT agent, singlet oxygen, was quantified to observe the 
relationship between the singlet oxygen production and cell cytoxicity assays. Singlet 
oxygen production of PCNP (30,000 – 70,000 Da) was 360% more than the singlet oxygen 
production of PCNP (15,000 - 30,000 Da). The singlet oxygen production of PCNP-P 
(30,000 – 70,000 Da) was 20% more than PCNP (30,000 – 70,000 Da).  
 
Uptake of the NPs by HT29 cells was investigated using flow cytometry. First, fluorescein 
reference dye (fluorescein dextran 10,000MW) entrapped NPs were used to conduct the 
time course experiment that established an oscillation pattern with the NP uptake. PI was 
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used to confirm how long HT29 cells can be kept alive under the experimental conditions. 
No peaks were observed in the FL3 and FL4 detectors in the experiment. Only the 
fluorescence peak from fluorescein (FL1 peak) was observed. Although it could have been 
possible to continue the experiment and observe how much longer these cells can be kept 
alive under the present conditions, as 48 hours is generally much more time than required 
for assay experiments, the study was discontinued at 48 hours and it was confirmed that 
the HT29 cells can be used in NP assays up to 48 hours. 
 
Subsequently, the fluctuation of the NP net uptake by flow cytometry was studied over 28 
hours using PCNP with HT29 cells incubated at 37°C in a humidified environment of 5% 
CO2. Two concentrations (3 mg/mL and 5mg/mL) of NPs were studied and the percentage 
uptake values confirmed that NP uptake by HT29 was concentration dependent. According 
to the quantified NP uptake profile, NP uptake reaches its maximum within 18 hours and 
then remains constant but with regular fluctuations. 
 
Intracellular distribution of NPs was determined by confocal microscopy and maximum 
uptake was observed after 18 hours of incubation. Cells showed granular fluorescence 
from the PSs suggesting localisation of the NPs in endocytic vessels. 
 
PDT cytotoxicity assays were carried out using the maximum and minimum uptake times 
with the chosen NP-PCNP and PCNP-P. 
 
When irradiated at the maximum uptake time (25 hour), the cell viability of the light 
controlled PCNP experiment was 18% and the cell viability of the dark controlled 
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experiment was 87%.  After irradiation (maximum uptake) the viability of cells loaded 
with PCNP-P was 20% while the non-irradiated dark control was 91%. 
 
The cell viability of HT29 cells surrounded with PCNP in the extracellular media at the 
minimum uptake time (<5 minutes) was 33%. However, no noticeable dark toxicity was 
observed with PCNP. This result could be due to, in this instance, the NPs being mixed 
with cells only for the duration of the irradiation (approximately 90 minutes). In the 
minimum uptake study, PCNP-P showed the lowest cell viability post-irradiation with only 
3.7% of cells surviving and the cell survival for non-irradiated cells was 100%. In the 
project, PCNP-P is established as a potential delivery system to use in vivo. 
 
The results presented here indicate that polyacrylamide NPs have potential as delivery 
vehicles for photodynamic agents in PDT for cancer. Both internally trapped PSs and 
analogues with a second PS conjugated to the particles after formation were active against 
HT-29 cells, but the latter was the more powerful PDT agent when the particles were 
internalised. The ability to deliver more than one class of PS could be advantageous 
clinically as the larger spectral region covered could lead to more efficient absorption of 
light. The cationic nature of PCNP-P also makes it potentially attractive for Photodynamic 
Antimicrobial Chemotherapy (PACT).  
 
Results also show that cellular internalisation is not necessary to photodynamically kill 
cancer cells, although internalised particles are also active, this could be important in vivo 
as significant amounts of nanoparticle would be expected to accumulate in the 
extracellular space in tumours due to the enhance permeability and retention effect. 
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4.1 Future work 
The project compares the PDT cytotoxicity of PCNP with PCNP-P. Another interesting 
step could be to synthesise a nanoparticle system with only the 5-[4-(Succinimide-N-
oxycarbonyl)phenyl]-10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin trichloride 
attached external to the nanoparticle and compare the PDT assay results with PCNP and 
PCNP-P.  
 
In the project, 5-(4-phenylpropenoate)-10,15,20-triphenylporphyrinatozinc was 
successfully synthesised to use in GTP. However, the porphyrin molecule (monomer) did 
not copolymerise in the reaction and thus, with the limited time frame of the Project, this 
concept has not been pursued further.  
 
Steps to consider, facilitating the reaction:  
 
- Increase the length of the link between the functional handle of the porphyrin to enable 
spacing the steric bulk of the porphyrin further from the polymerisation centre. 
 
-  Perform the reaction over a longer period. 
 
In the study with biofilms, it was shown that NPs have the potential to penetrate efficiently 
into a biofilm. This would be an interesting area to investigate with a photosensitiser NP 
delivery system. 
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In the Project the system relies on passive targeting due to the attractive physical 
properties of the NPs. To enhance the current system, targeting agents can be attached to 
NPs to increase localised tumour concentrations
146, 157, 169
.  
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5 Chapter 5:  Experimental 
5.1 Organic synthesis 
General 
 Starting materials were purchased from Fluka, Lancaster or Sigma Aldrich and used 
without further purification unless otherwise stated.  
 
 Solvents were of general purpose or HPLC grade and were purchased from Fischer 
Scientific. 
 All NMR spectra were acquired in the solvent indicated with chemical shifts (δ) 
quoted as parts per million values (ppm) and coupling constants (J) quoted in Hertz 
(Hz). NMR spectra were obtained from either a JEOL JNM-ECP 400 MHZ FT-NMR 
spectrometer or JEOL JNM-LA400 FT NMR spectrometer, at a frequency of 400MHz 
for 1H, 100 MHz for 13C and 376 Hz for 19F spectra.  Chemical shifts are quoted in 
ppm relative to SiMe4, which was used as an internal standard, unless the solvent 
used was DMSO, in which case ppm values are relative to the DMSO singlet at 
2.62.  
 Ultra violet/visible absorption spectra were recorded on a Varian Cary 50Bio UV- Vis 
spectrometer. Cuvettes used were Starna opti glass 2 type 23 (optical glass, 10 mm) 
and a VWR International, uv-vis. Optical glass, 10 mm, from Starna (Hainault) and 
VWR International Limited (Leicestershire) respectively. 
 
 Fluorescence spectra were recorded on a Cary Eclipse Fluorescence spectrometer. 
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 Analytical TLC was carried out using aluminium backed silica gel 60 F254 (Merck 
plates) and visualised using UV light (254/365 nm). 
 
 Column chromatography was performed using ICN silica 32-63, 60Å.  
 All water used was deionised, ELGASTAT Prima Reverse Osmosis unless 
otherwise stated. 
 
 Mass spectrometry results, where the most abundant peak of the M+ is quoted, were 
obtained via services provided by: 
- EPSRC National Mass Spectrometry Service Centre, Chemistry Department 
University of Wales Swansea. Analyses were made using the following 
instrumentation: MALDI Applied Biosystems 
- Mass spectra were recorded on a Bruker Reflex IV matrix assisted laser 
desorption ionisation-time of flight (MALDI-TOF) mass spectrometer.  
 Gel Permeation Chromatography (GPC) was performed using Viscotek 270 Dual 
detector 
 
 Elemental analyses were obtained on a Fisons EA1108 CHN 
 
 THF was dried over sodium under a nitrogen atmosphere with benzophenone as the 
indicator.  
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Synthesis 
5.1.1 Disulphonated 4,7-diphenyl-1,10-phenanthroline ruthenium (II) 
chloride (DSRuCl) synthesis (1)  
 
 
The compound was synthesised according to literature procedures
198, 199
.
 
RuCl3 (57 mg, 
0.0276 mmol) was refluxed while stirring in 4,7-diphenyl-1,10-phenanthrolinedisulfonic 
acid disodium salt (518 mg, 0.0965 mmol, 3.5 equiv.) in 20 mL of deionised water for 48 
hours. The colour of the reaction mixture changed from dark green to red over the period. 
The solution was cooled to room temperature, filtered and excess solvent removed in 
vacuo.  
 
The resultant red-brown solid was purified by size exclusion chromatography with a 
Sephadex-medium (solvent distilled water). The bright red fraction was collected and 
concentrated in vacuo to obtain the product, DSRuCl (yield 44.8 mg, 90%). 

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ex (DI water)/nm 461 (em 612 nm) 
 
Elemental analysis:  
Element Expected results % Actual results % 
Carbon 47.18 42.61 
Hydrogen 3.96 2.81 
Nitrogen 4.23 4.08 
Sulphur 9.69 7.88 
 
The discrepancy between the calculated and results obtained is discussed in Chapter 2.2 
(page 76). 
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5.1.2 5,10,15,20-Tetrakis (4-N-methylpyridiniumyl)porphyrin 
tetraiodide synthesis (2) 
 
 
The compound was synthesised according to literature procedure
231
. Iodomethane (2 mL, 
32.326 mmol, 200 equiv.) was added to a stirred solution of 5,10,15,20-tetra 4-pyridyl 
porphyrin (100 mg, 0.161 mmol) in dry DMF (20 mL). The reaction was stirred at 40°C 
for 17 hours. The crude product was precipitated with ice cold diethyl ether after cooling 
the solution to room temperature. The precipitate was washed several times with diethyl 
ether to remove any trace of iodomethane. The precipitate was dissolved in water:acetone 
(1:1). The solvents were removed under reduced pressure. The porphyrin was precipitated 
from acetone (190 mg, 99.44%) as a purple solid.  
 
1
H NMR [400MHz, (CD3)2SO], δ: -3.12 (2H, br s, NH), 4.71 (12H, s, CH3), 8.99 (8H, d, 
J = 6.2Hz Ar-3, 5-H), 9.20 (8H, s, β-H), 9.48 (8H, d, J= 6.2Hz Ar- 2, 6-H); 13C NMR  
[100MHz, (CD3)2SO], δ: 47.9, 120.5, 127.7, 133.9, 134.6, 135.8, 142.3, 156.2; UV-Vis 
(H2O) λmax 423, 512, 519 nm; Mass (MALDI) m/z 677[M+3e]. 
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5.1.3 5-(4-Hydroxyphenyl)-10,15,20-triphenylporphyrin synthesis (3)  
 
 
The compound was synthesised adopting the Adler method
201
. 4-Hydroxybenzaldehyde 
(1.808 g, 14.81 mmol) and benzaldehyde (4.5 mL, 44.43 mmol) were added to the 
refluxing propionic acid (222.5 mL). Once the aldehydes were dissolved, pyrrole (4 mL, 
59.25 mmol) was added cautiously. The reaction mixture was reacted at reflux for one 
hour and then the solvent was removed in vacuo. The resulting solid was separated by 
flash chromatography (silica, eluent dichloromethane), to obtain 5-(4-hydroxyphenyl)-
10,15,20-triphenylporphyrin (0.54 g, 5.8%). 
 
1
H NMR [400MHz, CDCl3] δ: -2.79 (2H, br s, CH2), 5.35 (1H, br s, OH), 7.22 (2H, m, 5-
Ar-o-H), 7.70-7.82 (9H, m, 10,15,20-Ar-m,p-H), 8.08 (2H, m, 5-Ar-o-H), 8.22 (6H, m, 
10,15,20-Ar-o-H),  8.09-8.85 (6H, m, β-H), 8.88 (2H, m, β-H); 13C NMR [100MHz, 
CDCl3],δ: 113.7, 120.1, 120.5, 126.7, 127.3, 127.7, 133.7, 133.9, 134.6, 135.8, 142.3, 
156.7; UV-Vis (CDCl3) λmax 416, 417,419, 420,516,552,593,647 nm; Mass (MALDI) m/z 
630 (M+).  
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5.1.4 5-(4-Hydroxyphenyl)-10,15,20-triphenylporphyrinatozinc synthesis 
(4)  
 
 
The compound was synthesised according to the literature procedure
238
. A solution of zinc 
acetate (1.87 g, 8.56 mol) dissolved in methanol (40 mL) was added to a solution of 5-(4-
hydroxyphenyl)-10,15,20-triphenylporphyrin (0.54 g, 0.856 mmol) dissolved in DCM 
(100 mL). The mixture was stirred at 40°C for 2 hours protected from light. The residue 
was washed with water (2 x 100 mL) and brine (100 mL) followed by an extraction with 
DCM (200 mL). A fine purple residue was obtained after removal of the solvent under 
reduced pressure (0.549 g, 92.4%). 
 
1
H NMR [400MHz, CDCl3] δ 5.35 (1H, br s, OH), 7.14 (2H, d, J= 8.0Hz, 5-Ar-o-H), 
7.71-7.75 (9H, m, 10,15,20-Ar-m,p-H), 8.04 (2H, d, J= 8.0Hz, 5-Ar-o-H), 8.21 (6H, m, 
10,15,20-Ar-o-H), 8.89 (6H, d, J = 4.5Hz, β-H), 8.95 (2H, d, J = 4.5Hz, β-H); 13C NMR 
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[100MHz, CDCl3],δ: 113.4, 126.4, 127.3, 131.7, 131.9, 134.5, 135,6, 143.2, 150.1; UV-
Vis (CDCl3) λmax 417, 419, 421, 548, 588 nm; Mass (MALDI) m/z 692 (M+).  
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5.1.5 5-(4-Phenylpropenoate)-10,15,20-triphenylporphyrinatozinc 
synthesis (5) 
 
 
The compound was synthesised adopting the literature procedure
204
. Triethylamine (1.32 
mL, 7.9 mmol) was added to the solution of 5-(4-hydroxyphenyl)-10,15,20-
triphenylporphyrinatozinc (0.549 g, 0.79 mmol) in dry DCM under nitrogen. Acryloyl 
chloride (0.64 mL, 7.9 mmol) was added dropwise, by syringe, to the solution at 5°C and 
the solution was left stirring for 25 minutes. Saturated sodium hydrogen carbonate (30 mL) 
solution was added to quench the reaction and the organic phase was washed with water (3 
x 100 mL). The solvent was removed in vacuo and the crude purple solid was purified by 
flash chromatography (silica, eluent hexane:DCM (90:10)). Purified yield: 0.33 g, 
(55.8%). 
 
 
1
H NMR [400MHz, CDCl3] – δ: 6.06 (1H, d, J=10.4Hz, Hb’), 6.41 (1H, dd, J=10.4Hz 
and 17.5Hz, Ha), 6.69 (1H, d, J=17.5Hz, Hb’’), 7.37-7.54 (2H, m, 5-Ar-o-H), 7.57 -7.82 
(9H, m, 10,15,20-Ar-m,p-H), 8.05-8.30 (8H, m, 10,15,20-Ar-o-H),8.82-9.05 (2H, m, β-H); 
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13
C NMR [100MHz, CDCl3],‎δ: 119.4, 126.4, 127.3, 128.0, 131.6, 131.8, 132.9, 150.1; 
UV-Vis (CDCl3)‎λmax/nm 419, 548, 581 nm;  Mass (MALDI) m/z 746 [M]
+
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5.1.6 4-Toluenesulfonic acid-1-(2-(2-(2-methoxy)ethoxy)ethoxy)ethyl 
ester (TEGTs) synthesis (6)  
 
 
The compound was synthesised according to the literature procedure
206
. Monomethoxy 
tri(ethyleneglycol) (9.9 g, 60.51 mmol) was added to a solution of triethyl amine (9.10 g, 
12.7 mL, 90.8 mmol) in dry, alcohol-free chloroform (200 mL) under nitrogen. After 
cooling the mixture to 0°C in an ice/salt bath, 4-toluenesulfonyl chloride (15.0 g, 78.7 
mmol) was added and the reaction was stirred for 20 minutes. Ice/salt bath was removed 
and the reaction was stirred at room temperature for 17 hours under nitrogen. Toluene (100 
mL) was added to the reaction mixture and the solvent was removed in vacuo. The residue 
was dissolved in ethyl acetate (300 mL) and the triethylammonium chloride was removed 
by vacuum filtration. The residue was further washed with ethyl acetate (2 x 50 mL). The 
organic filtrates were combined and the ethyl acetate solution was washed once with 
potassium hydrogen sulphate 1M solution (100 mL) followed by saturated sodium 
hydrogen carbonate solution (100 mL) and twice with water (100 mL). The organic phase 
was dried over anhydrous magnesium sulphate, filtered and the solvent removed from the 
filtrate in vacuo. The crude product was purified by flash chromatography (silica, eluent: 
ethyl acetate: hexane (60:40)), Yield 3.89 g, 20.2%.  
 
1
H NMR [400 MHz, CDCl3],δ: 2.45 (3H, s, CH3), 3.37 (3H, s, OCH3), 3.52- 3.54 (2H, t, 
J= 4.7Hz CH2), 3.59 – 3.62 (6H, s, CH2), 3.67-3.70(2H, t, J= 4.7Hz  CH2), 4.15- 4.17 (2H, 
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t, J= 4.7Hz CH2), 7.35 (2H, d, J=8.0Hz, Ar-3, 5-H), 7.80 (2H, d, J= 8.0Hz, Ar- 2, 6-H); 
13
C NMR [100 MHz, CDCl3],δ:‎21.5, 58.7, 68.3, 70.2, 71.6, 127.7, 129.6, 130.0, 132.7, 
144.6; Mass (Nanospray Ionisation) m/z 318 (M+). 
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5.1.7 5,10,15,20-Tetra-(4-carbomethoxyphenyl)porphyrin synthesis (7)  
 
 
The compound was synthesised adopting the Adler method
201
 according to the method 
described in the literature
207
. Methyl 4-formylbenzoate (19.45 g, 0.1185 mol) was added to 
refluxing propionic acid (445 mL). Pyrrole (8 mL, 0.1185 mol) was added cautiously to 
the solution. The mixture was refluxed for 30 minutes and left at room temperature for 16 
hours, then filtered to yield a purple solid. Using a mixture of dichloromethane/methanol 
(98:2) as an eluent and precipitation with methanol over dichloromethane the pure product 
was obtained as a purple solid in 22.20% yield (5.57 g). 
 
Rf = 0.25 (silica, 0.05% MeOH: CH2Cl2); 
1
H NMR [400MHz, CDCl3],‎δ: -2.79 (2H, br s, 
NH), 4.09 (12H, s, OCH3), 8.30 (8H, d, J = 8.0Hz, Ar-3,5-H), 8.46 (8H, d, J= 8.0Hz, Ar- 
2, 6-H), 8.83 (8H, s, β-H); 13C NMR [100MHz, CDCl3],‎δ: 52.5 (OCH3), 119.4, 128.0, 
130.0, 134.5, 146.6, 167.2 (CO2CH3); UV-Vis (CHCl3)‎λmax 421, 516, 551, 591, 625, 646 
nm ; Mass (MALDI) m/z 847 [M+H]
+
 
197 
 
5.1.8 5,10,15,20-Tetra-(4-hydroxymethylphenyl)porphyrin synthesis (8) 
 
 
The compound was synthesised adopting the Adler method
201
 according to the method 
described in the literature
207
. 5,10,15,20-Tetra(4-carbomethoxyphenyl) porphyrin (100 mg, 
0.118 mmol) was added to freshly distilled (dried and degassed) tetrahydrofuran (75 mL), 
stirred under nitrogen and cooled to 0°C. Once the porphyrin was fully dissolved, lithium 
aluminium hydride (516 mg, 13.6 mmol, 115 equiv.) was added to the reaction mixture 
and left stirring in the dark at room temperature for 48 hours. The unreacted LiAlH4 was 
decomposed with moist ether at 0°C and the solution was filtered through a celite bed. The 
colourless filtrate was extracted with dichloromethane:methanol (70:30). The combined 
extracts were distilled in vacuo. The solid was washed with DCM followed by MeOH and 
this was recrystallised from hexane - DCM. The residual lithium aluminium hydroxide was 
washed with water (2 x 200 mL) followed by MeOH (2 x 200 mL). A fine purple solid was 
obtained after filtration (1.2 mg, 1.38%).  
 
1
H NMR [400MHz, (CD3)2SO],‎δ: -2.93 (2H, br s, NH), 4.86 (8H, s, CH2) 5.51(4H, br s, 
OH), 7.75 (8H, d, J = 7.8Hz Ar-3, 5-H), 8.15 (8H, d, J= 7.8Hz, Ar- 2, 6-H), 8.82(8H, s, β-
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H); 
13
C NMR [100MHz, CDCl3],‎ δ: 62.9, 120.0, 125.0, 134.0, 139.3, 142.3; UV-Vis 
(CD3)2SO)‎λmax 417, 419, 515, 550,590,648 nm ; Mass (MALDI) m/z 734 (M+).  
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5.1.9 5,10,15,20-Tetra-[4-(bromomethyl)phenyl]porphyrin synthesis (9) 
 
The compound was synthesised adopting the Lyndsey method
239
. To 1.5 L of chloroform 
were added 4-bromomethylbenzaaldehyde (2.99 g, 0.015 mol) and pyrrole (1.05 mL, 0.015 
mol). After degassing the mixture (under nitrogen for 30 minutes), BF3.OEt2 (0.6 mL, 5 
mmol) was added and the reaction was allowed to stir at room temperature, protected from 
the light and under a nitrogen atmosphere for one hour. After this period, triethylamine 
(0.84 mL, 16 mmol) and tetrachlorobenzoquinone (2.78 g, 11.3 mmol) were added, the 
temperature was raised and the reaction kept under reflux for one hour. The volume of the 
reaction was then reduced to c.a.250 mL and filtered through a short plug of silica gel 
(eluent CH2Cl2/MeOH initially 99:1 rising to 9:1). The product was obtained pure after 
precipitation with methanol over dichloromethane (1.29 g, 32.44%).  
 
1
H NMR [400MHz, CDCl3], δ: -2.81 (2H, br s, NH), 4.86 (8H, s, CH2), 7.80 (8H, d, 
J=8.1Hz, 5,10,15,20-Ar-m-H), 8.19 (8H, d, J=8.1Hz, 5,10,15,20-Ar-o-H), 8.85 (8H, br s, 
H-β); 13C NMR [100MHz, CDCl3], δ:33.5 (CH2), 119.5 (meso-C), 127.5 (5,10,15,20-Ar-
m-C), 130.0 (5,10,15,20-Ar-o-C), 134.9, 137.4, 142.2; UV-Vis (CHCl3) λmax 419, 421, 
423, 425, 516, 552, 591, 646 nm ; Mass (MALDI) m/z 987 [M+H]
+
.  
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5.1.10 5,10,15,20-Tetra(pentafluorophenyl) porphyrin synthesis (10)  
 
The compound was synthesised according to literature procedure
211
. Pyrrole (6 mL, 0.0865 
mol) was added drop wise to a refluxing mixture of acetic acid (300 mL), nitrobenzene 
(150 mL) and pentafluorobenzaldehyde (10.68 mL, 0.0865 mol) and the mixture was 
refluxed for a further 45 minutes. Once the mixture had cooled to room temperature, 
methanol (100 mL) was added to induce crystallisation and the solvents were removed in 
vacuo. The product was purified by flash chromatography (silica, eluent CH2Cl2:C6H6 3:7) 
and was concentrated in vacuo to give 5,10,15,20-tetra(pentafluorophenyl) porphyrin as a 
purple solid (1.26 g, 5.98%). Note: hexane was used to remove the last traces of 
nitrobenzene. The spectral data for the compound was consistent with the data reported in 
the literature and the assignments of the signals were carried out accordingly
240
.   
1
H NMR [400MHz, CDCl3],‎δ:‎-2.9 (2H, s, NH), 8.92 (8H, s, β-H); 
19
F NMR [376MHz, 
CDCl3],‎δ:‎-160.9 (m, 2F, m-F), -151.1 (t, 1F, J=18.4Hz, p-F), -136.35 (m, 2F, 51.4Hz, o-
F); UV-Vis (CHCl3)‎λmax 410, 516, 552, 591, 636 nm ; MS (MALDI): m/z 975 (M+).  
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5.1.11 5,10,15,20-Tetrakis[2,3,5,6-tetrafluoro-4-{PEG(750)-sulfanyl}-
phenyl]-porphyrin synthesis (11) 
 
 
The compound was synthesised according to literature procedure procedures
211
.5,10,15,20-
Tetra(pentafluorophenyl) porphyrin (20 mg, 0.021 mmol) and polyethylene glycol(750)Br 
(130 mg, 0.21 mmol) were dissolved in DMF (5 mL). Na2S (18 mg, 0.21 mmol) was then 
added and solution stirred at RT for 72 hours. Saturated NaHCO3(aq) (10 mL) was then 
added and the precipitate that formed was removed by filtration. The filtrate was 
concentrated under reduced pressure and the isolated violet oil was then washed repeatedly 
with hexane until the washings were clear to give a purple oil (70 mg, 85%).  
The spectral data for the compound was consistent with the data reported in the literature 
and the assignments of the signals were carried out accordingly
240
.   
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1
H NMR [400MHz, CDCl3],‎δ:‎-2.9 (2H, br s, NH), 2.9 (xH, t, J=6.15 Hz, PEG), 3.54-3.7 
(xH, m, PEG), 3.9 (xH, t, J=6.01Hz, PEG), 8.8-9.1 (8H, m, H-β); 19F NMR [376MHz, 
CDCl3],‎δ:‎-137.1 (m, 2F, p-F), -133.7 (m, 2F, m-F); UV-Vis (CHCl3)‎λmax 415, 518, 548, 
591, 645 nm.  
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5.1.12 MW 15,000-30,000 Poly-D-lysine conjugated phthalocyanine 
synthesis (12) 
 
 
Aluminium phthalocyanine(AlPc) tetrasulfonyl chloride 0.22 g (95%) was synthesised 
adopting the procedure described in Brasseur et al.,
213
. Briefly, AlPc-tetrasulfonic acid 
(200 mg, 0.23 mmol) and chlorosulfonic acid (0.8 mL) were stirred for 3 hours at 100°C. 
Thionyl chloride (1.2 mL) was added followed by stirring for 2 hours at 80°C. Once 
cooled to room temperature, the solution was poured onto ice and the AlPc-tetrasulfonyl 
chloride collected by centrifugation, filtration and was dried in vacuo to receive 
Aluminium phthalocyanine(AlPc) tetrasulfonyl chloride in 95% yield (0.22 g).  
 
AlPc-tetrasulfonyl chloride (100 mg, 0.1 mmol) was added, in small portions, to a solution 
of poly-D-lysine hydrobromide (MW 15,000-30,000) (50 mg, 0.4 mmol, 4 equiv., with 
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respect to lysine groups) and sodium carbonate (85 mg, 0.8 mmol, 8 equiv.) in water (4 
mL), while mixing (vortex) for 1 minute between each addition. 10 mL of the dispersion 
was dialysed against PBS buffer using ultra membrane filters (MWCO 14,000) over 4 days 
to remove any unconjugated PC. MW 15,000-30,000 POLPC was collected and dried in 
vacuo to yield 110 mg. 
ex (DI water)/nm 681 (em 686 nm).  
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5.1.13 MW 30,000-70,000 Poly-D-lysine conjugated phthalocyanine 
synthesis (13) 
 
 
 
Aluminium phthalocyanine(AlPc) tetrasulfonyl chloride 0.22 g (95%) was synthesised 
adopting the procedure described in Brasseur et al.,
213
. Briefly, AlPc-tetrasulfonic acid 
(200 mg, 0.23 mmol) and chlorosulfonic acid (0.8 mL) were stirred for 3 hours at 100°C. 
Thionyl chloride (1.2 mL) was added followed by stirring for 2 hours at 80°C. Once 
cooled to room temperature, the solution was poured onto ice and the AlPc-tetrasulfonyl 
chloride collected by centrifugation, filtration and was dried in vacuo to receive 
Aluminium phthalocyanine(AlPc) tetrasulfonyl chloride in 95% yield (0.22 g).  
 
AlPc-tetrasulfonyl chloride (100 mg, 0.1 mmol) was added, in small portions, to a solution 
of poly-D-lysine hydrobromide (MW 30,000-70,000) (50 mg, 0.4 mmol, 4 equiv., with 
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respect to lysine groups) and sodium carbonate (85 mg, 0.8 mmol, 8 equiv.) in water (4 
mL), while mixing (vortex) for 1 minute between each addition. 10 mL of the dispersion 
was dialysed against PBS buffer using ultra membrane filters (MWCO 14,000) over 4 days 
to remove any unconjugated PC. MW 30,000-70,000 polylysine conjugated PC was 
collected and dried in vacuo to yield 104 mg. 
ex (DI water)/nm 681 (em 686 nm).  
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5.1.14 5-(4-Carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin synthesis 
(14)  
 
 
The compound was synthesised according to literature procedure
231
. Dropwise, pyrrole (4 
mL, 57.8 mmol) was added to a refluxing mixture of 4-formylbenzoic acid (2.54 g, 17 
mmol) and 4-pyridinecarboxaldehyde (9.78 mL, 104 mmol) in acetic acid (200 mL) and 
nitrobenzene (150 mL). The reaction mixture was kept under reflux and intense stirring for 
1 hour. The solvents were removed under reduced pressure and the residue was purified by 
column chromatography using a mixture of 15% dichloromethane/methanol as an eluent 
system. Pure 5-(4-carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin was obtained after 
precipitation from methanol over chloroform in 5.3% yield (510 mg). 
 
1
H NMR (CDCl3, 400MHz) : -2.79 (2H, br s, CH2), 8.2 (9H, m, 10,15,20-Ar-m,p-H), 8.2 
(2H, d, J=  7.8Hz, 5-Ar-o-H), 8.4 (2H, d, J=7.8Hz, 5-Ar-o-H), 8.8 (6H, s, 5-Ar-o-H), 8.97 
(8H, m, β-H); 13C NMR (CDCl3, 100MHz) : 117.1, 120.6, 128.3, 129.5, 129.6, 134.4, 
145.8, 147.3, 150.9, 168.8; UV Vis 420, 519, 555, 580, 636 nm; Mass (MALDI) m/z: 662 
[M
+
+H].  
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5.1.15 5-[4-(Succinimide-N-oxycarbonyl)phenyl]-10,15,20-tri-(4-
pyridyl)porphyrin synthesis (15) 
 
 
The compound was synthesised according to literature procedure
231
. To a stirred solution 
of 5-(4-carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin (51.1 mg, 0.077 mmol) in dry 
pyridine (5 mL) was slowly added thionyl chloride ( 0.1 mL, 1.37 mmol, 18 equiv.). The 
reaction was stirred at 50
o
C, protected from light and atmospheric moisture, for 30 
minutes. N-Hydroxysuccinimide (200 mg, 1.74 mmol, 22.6 equiv.) was then added and the 
mixture was kept stirring under the previous conditions for further 3 hours. Pyridine was 
removed under vacuum, the residue taken up in dichloromethane and washed with an 
aqueous saturated solution of sodium carbonate. The organic layer was dried over sodium 
sulphate and evaporated to dryness under reduced pressure. Crystallisation of the residue 
in light petroleum over chloroform afforded pure 5-[4-(succinimide-N-
oxycarbonyl)phenyl]-10,15,20-tri-(4-pyridyl)porphyrin in 89.5% yield (52.3 mg).  
 
1
H NMR (CDCl3, 400MHz), : -2.90 (2H, br s, NH), 3.10 (4H, br s, CH2), 8.24 (6H, dd, 
J=1.4, 1.4Hz, 10,15,20-H-Ar-o), 8.44 (2H, dd, J=1.4, 1.4 Hz, 5-H-Ar-m), 8.64 (2H, dd, 
J=1.4, 1.6Hz, 5-H-Ar-o), 8.87-8.978 (8H, m, H-β), 9.13 (6H, dd, J=1.4, 1.6Hz, 10,15,20-
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H-Ar-m). 
13
C NMR (CDCl3, 100MHz) : 25.8, 26.0 (CH2), 117.7, 129.1, 129.3 (10,15,20-
Ar-o-C), 134.8, 148.4 (10,15,20-Ar-m-C),149.8, 150.0, 161.7 (CO2N), 169.3 (CON); UV 
Vis 420, 519, 555, 580, 636 nm; Mass (MALDI) m/z 759[M+H]
+
. 
 
  
210 
 
5.1.16 5-[4-(Succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-
methylpyridimiumyl)porphyrin triiodide synthesis (16) 
 
 
The compound was synthesised according to literature procedure
231
. To a stirred solution 
of 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tri-(4-pyridyl)porphyrin (26 mg, 
0.0343 mmol) in dry DMF (5 mL) a large excess of methyl iodide (0.5 mL, 8.03 mmol)  
was added via syringe. The reaction mixture was kept stirring at 40
o
C, under a nitrogen 
atmosphere and protected from light overnight. The product was then precipitated with 
diethyl ether to remove any trace of methyl iodide and DMF. The resulting solid was 
filtered, dissolved in acetone/water (50:50) and the solvents removed under reduced 
pressure. Pure 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-
methylpyridimiumyl)porphyrin triiodide was obtained after precipitation in acetone over 
water in 77.8% yield (31.6 mg).  
 
1
H NMR (CDCl3, 400MHz), : -3.05 (2H, br s, NH), 3.01 (4H, br s, CH2), 4.71 and 4.72 
(6+3H, 2s, CH3), 8.50 (2H, d, J=8.2 Hz, 5-H-Ar-m), 8.60 (2H, d, J=8.2 Hz, 5-H-Ar-o), 
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9.00 (6H, d, J=6.6Hz, 10,15,20-H-Ar-o), 9.06-9.15 and 9.15-9.26 (8H, 2m, H-β), 9.48 (6H, 
d, J=6.6Hz, 10,15,20-H-Ar-m); 
13
C NMR (CDCl3, 100MHz) : 25.8, 29.7 (CH2), 117.8, 
129.1, 129.3 (10,15,20-Ar-o-C), 134.8, 148.4 (10,15,20-Ar-m-C),149.8, 150.3, 162.0 
(CO2N), 169.3 (CON); UV Vis 420, 520, 554, 582, 635 nm; Mass (MALDI) m/z 804 
[M+H]
+
.  
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5.1.17 5-[4-(Succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-
methylpyridimiumyl)porphyrin trichloride synthesis (17)  
 
 
The compound was synthesised according to literature procedure
231
. To a solution of 5-[4-
(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin 
triiodide (56.9 mg, 0.0481 mmol) in anhydrous methanol (57 mL) Dowex 1x8 200-400  Cl 
(1.81 g) was added and the reaction mixture was allowed to stir at room temperature for 1 
hour, protected from moisture and light. The resin was separated by filtration and the 
reaction mixture concentrated under reduced pressure. After precipitation with acetone, 
pure 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-
methylpyridimiumyl)porphyrin trichloride was obtained as a brown solid in 95.5% yield 
(41.8 mg).  
 
1
H NMR (DMSO-d6, 400MHz), : -3.05 (2H, br s, NH), 3.01 (4H, br s, CH2), 4.72 and 
4.73 (6+3H, 2s, CH3), 8.51 (2H, d, J=7.8Hz, 5-H-Ar-m), 8.61 (2H, d, J=7.8Hz, 5-H-Ar-o), 
9.00 (6H, d, J=5.6 Hz, 10,15,20-H-Ar-o), 9.04-9.13 and 9.13-9.23 (8H, 2m, H-β), 9.52 
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(6H, d, J=5.6 Hz, 10,15,20-H-Ar-m); 
13
C NMR (DMSO-d6, 100MHz): : 25.8 (CH2), 
47.9 (CH3), 117.8, 119.1, 120.1, 124.9, 129.3, 134.8 (10,15,20-Ar-o-C), 135.1, 144.2 
(10,15,20-Ar-m-C), 148.4, 149.8, 150.4 (CO2N), 169.3 (CON); UV Vis 421, 519, 554, 
584, 637 nm; Mass (MALDI) m/z 804[M+H]
+
. 
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5.2 Nanoparticle synthesis 
General 
 All starting materials were purchased from Fluka, Lancaster or Sigma Aldrich and 
used without further purification unless otherwise stated.  
 Photocorrelation spectra were recorded on a Malvern Zetasizer 1000/2000/3000. 
 Centrifugation was carried out Denley BS400. 
 A Millipore filter unit (fritted glass) with 0.02 mm, 25 mm, Whatman® Anodisc 25 
filters and 0.22 µm in-line Millex GP filters (Millipore) were used to recover the 
nanoparticles or sterilise them before biological experiments. 
 Cuvettes used were Starna opti glass 2 type 23 (optical glass, 10 mm) and a VWR 
International, uv-vis. Optical glass, 10 mm, from Starna (Hainault) and VWR 
International Limited (Leicestershire) respectively. 
 Jeol 2010 transmission electron microscope (Jeol (UK) Ltd. Welwyn Garden City), 
and UltraScan 4000 digital camera (Gatan UK, Abingdon) were used for NP TEM 
imaging. 
 Hydrophilic carbon coated copper grid used in TEM imaging were from Agar 
Scientific Ltd, Stansted, Essex, UK. 
 High performance liquid chromatography (HPLC) was performed on a HPLC 
system with a UV detector, Phenomenex Luna 5 µm C18 column (250 x 4.60 mm) 
and analysed using Azur software version 5.0 
 The solid NMR on the nanoparticles was performed on a Bruker Avance II. 500 
MHz. Measurements were conducted with a 4 mm double resonance Magic angle 
spinning probe. Samples were spun at 8 Khz. The chemical shifts were referenced 
externally to TMS at 0 ppm. 
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Synthesis  
5.2.1 Polyacrylamide nanoparticles synthesis (18) 
 
 
The compound was synthesised according to literature procedure
28
. A final volume (2.00 
mL) of solution containing acrylamide (540 mg, 7.60 mmol) and N,N’-
methylenebisacrylamide (160 mg, 1.04 mmol) in water (1.8 mL) were added to a 
deoxygenated hexane (42 mL) solution containing Brij
®
 30 (3.08 g, 8.49 mmol) and 
completely dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution 
(30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 
mL) followed by TEMED (15 µL, 0.1 µmol) were added and the reaction was stirred for 2 
hours under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous solid was washed with ethanol, centrifuged (8 x 50 mL, 10 
minutes, 4500 rpm) and was recovered by microfiltration (Whatman
®
 Anodisc 25, 0.02 
µm, 25 mm filters) to yield the desired polyacrylamide nanoparticles (610 mg, 87%). An 
optically clear dispersion was obtained from the nanoparticles upon addition to aqueous 
media (water or NaHCO3 (aq)).  
PCS mean (zave, DI water)/nm 38; fluorescamine test (ex/nm 365) negative. 
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5.2.2 Amino functionalised nanoparticles synthesis (19)  
 
The compound was synthesised according to literature procedure
28
. A final volume of 
(2.00 mL) containing acrylamide (527 mg, 7.41 mmol), N,N’-methylenebisacrylamide 
(160 mg, 1.04 mmol) and N-(3-aminopropyl)methacrylamide hydrochloride (13 mg, 0.073 
mmol) in water (1.8 mL) were added to a deoxygenated hexane (42 mL) solution 
containing Brij
®
 30 (3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate 
sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 0.4382 moldm
-3
) of ammonium 
persulphate (100 mg, 0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 
µmol) was added and the reaction was stirred for 2 hours under a positive argon pressure at 
room temperature.  
 
Excess hexane was removed in vacuo. The resulting viscous solid was washed with 
ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and was recovered by 
microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the amino 
functionalised nanoparticles (630 mg, 90.0%). An optically clear dispersion was obtained 
from the nanoparticles upon addition to aqueous media (water or NaHCO3 (aq)). 
 
 PCS mean (zave, DI water)/nm 37; fluorescamine test (ex/nm 365) positive.  
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5.2.3 Cationic nanoparticles synthesis (20) 
 
 
Blank amino nanoparticles (90 mg) and methyl iodide (2.0 mL) were added to a dry DMF 
(5 mL) solution at 40°C under an argon atmosphere. After one hour the argon supply was 
removed and the solution was kept stirring for 72 hours at 40°C. Aqueous triethylamine 
(10 mL) was added and the solution was microfiltered (Whatman
®
 Anodisc 25, 0.02 µm, 
25 mm filter). The particles were then repeatedly washed with ethanol (4-5 times). The 
product was filtered and vacuum dried (5 hours) to obtain dry cationic polyacrylamide 
nanoparticles (80 mg, 89%).  
 
1
H NMR [500MHz],‎ δ: 3.35 (3H, d, CH3-N); 
13
C NMR [500MHz],‎ δ: 57.5 (CH3-N); 
PCS mean (zave, DI water)/nm 38; fluorescamine test (ex/nm 365) negative. 
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5.2.4 Methylene blue entrapped nanoparticles synthesis (21) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by an aliquot (100 L, 15.6 mmoldm-3) of a 
solution of MB (5 mg, 15.6 µmol) in water (1 mL) were added to a deoxygenated hexane 
(42 mL) solution consisting of Brij
®
 30 (3.08 g, 8.49 mmol) and completely dissolved 
dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 0.4382 moldm
-
3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 mL) followed by TEMED 
(15 µL, 0.1 µmol) was added and the reaction was stirred for 2 hours under a positive 
argon pressure at room temperature. Excess hexane was removed in vacuo. The resulting 
viscous yellow solid was washed with ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 
rpm) and recovered by microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to 
yield the desired MB entrapped nanoparticles (451 mg, 64%). An optically clear blue 
dispersion was obtained from the nanoparticles upon addition to aqueous media (water or 
NaHCO3 (aq)).  
 
PCS mean (zave, DI water)/nm 36; fluorescamine test (ex/nm 365) negative; ex (DI 
water)/nm 658(em 674 nm); concentration of MB present in 1 mg of nanoparticles ~ 5.6 
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µmoldm
-3
, R² = 0.9998, y = 30.243x (5.6 µmoldm
-3 
of MB per 1 mg of MB entrapped NPs 
in 1 mL of H2O). 
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5.2.5 Methylene blue entrapped amino functionalised nanoparticles 
synthesis (22) 
 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (527 mg, 7.41 mmol), N,N’-methylenebisacrylamide (160 mg, 
1.04 mmol) and N-(3-aminopropyl)methacrylamide hydrochloride (13 mg, 0.073 mmol) in 
water (1.8 mL) followed by an aliquot (100 L, 15.6 mmoldm-3) of a solution of MB (5 
mg, 15.6 µmol) in water (1 mL) were added to a deoxygenated hexane (42 mL) solution 
consisting of Brij
®
 30 (3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate 
sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 0.4382 moldm
-3
) of ammonium 
persulphate (100 mg, 0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 
µmol) was added and the reaction was stirred for 2 hours under a positive argon pressure at 
room temperature. Excess hexane was removed in vacuo. The resulting viscous yellow 
solid was washed with ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and 
recovered by microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the 
desired MB entrapped nanoparticles (681 mg, 97%). An optically clear blue dispersion 
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was obtained from the nanoparticles upon addition to aqueous media (water or NaHCO3 
(aq)).  
PCS mean (zave, DI water)/nm 42; fluorescamine test (ex/nm 365) positive; ex (DI 
water)/nm 658(em 674 nm); concentration of MB present in 1 mg of nanoparticles ~ 4.9 
µmoldm
-3
, R² = 0.9998, y = 30.243x (4.9 µmoldm
-3 
of MB per 1 mg of MB entrapped NPs 
in 1 mL of H2O). 
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5.2.6 Uranyl acetate entrapped polyacrylamide nanoparticles synthesis 
(23) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.95 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by a solution of uranyl acetate (1 mg, 2.4 
µmol) in water (50 µL) were added to a deoxygenated hexane (42 mL) solution consisting 
of Brij
®
 30 (3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate sodium 
salt (1.59 g, 3.58 mmol). A solution (30 µL, 0.4382 mol dm
-3
) of ammonium persulphate 
(100 mg, 0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 µmol) was 
added and the reaction was stirred for 2 hours under a positive argon pressure at room 
temperature. Excess hexane was removed in vacuo. The resulting viscous yellow solid was 
washed with ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and recovered by 
microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the desired uranyl 
acetate entrapped nanoparticles (580 mg, 83%). An optically clear yellow dispersion was 
obtained from the nanoparticles upon addition to aqueous media (water or NaHCO3 (aq)).  
 
PCS mean (zave, DI water)/nm 51.5; fluorescamine test (ex/nm 365) negative; TEM 
imaging stain positive. 
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5.2.7 Disulphonated 4,7-diphenyl-1,10-phenanthroline ruthenium (II) 
chloride (DSRuCl) entrapped NPs synthesis (24) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by an aliquot (100 L, 2.8 mmoldm-3) of a 
solution of DSRuCl (5 mg, 2.8 µmol) in water (1 mL) were added to a deoxygenated 
hexane (42 mL) solution containing Brij
®
 30 (3.08 g, 8.49 mmol) and completely 
dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 
0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 mL) 
followed by TEMED (15 µL, 0.1 µmol) was added and the reaction was stirred for 2 hours 
under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous orange solid was washed with ethanol, centrifuged (8 x 50 
mL, 10 minutes, 4500 rpm) and was recovered by microfiltration (Whatman
®
 Anodisc 25, 
0.02 µm, 25 mm filters) to yield the desired DSRuCl entrapped nanoparticles (570 mg, 
81%). An optically clear dispersion was obtained from the nanoparticles upon addition to 
aqueous media (water or NaHCO3 (aq)).  
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PCS mean (zave, DI water)/nm 58; fluorescamine test (ex/nm 365) negative; ex (DI 
water)/nm 461(em 610 nm); concentration of DSRuCl present in 1 mg of nanoparticles 
~4.0 µmoldm
-3
, R² = 0.9968, y = 11.973x (4.0 µmoldm
-3 
of DSRuCl per 1 mg of DSRuCl 
entrapped NPs in 1 mL of H2O). 
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5.2.8 Disulphonated 4,7-diphenyl-1,10-phenanthroline ruthenium (II) 
chloride (DSRuCl) entrapped amino functionalised nanoparticles 
synthesis (25) 
 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (527 mg, 7.41 mmol), N,N’-methylenebisacrylamide (160 mg, 
1.04 mmol) and N-(3-aminopropyl)methacrylamide hydrochloride (13 mg, 0.073 mmol) in 
water (1.8 mL) followed by an aliquot (100 L, 2.8 mmoldm-3) of a solution of DSRuCl (5 
mg, 2.8 µmol) in water (1 mL) were added to a deoxygenated hexane (42 mL) solution 
containing Brij
®
 30 (3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate 
sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 0.4382 moldm
-3
) of ammonium 
persulphate (100 mg, 0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 
µmol) was added and the reaction was stirred for 2 hours under a positive argon pressure at 
room temperature. Excess hexane was removed in vacuo. The resulting viscous orange 
solid was washed with ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and was 
recovered by microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the 
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desired DSRuCl entrapped nanoparticles (580 mg, 83%). An optically clear dispersion was 
obtained from the nanoparticles upon addition to aqueous media (water or NaHCO3 (aq)).  
 
PCS mean (zave, DI water)/nm 58; fluorescamine test (ex/nm 365) positive; ex (DI 
water)/nm 461(em 610 nm); concentration of DSRuCl present in 1 mg of nanoparticles 
~4.9 µmoldm
-3
, R² = 0.9968, y = 11.973x (4.9 µmoldm
-3 
of DSRuCl per 1 mg of DSRuCl 
entrapped NPs in 1 mL of H2O). 
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5.2.9 5,10,15,20-Tetrakis(4-N-methylpyridiniumyl)porphyrin tetraiodide 
entrapped polyacrylamide nanoparticles synthesis (26) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by an aliquot (100 L, 4.2 mmoldm-3) of a 
solution of PyPorphyrin (5 mg, 4.2 µmol) in water (1 mL) were added to a deoxygenated 
hexane (42 mL) solution consisting of Brij
®
 30 (3.08 g, 8.49 mmol) and completely 
dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 
0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 mL) 
followed by TEMED (15 µL, 0.1 µmol) was added and the reaction was stirred for 2 hours 
under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous yellow solid was washed with ethanol, centrifuged (8 x 50 
mL, 10 minutes, 4500 rpm) and recovered by microfiltration (Whatman
®
 Anodisc 25, 0.02 
µm, 25 mm filters) to yield the desired porphyrin entrapped nanoparticles (640 mg, 
91.4%). An optically clear yellow dispersion was obtained from the nanoparticles upon 
addition to aqueous media (water or NaHCO3 (aq)).  
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PCS mean (zave, DI water)/nm 51.5; fluorescamine test (ex/nm 365) negative; ex (DI 
water)/nm 429(em 665 nm); concentration of PyPorphyrin present in 1 mg of 
nanoparticles ~ 0.34 µmoldm
-3
, R² = 0.996, y = 1.7894x (0.34 µmoldm
-3 
of PyPorphyrin 
per 1 mg of PyPorphyrin entrapped NPs in 1 mL of H2O). 
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5.2.10 5,10,15,20-Tetrakis(2,3,5,6-tetrafluoro-4-{PEG(750)-sufanyl}-
phenyl)-porphyrin entrapped polyacrylamide nanoparticles 
synthesis (27) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by an aliquot (100 L, 1.3 mmoldm-3) of a 
solution of PEG(750)Porphyrin (5 mg, 1.3 µmol) in water (1 mL) was added to a 
deoxygenated hexane (42 mL) solution containing Brij
®
 30 (3.08 g, 8.49 mmol) and 
completely dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution 
(30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 
mL) followed by TEMED (15 µL, 0.1 µmol) was added and the reaction was stirred for 2 
hours under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous yellow solid was washed with ethanol, centrifuged (8 x 50 
mL, 10 minutes, 4500 rpm) and was recovered by microfiltration (Whatman
®
 Anodisc 25, 
0.02 µm, 25 mm filters) to yield the desired 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-
{PEG(750)-sufanyl}-phenyl)-porphyrin entrapped nanoparticles (552 mg, 79%). An 
optically clear dispersion was obtained from the nanoparticles upon addition to aqueous 
media (water or NaHCO3 (aq)).  
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PCS mean (zave, DI water)/nm 37; fluorescamine test (ex/nm 365) negative; ex (DI 
water)/nm 410 (em 653 nm); concentration of PEG(750)Porphyrin present in 1 mg of 
nanoparticles 0.34 µmoldm
-3
, R² = 0.9944, y = 2.1428x (0.34 µmoldm
-3 
of 
PEG(750)Porphyrin per 1 mg of PEG(750)Porphyrin entrapped NPs in 1 mL of H2O). 
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5.2.11 5,10,15,20-Tetrakis(2,3,5,6-tetrafluoro-4-{PEG(750)-sufanyl}-
phenyl)-porphyrin entrapped amino functionalised polyacrylamide 
nanoparticles synthesis (28) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (527 mg, 7.41 mmol), N,N’-methylenebisacrylamide (160 mg, 
1.04 mmol) and N-(3-aminopropyl)methacrylamide hydrochloride (13 mg, 0.073 mmol) in 
water (1.8 mL) followed by an aliquot (100 L, 1.3 mmoldm-3) of a solution of 
PEG(750)Porphyrin (5 mg, 1.3 µmol) in water (1 mL) was added to a deoxygenated 
hexane (42 mL) solution containing Brij
®
 30 (3.08 g, 8.49 mmol) and completely 
dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution (30 µL, 
0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 mL) 
followed by TEMED (15 µL, 0.1 µmol) was added and the reaction was stirred for 2 hours 
under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous yellow solid was washed with ethanol, centrifuged (8 x 50 
mL, 10 minutes, 4500 rpm) and was recovered by microfiltration (Whatman
®
 Anodisc 25, 
0.02 µm, 25 mm filters) to yield the desired 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-
{PEG(750)-sufanyl}-phenyl)-porphyrin entrapped nanoparticles (601 mg, 86%). An 
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optically clear dispersion was obtained from the nanoparticles upon addition to aqueous 
media (water or NaHCO3 (aq)).  
 
PCS mean (zave, DI water)/nm 40; fluorescamine test (ex/nm 365) positive; ex (DI 
water)/nm 410 (em 653 nm); concentration of PEG(750)Porphyrin present in 1 mg of 
nanoparticles 0.42 µmoldm
-3
, R² = 0.9944, y = 2.1428x (0.42 µmoldm
-3 
of 
PEG(750)Porphyrin per 1 mg of PEG(750)Porphyrin entrapped NPs in 1 mL of H2O). 
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5.2.12 MW 10,000 dextran fluorescein entrapped polyacrylamide 
nanoparticles synthesis (29) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by an aliquot (100 L, 50 mmoldm-3) of a 
solution of fluorescein conjugated to a dextran polymer (MW 10,000 Da) (5 mg, 50 µmol) 
in water (1 mL) was added to a deoxygenated hexane (42 mL) solution consisting of Brij
®
 
30 (3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate sodium salt (1.59 
g, 3.58 mmol). A solution (30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 
0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 µmol) was added and the 
reaction was stirred for 2 hours under a positive argon pressure at room temperature. 
Excess hexane was removed in vacuo. The resulting viscous light orange solid was washed 
with ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and recovered by 
microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the desired 
fluorescein entrapped nanoparticles (660 mg, 94%). An optically clear dispersion was 
obtained from the nanoparticles upon addition to aqueous media (water or NaHCO3 (aq)).  
PCS mean (zave, DI water)/nm 46; fluorescamine test (ex/nm 365) negative; ex (DI 
water)/nm 480(em 520 nm). 
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5.2.13 MW 15,000-30,000 Poly-D-lysine conjugated phthalocyanine 
entrapped polyacrylamide nanoparticles synthesis (30) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.8 mL) followed by a solution (100 µL) of PCPOL ( 1.34 
moldm
-3
) were added to a deoxygenated hexane (42 mL) solution containing Brij
®
 30 
(3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 
3.58 mmol). A solution (30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 
0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 µmol) was added and the 
reaction was stirred for 2 hours under a positive argon pressure at room temperature. 
Excess hexane was removed in vacuo. The resulting viscous yellow solid was washed with 
ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and was recovered by 
microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the desired 
PCPOL entrapped nanoparticles (590 mg, 84%). An optically clear dispersion was 
obtained from the nanoparticles upon addition to aqueous media (water or NaHCO3 (aq)).  
 
PCS mean (zave, DI water)/nm 40; fluorescamine test (ex/nm 365) negative; ex (DI 
water)/nm 681 (em 686 nm); concentration of phthalocyanine loaded to 1 mg of 
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nanoparticles ~0.36 µmoldm
-3
, ε Al-Pc 1.5 x 105 M-1cm-1 (ex (DI water)/666 nm), R² = 
0.9987, y = 0.1545x (0.36 µmoldm
-3
 of phthalocyanine per 1 mg of NPs in 1 mL of H2O). 
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5.2.14 MW 15,000-30,000 Poly-D-lysine conjugated phthalocyanine 
entrapped amino functionalised polyacrylamide nanoparticles 
synthesis (31) 
 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (527 mg, 7.41 mmol), N,N’-methylenebisacrylamide (160 mg, 
1.04 mmol) and N-(3-aminopropyl)methacrylamide hydrochloride (13 mg, 0.073 mmol) in 
water (1.7 mL) followed by a solution (100 µL) of PCPOL (1.34 moldm
-3
) were added to a 
deoxygenated hexane (42 mL) solution containing Brij
®
 30 (3.08 g, 8.49 mmol) and 
completely dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution 
(30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 
mL) followed by TEMED (15 µL, 0.1 µmol) was added and the reaction was stirred for 2 
hours under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous yellow solid was washed with ethanol, centrifuged (8 x 50 
mL, 10 minutes, 4500 rpm) and was recovered by microfiltration (Whatman
®
 Anodisc 25, 
0.02 µm, 25 mm filters) to yield the desired Pc polylysine entrapped nanoparticles (625 
mg, 89%). An optically clear dispersion was obtained from the nanoparticles upon addition 
to aqueous media (water or NaHCO3 (aq)).  
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PCS mean (zave, DI water)/nm 40 (±10 nm); fluorescamine test (ex/nm 365) positive; ex 
(DI water)/nm 681 (em 686 nm); concentration of phthalocyanine loaded to 1 mg of 
nanoparticles ~0.36 µmoldm
-3, ε Al-Pc 1.5 x 105 M-1cm-1 (ex (DI water)/666 nm), R² = 
0.9987, y = 0.1545x (0.36 µmoldm
-3
 of phthalocyanine per 1 mg of NPs in 1 mL of H2O).  
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5.2.15 MW 30,000-70,000 Poly-D-lysine conjugated PC entrapped 
polyacrylamide nanoparticles synthesis (32) 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (540 mg, 7.60 mmol) and N,N’-methylenebisacrylamide (160 
mg, 1.04 mmol) in water (1.7 mL) followed by a solution (100 µL) of PCPOL (1.34 
moldm
-3
) were added to a deoxygenated hexane (42 mL) solution containing Brij
®
 30 
(3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 
3.58 mmol). A solution (30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 
0.4382 mmol) in water (1 mL) followed by TEMED (15 µL, 0.1 µmol) was added and the 
reaction was stirred for 2 hours under a positive argon pressure at room temperature. 
Excess hexane was removed in vacuo. The resulting viscous yellow solid was washed with 
ethanol, centrifuged (8 x 50 mL, 10 minutes, 4500 rpm) and was recovered by 
microfiltration (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filters) to yield the desired Pc 
polylysine entrapped nanoparticles (602 mg, 86%). 
 
PCS mean (zave, DI water)/nm 45 (±10 nm); fluorescamine test (ex/nm 365) negative; ex 
(DI water)/nm 681 (em 686 nm); concentration of phthalocyanine loaded to 1 mg of 
nanoparticles ~1.9 x 10
-4 
moldm
-3
 (ST DEV 5.09 x 10
-8 
moldm
-3
), ε AlPc 1.5 x 105 M-1cm-1 
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(ex (DI water)/666 nm), R² = 0.9987, y = 0.1545x (1.9 x 10
-4 
moldm
-3
 of phthalocyanine 
per 1 mg of NPs in 1 mL of H2O). 
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5.2.16 MW 30,000-70,000 Poly-D-lysine conjugated PC entrapped amino 
functionalised polyacrylamide nanoparticles synthesis (33) 
 
 
The compound was synthesised adopting literature procedure
28
. A final volume of (1.90 
mL) containing acrylamide (527 mg, 7.41 mmol), N,N’-methylenebisacrylamide (160 mg, 
1.04 mmol) and N-(3-aminopropyl)methacrylamide hydrochloride (13 mg, 0.073 mmol) in 
water (1.7 mL) followed by a solution (100 µL) of PCPOL (1.34 moldm
-3
)  were added to 
a deoxygenated hexane (42 mL) solution containing Brij
®
 30 (3.08 g, 8.49 mmol) and 
completely dissolved dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution 
(30 µL, 0.4382 moldm
-3
) of ammonium persulphate (100 mg, 0.4382 mmol) in water (1 
mL) followed by TEMED (15 µL, 0.1 µmol) was added and the reaction was stirred for 2 
hours under a positive argon pressure at room temperature. Excess hexane was removed in 
vacuo. The resulting viscous yellow solid was washed with ethanol, centrifuged (8 x 50 
mL, 10 minutes, 4500 rpm) and was recovered by microfiltration (Whatman
®
 Anodisc 25, 
0.02 µm, 25 mm filters) to yield the desired Pc polylysine entrapped nanoparticles (616 
mg, 88%). 
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PCS mean (zave, DI water)/nm 45 (±10 nm); fluorescamine test (ex/nm 365) positive; ex 
(DI water)/nm 681 (em 686 nm); concentration of phthalocyanine loaded to 1 mg of 
nanoparticles ~1.9 x 10
-4 
moldm
-3
 (ST DEV 5.09 x 10
-8 
moldm
-3), ε AlPc 1.5 x 105 M-1cm-1 
(ex (DI water)/666 nm), R² = 0.9987, y = 0.1545x (1.9 x 10
-4 
moldm
-3
 of phthalocyanine 
per 1 mg of NPs in 1 mL of H2O). 
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5.2.17 MW 30,000-70,000 Poly-D-lysine conjugated phthalocyanine 
entrapped methylated NHS ester conjugated nanoparticles 
synthesis (34) 
 
 
The compound was synthesised adopting literature procedure
28
. An aliquot of (500 µL, 2.2 
mmoldm
-3
) of 5-[4-(succinimide–N-oxycarbonyl)phenyl]-10,15,20-tri(4-N-
methylpyridiniumyl)porphyrin trichloride [17] was added to a dispersion (10 mL) of 
filtered (Millex
®
 GP, 0.22 µm filter unit) amino functionalised PC-polylysine entrapped 
nanoparticles (50 mg) and triethylamine (250 µL). The mixture was spun in Falcon 
polystyrene (12x75 mm) tubes for 2 hours on a spinning rotator at room temperature, 
protected from light. The resulting suspension was washed with ethanol, centrifuged (7x50 
mL, 10 minutes, 5500 rpm), microfiltered (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm 
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filters) and dried for 8 hours at 40°C to yield the desired porphyrin conjugated PC 
entrapped nanoparticles as a green solid (39 mg, 78%). 
 
PCS mean (zave, DI water)/nm 95 ± 10 nm; fluorescamine test (ex/nm 365) negative; ex 
(DI water)/nm 424 (em  656 nm and 708 nm); ex (DI water)/nm 680 (em 685 nm); 
concentration of phthalocyanine loaded to 1 mg of nanoparticles ~1.6 x 10
-4 
moldm
-3
 (ST 
DEV 5.09 x 10
-8 
moldm
-3), ε AlPc 1.5 x 105 M-1cm-1 (ex (DI water)/666 nm), R² = 0.9987, 
y = 0.1545x, (1.6 x 10
-4 
moldm
-3
 of phthalocyanine per 1 mg of NPs in 1 mL of H2O); 
concentration of porphyrin loaded to 1 mg of nanoparticles ~1.8 x 10
-4 
moldm
-3
 (ST DEV 
5.09 x 10
-8 
moldm
-3), ε NHS Porphyrin 2.3 x 105 M-1cm-1 (ex (DI water)/520 nm) (1.8 x 
10
-4 
moldm
-3
 of porphyrin per 1 mg of NPs in 1 mL of H2O). 
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5.3 Nanoparticle characterisation Methods 
 
5.3.1 Particle Size  
The particle size and size distribution properties of the nanoparticles were measured by 
PCS, Zetaplus
TM 
particle size analyzer (Malvern 3000) at 25°C and at a scattering angle of 
90°. A dilute sample of nanoparticles (1 mg/mL) was prepared in MilliQ water, sonicated 
for 30s and filtered (Millex
®
 GP, 0.22 µm filter unit) before analysis. The value was 
recorded as the average of 30 data measurements. 
 
5.3.2 TEM Imaging 
The nanoparticles were suspended in deionised water and placed in an ultrasonic bath for 3 
minutes.  The suspension was then passed through a Millex
®
 GP, 0.22 µm filter unit and 
the resulting suspension returned to the ultrasonic bath for a further 2 minutes to disperse 
any aggregates. 5 µL of the suspension was immediately put onto a hydrophilic carbon 
coated copper grid (Agar Scientific Ltd, Stansted, Essex, UK) and allowed to air dry.  Dry 
ethanol (5 µL) was then added to the grid and left to air dry.  TEM images were obtained 
using an UltraScan 4000 digital camera (Gatan UK, Abingdon) attached to a Jeol 2010 
transmission electron microscope (Jeol (UK) Ltd., Welwyn Garden City) running at 120 
kV. 
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5.3.3 Entrapped/conjugated PS/probe concentration quantification 
1 mg of filtered (Millex
®
 GP, 0.22 µm filter unit) nanoparticles were dispersed in 1 ml of 
deionised water and the absorbance of the particles measured by UV spectrophotometry 
(Varian Cary50 Bio, Cary WinUV) between the wavelengths 400-800 nm.   
 
5.3.3.1 DSRuCl NP 
The calibration “straight” line for DSRuCl was plotted against the absorbance of the 
DSRuCl at 461 nm for a known concentration range of the (DSRuCl) (solvent deionised 
water). The calibration “straight” line was then used in measuring the approximate 
concentrations of DSRuCl present in a pre-determined weight of NPs by measuring its 
absorbance.  
 
5.3.3.2 MB NP 
The calibration “straight” line was plotted using the MB absorbance at 665 nm against 
known concentrations of MB. This calibration “straight” line was used in quantifying the 
approximate concentrations of MB present in a given weight of NPs by measuring its 
absorbance.  
 
5.3.3.3 PyPorphyrin NP 
A calibration “straight” line was used to measure the approximate concentrations of 
PyPorphyrin present per set weight of NPs by measuring its absorbance (solvent deionised 
water) at 421 nm.  
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5.3.3.4 PEG(750)Porphyrin NP 
The calibration “straight” line for 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-{PEG(750)-
sulfanyl}-phenyl)-porphyrin was plotted using the porphyrin absorbance at 410 nm and 
known concentrations of  the porphyrin (solvent deionised water). This calibration 
“straight” line was then used to measure the approximate concentrations of porphyrin 
present per specified weight of NPs.  
 
5.3.3.5 PCNP 
The concentrations of the entrapped PC was quantified using the Beer-Lambert Law 
(A=εcl; A- Absorbance, ε- extinction coefficient of the compound, c- concentration, l- path 
length). The reported extinction coefficient for AlPc was 1.5 x 10
5 
M
-1
cm
-1
 (λex (DI 
water)/666 nm)
214
. A calibration “straight” line for PC was also plotted using the published 
PC absorbance maxima at 680 nm and known concentrations of the PC (solvent deionised 
water). This calibration “straight” line was then used to measure the approximate 
concentrations of PC present per specified weight of NPs. The results obtained using both 
reported extinction coefficient and the plotted curve were within the standard deviation.  
 
5.3.3.6 PCNP-P  
Above detailed PC calibration “straight” line ( 5.3.3.5) and the measured extinction 
coefficient for NHS porphyrin, 2.3 x 10
5 
M
-1
cm
-1
(ex (DI water)/520 nm) was used to 
estimate the concentration of the photosensitisers present in the PCNP-P.  
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5.3.4 Leaching studies 
The absorbance reading of the leachates with the MB NP was significant. Thus, it was 
possible to calculate the percentage of MB leached from the MB NPs. For all the other 
NPs synthesised in the Project, fluorescence intensity was measured in the leaching 
experiment. 
 
5.3.4.1 MB NP  
200 mg of NPs were dispersed in 80 mL of MilliQ water and the dispersion was kept 
stirring at room temperature. At given time intervals (hourly), three 2 mL samples were 
drawn from the suspension and the absorbances were measured using UV-vis. NP 
suspensions were microfiltered (Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filter) and the 
absorbance readings of the leachates were analysed. Average readings at each time point 
before and after filtration were taken for 24 hours. Percentage of leached dye was 
calculated using the formulae below. 
 
 
% Leached = (Filtrate absorbance/NP suspension aliquot absorbance) * 100 
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5.3.4.2 All the other NPs produced 
Leaching of the POLPC from the nanoparticles was studied to assess the porosity of the 
nanoparticles. Nanoparticles (200 mg) were dispersed in 80 mL of MilliQ water. The 
dispersion was kept stirring at room temperature. At given time intervals (hourly), three 2 
mL samples were drawn from the suspension and the nanoparticles were microfiltered 
(Whatman
®
 Anodisc 25, 0.02 µm, 25 mm filter). The filtrate was analysed by fluorescence 
spectroscopy.   
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5.3.5 Determination of singlet oxygen production 
2 mL of DCM followed by 3 mL of cholesterol 10 mM (1:9 DCM:MeOH) were added to a  
nanoparticle (5 mg/1 mL MeOH) suspension. Oxygen was bubbled through the resulting 
suspension mixture, which was then irradiated with white light (400–700 nm) for one 
hour. The volume was reduced to dryness by flowing argon into (over) the suspension. 1 
mL of MeOH was added and the suspension was filtered through a 15 nm filter 
(Whatman
®
 Nuclepore Track Etch membrane; 25 mm, 0.015 µm). 200 µL of this solution 
was transferred to an Epindorf
®
 tube and 200 µL of methanol was added. 1-2 crystals of 
NaBH4 were added to the solution, which was left for 1 minute until complete reduction 
had taken place. The volume of the solvent was reduced to approximately 100–150 µL by 
flowing argon over the solution. 
 
A TLC plate was placed in a tank containing a 1:1 hexane:ethyl acetate mixture. The 
solvent was allowed to migrate 2/3 of the way up the plate; the plate was then removed 
from the TLC chamber and allowed to air dry. Once dried, the plate was returned to the 
tank and the solvent was allowed to migrate to the top of the plate and was left to dry 
again. To visualise the sterols on the TLC plate, a 5% H2SO4 in ethanol mist was sprayed 
onto the TLC plate and the plate placed on a 100-120°C hot plate to allow development of 
the coloured spots. 
 
Cholesterol and its oxidation products were separated on a Phenomenex Luna 5 µm C18 
column (250 x 4.60 mm) using a mixture of methanol:acetonitrile (60:40 vol/vol) mobile 
phase. The flow rate was maintained at 1.0 mL/min. for 20 minutes prior to analysis. UV 
detection was performed at 205 nm. 10 µL of the sample was injected manually into the 
HPLC analysis system and the separation was detected using the Azur software version 5.  
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5.4 Biological methods 
General 
 All starting materials were purchased from Sigma Aldrich.  
 FACS – Becton Dickinson FACS calibur BD Biosciences software. 
 Autoclavable Nichiryo Nichipet Ex Plus micropipettes (Japan) were used for 
measuring/pipetting small volumes. 
 The white light source was a 3M Overhead Projector, 1700 A4, Visual Systems 
Division, Austin, Texas, U.S.A. 
 Paterson PDT light system BL1000A equipped with red Glens 100 367 0134 filter 
(670WB, 630 110). 
 Omnilux EL1000A LED light system (Phototherapeutics Limited) with a 
wavelength of 633±3 nm. 
 Oriel light system (1000W quartz tungsten halogen lamp model 66188, Newport 
power supply Model 69935) equipped with a red Schott glass filter (wavelength 
560 to 1940 nm).  
 Biotek ELX80 Universal Microplate Reader was used to determine the cell 
viability after MTT assay.  
 Centrifuge: Heraeus Biofuge Primo was used to pellet cells during washing steps.  
 Heraeus Hera Cell incubator was used to incubate the biological assay. 
 UltraScan 4000 digital camera (Gatan UK, Abingdon) attached to a Jeol 2010 
transmission electron microscope (Jeol (UK) Ltd. Welwyn Garden City). 
 Hydrophilic carbon coated copper grid for TEM imaging was obtained from Agar 
Scientific Ltd, Stansted, Essex, UK. 
 Leica Microsystems CMS GmbH (LAS AF version: 2.2.1 build 4842). 
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5.4.1 Cell culture 
Human Caucasian colon adenocarcinoma cells (HT29) cells were routinely cultured in 
75cm
3
 tissue culture flasks in McCoy’s media supplemented with 10% fetal calf serum 
(FCS), 1% L-glutamine (all purchased from PAA) at 37°C in a humidified environment of 
5% CO2. The medium was replenished daily and the cells were sub-cultured after reaching 
confluence. PBS, BSA and sodium azide were purchased from Sigma Aldrich,UK.  
 
5.4.2 Cellular uptake  
5.4.2.1 Fluorescein entrapped NP uptake 
A time course experiment was carried out by setting up controls (cells only) and samples 
(cells and NPs). Cell-only controls contained 50,000 cells in 400 µL of McCoy’s media 
(complete) and each sample contained 50,000 HT29 cells and 5 mg of filtered (through a 
220 nm filter) dextran conjugated fluorescein encapsulated NPs in 400 µL media (i.e. 5 mg 
of NPs in 200 µL media were added to a sterile sample tube containing 50,000 cells in 200 
µL media).  
 
Both the control and NPs samples were incubated at 37°C, in an atmosphere of 5% CO2 
within a humidified incubator. Every 15 minutes, duplicate sample tubes and a control tube 
were taken out of the incubator, washed and resuspended in PBS/BSA/azide before 
preparation for flow cytometry. Following incubation, 4 mL of PBS/BSA/azide was added 
to all three tubes, the cells were pelleted by centrifugation at 404 x g for 5 minutes. The 
supernatant was removed and discarded, and the cells were resuspended in 1 mL of 
PBS/BSA/azide and transferred to a clean tube. The cells were washed again by adding a 
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further 3 mL of PBS/BSA/azide. The cells were pelleted by centrifugation at 404 x g for 5 
minutes. The wash procedure was repeated twice more before the cells were resuspended 
in 200 µL of PBS/BSA/azide. Repeated washing steps washed away most of the 
fluorescein or NPs present in the surrounding media. Further, to quench any extracellular 
fluorescence, 10 µL of Trypan blue 4% was added to the washed cells. After 5 minutes the 
cell suspension was loaded into a haemocytometer to count the cells. 
 
Results were then acquired using a Becton Dickinson FACS Calibur
TM
 flow cytometer 
with the following settings: forward scatter (FSC) E -1 752, side scatter (SSC) 369; 
fluorescence (FL1) log 415; fluorescence (FL2) log 550. A minimum of 10,000 cells were 
measured in each sample. The fluorescein loaded NPs were detected in the fluorescence 
level (FL1) channel of the flow cytometer. Analysis was performed using CellQuest Pro V 
software (Becton Dickinson) and histograms plotted of FL1 fluorescence vs cell counts for 
each time point. The cell-only sample provided the negative control at each time point.  
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5.4.2.2 Cell viability over longer periods (~48 hours) 
A time course experiment was carried out by setting up controls (cells only) and samples 
(cells and NPs). Cell-only controls contained 50,000 cells in 400 µL of McCoy’s media 
(complete) and each sample contained 50,000 HT29 cells and 5 mg of filtered (through a 
220 nm filter) dextran conjugated fluorescein encapsulated NPs in 400 µL media (i.e. 5 mg 
of NPs in 200 µL media were added to a sterile sample tube containing 50,000 cells in 200 
µL media). 
 
Both the control and NP samples were incubated at 37°C, in an atmosphere of 5% CO2 
within a humidified incubator. Every 3 hours, for the duration of the experiment, duplicate 
sample tubes and a control tube were taken out of the incubator, cells were washed and 
resuspended in 30 µL PI/Triton X-100 staining solution before preparation for flow 
cytometry.  
Following incubation, 4 mL of PBS/BSA/azide was added to all three tubes and the cells 
were pelleted by centrifugation at 404 x g for 5 minutes. The supernatant was removed and 
discarded, and the cells were resuspended in 1 mL of PBS/BSA/azide and transferred to a 
clean tube. The cells were washed again by adding a further 3 mL of PBS/BSA/azide. The 
cells were pelleted by centrifugation at 404 x g for 5 minutes. The wash procedure was 
repeated twice more before the cells were resuspended in 200 µL of PBS/BSA/azide. 30 
µL of PI/Triton X-100 staining solution was added to the washed cells and after 5 minutes 
the cell suspension was loaded into a haemocytometer to count the cells. 
 
Results were then acquired using a Becton Dickinson FACS Calibur
TM
 flow cytometer 
with the following settings: forward scatter (FSC) E -1 752, side scatter (SSC) 369; 
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fluorescence (FL1) log 412; fluorescence (FL2) log 474, fluorescence (FL3) log 427. A 
minimum of 10,000 cells were measured in each sample. 
 
During the entire experiment no peaks were observed in the FL3 and FL4 detectors. Only a 
FL1 peak was observed - the fluorescence peak of fluorescein. 
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5.4.2.3 Nanoparticle uptake (PCNP, PCNP-A and PCNP-P) 
A time course experiment using HT29 was set up with a control (cells only) and 2 samples 
(cells and nanoparticles) at each given time point. Cell-only controls contained 50,000 
cells in 400 µL of McCoy’s high glucose media and each sample contained 50,000 HT29 
cells and 10 mg of the nanoparticles in 400 µL media (10 mg nanoparticles suspension of 
200 µL media were added to a sterile Falcon polystyrene (12x75 mm) tube containing 
50,000 cells in 200 µL media). 
 
Both the control and sample systems were incubated at 37°C, in an atmosphere of 5% CO2 
within a humidified incubator. At given time points, duplicate sample tubes and a control 
tube were taken out of the incubator, cells washed and resuspended in PBS/BSA/azide 
solution before preparation of the material for flow cytometry. 
 
Following incubation, 4 mL of the PBS/BSA/azide solution was added to all three tubes, 
the cells were pelleted by centrifugation at 404 x g for 5 minutes. The supernatant was 
removed and discarded and the cells were resuspended in 1 mL of PBS/BSA/azide solution 
and transferred to a clean tube. The cells were washed again by adding a further 3 mL of 
PBS/BSA/azide. The cells were pelleted once again by centrifugation at 404 x g for 5 
minutes. The washing procedure was repeated twice before the cells were resuspended in 
200 µL of PBS/BSA/azide solution.   
 
The cell suspension was loaded into a haemocytometer after 5 minutes to count the cells. 
Results were then acquired using a Becton Dickinson FACS Calibur
TM
 flow cytometer 
with the following settings: forward scatter (FSC) E -1 752, side scatter (SSC) 369; 
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fluorescence (FL1) log 412; fluorescence (FL2) log 474, fluorescence (FL3) log 427, 
fluorescence (FL4) log 377 . A minimum of 10,000 cells were measured in each sample. 
 
PC entrapped in the NPs was detected in the fluorescence level (FL4) channel of the flow 
cytometer. Analysis was performed using CellQuest Pro V software (Becton Dickinson) 
and histograms were plotted of FL4 fluorescence versus cell counts for each time point. 
The cell-only sample provided the negative control at each time point.  
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5.4.3 Phototoxicity - In vitro (Maximum uptake) 
10 mg of nanoparticles were added to 1 mL McCoy’s media, agitated (Vortex) (60 
seconds), sonicated (60 seconds) and filtered (Millex
®
 GP, 0.22 µm filter unit). The 
obtained volume (approximately 800 µL) was added to the same volume of cells (2.5 × 
10
5
cells/mL) in a Falcon polystyrene (12x75 mm) tube. The tube was incubated for 25 
hours at 37°C in a humidified environment of 5% CO2. The volume of the media was 
increased to 4 mL and the supernatant discarded to eliminate any interference from 
nanoparticle conjugates that had not been internalised or attached to the HT29 cells. The 
volume of media was increased to the initial volume (approximately 800 µL). HT29 cells 
were plated with 100 µL of cell suspension per well in two 96 well plates. The two 
controls, cells only (100% cell survival) and media only (background control) were plated 
onto each plate. 
 
One plate was irradiated with 7J/cm
2
 [~23 minutes] of cooled red light followed by a 40 
minute recovery period in the incubator (at 37°C in a humidified environment of 5% CO2) 
and another 7J/cm
2
 using an Oriel light system (>580 nm red Schott glass filter, 
51310/59510). The second plate was kept in the dark outside the incubator while the other 
plate was being irradiated. The plates were left to incubate overnight for 18-24 hours in the 
dark. The cell viability was determined using the MTT colorimetric assay. Briefly, 10 µL 
of 12 mM MTT solution was added to each well and incubated between 1 and 4 hours at 
37°C to allow MTT metabolisation. The crystals formed were dissolved by adding 150 µL 
of acid-alcohol mixture (0.04 M HCl in absolute 2-propanol). The absorbance at 570 nm 
was measured on a Biotek ELX80 Universal Microplate Reader. The results were 
expressed with respect to control values (cells without NPs).   
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5.4.4 Phototoxicity - In vitro (Minimum uptake) 
10 mg of nanoparticles were added to 1 mL McCoy’s media, agitated (Vortex) (60 
seconds), sonicated (60 seconds) and filtered (Millex
®
 GP, 0.22 µm filter unit). The 
obtained volume (approximately 800 µL) was added to the same volume of cells (2.5 × 
10
5
cells/mL) in a Falcon polystyrene (12x75 mm) tube. The cells were plated with 100 µL 
cell suspension per well in two 96 well plates. The two controls, cells only (100% cell 
survival) and media only (background control) were transferred onto each plate. 
 
The light control plate was irradiated with the same system described above soon after 
plating (<5 minutes) 7J/cm
2
 [~23 minutes] of cooled red light followed by a 40 minute 
recovery period in the incubator (at 37°C in a humidified environment of 5% CO2) and 
another 7J/cm
2
. Meanwhile the dark control plate was kept outside the incubator in the 
dark.  
 
The wells were washed with 3x100 µL of media. 100 µL of media was added to the wells 
and the plates were left to incubate overnight for 18-24 hours in the dark. The cell viability 
was using MTT colorimetric assay. Briefly, 50 µL of 0.5% MTT solution was added to 
each well and incubated for 4 hours at 37°C to allow MTT metabolisation. The crystals 
formed were dissolved adding 100 µL of HCl. The absorbance at 570 nm was measured on 
a Microtiter
®
 Plate reader. The results were expressed with respect to control values (cells 
without NPs). 
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5.4.5 Fluorescence confocal microscopy 
5.4.5.1 PCNP 
 
1 mL of the PCNP (10 mg/mL) were added to separate Falcon polystyrene (12x75 mm) 
tubes containing 1 mL (2.5x10
5
/mL) of HT29. These were incubated for 20 hours at 37°C 
in a humidified environment of 5% CO2 and washed three times with McCoy’s media. 
 
The intracellular localisation of the nanoparticles was observed with a Leica Microsystems 
CMS GmbH (LAS AF version: 2.2.1 build 4842). To observe the PCNP the incubated 
cells with PCNP were excited at 633 nm and the emission was collected between 648-790 
nm. 
 
5.4.5.2 PCNP-P 
 
1 mL of the PCNP-P (10 mg/mL) were added to separate Falcon polystyrene (12x75 mm) 
tubes containing 1 mL (2.5x10
5
/mL) of HT29. These were incubated for 20 hours at 37°C 
in a humidified environment of 5% CO2 and washed three times with McCoy’s media.  
 
The intracellular localisation of the nanoparticles was observed with a Leica Microsystems 
CMS GmbH (LAS AF version: 2.2.1 build 4842). PCNP-P localisation was observed by 
exciting the incubated cells with PCNP-P at 405 nm and 633 nm and emission collected 
between 420-790 nm and 648-794 nm respectively. 
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5.4.6 Bacteria identification experiments 
5.4.6.1 API® 20 E system  
This system was used to identify Escherichia coli. This is a standardised system containing 
20 microtubes of dehydrated substrates to identify Enterobacteriaceae and other non-
fastidious Gram–rods which use 21 miniaturised biochemical tests and an international 
database.  
 
The first step in the test is to prepare the incubation box with the tray and lid provided in 
the API
®
 20 E kit. To create a humid atmosphere in the incubation box approximately 5 
mL of distilled water was distributed into the honeycombed wells of the tray. The API
®
 
20E strip was then placed into the box. Every microtube on the API
®
 20E strip represents a 
test (Table 2.3). These tubes were inoculated with a bacterial suspension (a colony from an 
overnight cultured E.coli plate emulsified in 5 mL saline). The microtubes where then 
filled up, avoiding the formation of any bubbles, with the bacterial suspension following 
the procedure below. Both the tube and the capsule were filled in CIT, VP and GEL tests. 
ADH, LDC, ODC, H2S, URE tubes were filled with the bacterial suspension and 
anaerobiosis was created by covering the suspension with a drop of mineral oil. For the 
remaining tests only the tubes were filled with bacterial suspension. The strip was 
incubated at 37°C, in an atmosphere of 5% CO2 in a humidified incubator for 24 hours. 
During incubation, metabolism resulted in colour changes that were either spontaneous or 
revealed by addition of reagents after the incubation period. The reactions were read 
referencing the Reading Table from API
®
 20E Analytical Profile Index or/and using the 
identification software. Escherichia Coli identification was confirmed.   
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5.4.6.2 API STAPH test  
Staphylococci are perfectly spherical cells about 1µm in diameter. Staphylococcus aureus 
form fairly large golden yellow colonies on agar whereas S. epidermidis forms a relatively 
small white colony.  
 
Further identification was possible using API STAPH strips. The first step in the test is to 
prepare the incubation box with the tray and lid provided in the API STAPH kit. To create 
a humid atmosphere in the incubation box approximately 5 mL of distilled water was 
distributed into the honeycombed wells of the tray. The API STAPH strip was then placed 
into the box. Every microtube on the API STAPH strip represents a test (Table 2.4). The 
Staphylococcus strains (sub-cultured on agar and incubated at 37°C, in an atmosphere of 
5% CO2 within a humidified incubator for 24 hours) were emulsified on an API STAPH 
medium. In inoculating the strip the bacterial suspension was added to all the microtubes 
to fill only the tube. Anaerobiosis was created only on ADH and URE tests by filling the 
capsules with mineral oil.  
 
The strip was incubated at 37°C, in an atmosphere of 5% CO2 in a humidified incubator 
for 24 hours. The identification was facilitated by the use of the API STAPH Analytical 
Profile Index or/and the identification software. Both the Staphylococci strains were 
identified.  
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5.4.7 Primary bacteria assay 
The initial protocol consisted of two 96 well plates: dark control and light control. Two 
organisms were assayed on one plate (Figure  2.43). 10 µL of overnight bacteria culture 
was added to each well of a 96 conical well plate, fllowed by 10 µL of MB in distilled 
water (final drug concentration 0–50 µM) and 180 µL Luria-Bertani (LB) media. The 
cultures were incubated at 37°C, in an atmosphere of 5% CO2 in a humidified shaker 
incubator for 5 minutes. The plates were centrifuged for 10 minutes (404 g), the 
supernatant was removed and fresh LB added. The pellets (cells) were thawed and 
transferred to a flat bottom 96 well plate. The light controlled assay was irradiated with red 
light (40 J/cm
2
) and incubated for 30 minutes with shaking. The sample was irradiated (40 
J/cm
2
) again and incubated at 37°C, in an atmosphere of 5% CO2 in a humidified shaker 
incubator over night. The dark controlled assay culture was transferred to a flat bottom 
well plate and was also incubated at 37°C in an atmosphere of 5% CO2 in a humidified 
shaker incubator. 
 
Following the overnight incubation period the absorbance of each well was taken at 630 
nm using a microtitre plate reader. This was followed by the CellTiter 96
®
 aqueous non-
radioactive cell proliferation assay: 20 µL of MTS/PMS combined reagent was added to 
the wells, incubated for 1-4 hours and the absorbance of the samples read by a 
micropipette reader.  
  
263 
 
5.4.8 Optimised bacteria assay 
The protocol consisted of two plates: 1. dark control and 2. light control. Two organisms 
were assayed on one plate (Figure  2.43).  
 
10 µL of 32x10
5
 dilution of overnight bacteria culture, 10 µL of photosensitiser (i.e. MB) 
in distilled water (final drug concentration in the well 0-100 µM) and 160 µL of LB were 
placed in three 96 conical well plates. The amount of LB added to the wells was reduced to 
avoid any spillage while centrifuging the plates. The cultures were incubated at 37°C, in an 
atmosphere of 5% CO2 within a humidified shaker incubator for 15 minutes (15 minutes 
was found to be the best MB uptake time). The bacteria cultures were washed three times 
whilst changing plates at each washing (plates were centrifuged for 10 minutes, (404 g) of 
supernatant removed, fresh LB added and the cell pellets were thawed and then transferred 
to new plates). During the washings cultures were transferred to conical well plates with 
the exception of the last washing where the cultures were transferred to flat-bottom well 
plates. 
 
One light controlled plate was irradiated with Omnilux
®
 EL1000A with a wavelength of 
633±3 nm providing a dose of 11J/cm2 (~23 minutes) and the other light controlled plate 
was irradiated with Oriel Model 66188 wavelength set from 550 to 2000 nm providing a 
dose of 7J/cm
2 
(~23 minutes). The plates were incubated at 37°C, in an atmosphere of 5% 
CO2 within a humidified shaker incubator for 30 minutes (as above), and the irradiation 
step was repeated. The dark control assay was incubated at 37°C, in an atmosphere of 5% 
CO2 (as above conditions) in a humidified shaker incubator and the culture was transferred 
to flat-bottom well plates.  
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After the PDT treatment, the plates were incubated overnight (approximately 14 hours) at 
37°C, in an atmosphere of 5% CO2 within a humidified shaker incubator. The next day, 20 
µL of MTS reagent was added to the bacteria cultures to determine the bacteria viability. 
The cultures were incubated at 37°C, in an atmosphere of 5% CO2 within a humidified 
shaker incubator for 1 hour (this was found to be the optimum duration for MTS assays), 
protected from light. Absorbance of each well was taken at 490 nm using a microtitre plate 
reader. 
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